key: cord-0841889-fvwk5cv0
authors: nan
title: Proceedings of the World Molecular Imaging Congress 2021, October 5-8, 2021: Late-Breaking Abstracts
date: 2022-01-04
journal: Mol Imaging Biol
DOI: 10.1007/s11307-021-01694-x
sha: 826364c51f2b2d1cf071e15007e503d79c542b4a
doc_id: 841889
cord_uid: fvwk5cv0

Coronavirus 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a respiratory track disease characterized by fever, dry cough, fatigue, and gastrointestinal symptoms. Currently, there is no definite treatment for COVID-19 although some drugs are under investigation. To promptly identify patients and prevent further spreading, they must be diagnosed in time and extra care has to be taken to ensure healthcare providers are not infected at all. Early detection and diagnosis of COVID-19 increases the chances of recovery of patients and this can be achieved through the use of computed tomography (CT) and magnetic resonance imaging (MRI) scanning. Although chest CT and digital radiography (DR) is important in the diagnosis and treatment of COVID-19, MRI is crucial for not just diagnosis of the disease but also for detection of other complications. MRI examinations for COVID-19 patients, protection of medical personnel and disinfection of MRI equipment is a challenging due high contingency of the disease. In addition to these problems, MRI examinations are costly. In order to overcome these challenges, this study proposes a computational method based of magnetic resonance fingerprinting (MRF) data, Bloch NMR response and machine learning. Clinical MRF were obtained from a recent experimental study on COVID-19. Since the specific MRF measurements in individual patients are not currently available, R computer codes were developed to simulate the measurements per subject. Taking the simulated data as individual data points, the time-independent NMR Bloch flow equation was solved analytically (as shown in equations (1) to (6)) and employed to compute the MRI signal for each subject based on spleen analysis data. The simulations were also done for cardiac MRI, hepatic panel test and brain volume data. The dataset generated from these simulations were then splitted into two (80% as training set and 20% as test set). As shown in figure 1, machine learning algorithms were then used to train the dataset. Support vector machine, logistic regression, decision tree and gradient boosting classifier returned accuracies of 88%, 82%, 88% and 88% respectively for spleen analysis dataset. For the hepatic panel test, cardiac MRI and brain volume datasets, these algorithms all returned 100% accuracies. Logistic regression model was then selected to do deploy the machine learning algorithm with streamlit and Heroku. COVID-19 detection app making use of computed spleen analysis dataset is shown in figure 2. The advantage of the developed app is that it does not require costly MRI scanners but a significantly cheaper NMR relaxometer can be used to take MRF data and with the app, diagnosis can be done quite easily and remotely. Swabs can be taken by patients and sent for MRF analysis and diagnosis with the machine learning app developed, with which disinfection is now much easier with lower risks of infection on healthcare providers. Despite the results that have been obtained in this study, the algorithm will benefit from training with larger amount of data for improved detection efficiency. Also, a ground truthing process in clinical settings may be done to confirm that the simulated data points are realistic for real-time diagnosis.

Iris Zhou, Massachusetts General Hospital and Harvard Medical School, iris.zhou@mgh.harvard.edu Category: Systemic Diseases (Kidney, Liver and Pancreas) Abstract Body : Introduction NASH is a progressive form of nonalcoholic fatty liver disease that promotes fibrotic remodeling of the liver parenchyma which can progress to cirrhosis, hepatocellular carcinoma, and liver failure (1) . Invasive liver biopsy is the gold standard NASH diagnosis, and while elastography methods and serum biomarkers have sensitivity to advanced fibrosis, there are no methods available to assess disease activity, to sensitively detect early onset of disease, or to detect early response to treatment. Here, we use molecular MRI to detect liver fibrogenesis by targeting allysine residues formed on matrix proteins due to lysyl oxidase (LOX) enzymatic activity upregulated during active disease (2, 3) . We use Gd-1,4, a dual binding probe that targets fibrogenesis through nucleophilic reaction with allysine, to characterize the natural history of fibrogenesis in a diet model of NASH, to test whether molecular MRI can identify early disease onset and predict treatment response. Methods Gd-1,4, an allsyine targeting compound with two hydrazine arms, was synthesized by amide coupling of two tert-butyl piperazin-1-ylcarbamate to protected 1,4-DOTA-(GA)2 (4), followed by acid deprotection and gadolinium complexation. Male C57BL/6 mice were fed a choline-deficient, L-amino aciddefined, high-fat diet (CDAHFD) for 2, 6, 10 weeks (N=6 per time-point), or standard chow (N=10). Two additional groups (N=6) of mice received CDAHFD for 10 weeks and then standard chow for 1 or 4 weeks. Animals were anesthetized with isoflurane (1.5%) and imaged with a 4.7 Tesla Bruker MRI scanner. 3D T1-weighted FLASH images were acquired prior to and up to 50 minutes post intravenous administration of 100 µmol/kg Gd-1,4. Mice were euthanized 60 minutes p.i. and liver tissue was collected and analyzed for hydroxyproline (Hyp) content, histology, and immunohistochemistry. Results Steatosis (white fat globules on H&E) and fibrosis (red staining on Sirius Red) develop quickly with CDAHFD and increase with the duration on CDAHFD, accompanied by increased staining for LOX and α-SMA, markers of fibrogenesis ( Figure 1A ). Animals fed CDAHFD for 10 weeks and then switched to standard chow for one week showed still prominent fibrosis (Sirius Red) but marked reduction in LOX and α-SMA indicating that fibrogenesis ceases with switching diet but fibrosis takes longer to resolve. Gd-1,4 enhanced MR showed progressively higher liver signal enhancement with longer duration on CDAHFD (Fig. 1B) . Compared to controls, significantly greater percentage signal change (%SI) was seen in the livers of CDAHFD mice as early as 2 weeks after diet, while Hyp (a measure of total liver collagen and fibrosis severity) showed no significant difference from control ( Fig. 1C) , demonstrating that Gd-1,4 is sensitive to onset of fibrogenesis and allows early detection of disease. Switching to standard chow for 1 week after 10 weeks of CDAHFD resulted in significantly lower %SI, which further reduced after 4 weeks of diet reversal and tracked with LOX and α-SMA markers of fibrogenesis, indicating the sensitivity of Gd-1,4 MRI to predict treatment response. A significant correlation was found between Gd-1,4 %SI and tissue

Brian Madajewski, OncoNano Medicine Inc, bmadajewski@onconanomed.com

Abstract Body : Background Pegsitacianine (ONM-100) is a polymeric micelle nanoparticle comprised of amphiphilic polymers to which the near-infrared (NIR) imaging dye, indocyanine green (ICG), is covalently attached to the hydrophobic segment. Pegsitacianine micelles accumulate at tumor sites through the enhanced permeability and retention effect (EPR) and become activated via dissociation within and response to the acidic tumor microenvironment (i.e., Warburg effect). Relying on an ultra pH-sensitive activation mechanism, pegsitacianine exists in a fluorescently dark ("Off") state at physiological pH but transitions rapidly to a fluorescently "On" state when deposited at sites of disease. As acidic microenvironments are a hallmark of most solid tumors, pegsitacianine has the potential to function as a tumor agnostic imaging agent compatible with any clinical camera designed fro ICG imaging across a variety of solid tumor types. Pegsitacianine has previously been studied in a Phase 1 clinical trial where breast, head and neck, colorectal, and esophageal cancers were imaged following an intravenous dose of pegsitacianine (0.1-1.2 mg/kg) 24 hours prior to surgery. Pegsitacianine was well tolerated in patients, fluoresced in all tested tumor types, and detected positive surgical margins or occult disease missed by standard of care in 30% of patients. The current Phase 2 study (NCT03735680) is aimed at evaluating a range of dose schedules, and the feasibility of intraoperative fluorescence imaging in multiple tumor types. Methods The ongoing Phase 2 study is a non-randomized, open-label, multi-center study that is designed to be completed in three Parts. The design is intended to be adaptive in Parts 1 and 2, followed by a concentrated effort using the optimal dose-schedule and tumor type in Part 3. All enrolled patients were administered a single dose of pegsitacianine (0.5-3 mg/kg) either on the day of surgery or the day prior. Part 1 investigated 3 different dosing cohorts in two tumor types (breast, head and neck), while Part 2 evaluated an additional 2 dosing cohorts and included ovarian and prostate cancers. In the ongoing Part 3, head and neck cancer was chosen as the target tumor type using a doseschedule of 1 mg/kg administered 24-hours prior to surgery. Pegsitacianine efficacy was evaluated based on overall tumor visualization, tumor-to-background ratios (TBR), sensitivity, and specificity. Results A total of 25 patients have been enrolled in the study to date, 9 in Part 1, 10 in Part 2, and 6 in Part 3, across three U.S. centers. Here we demonstrate the optimization of the dose-schedule and imaging feasibility of pegsitacianine across multiple tumor types as demonstrated by favorable in vivo tumor-to-background ratios. Intraoperative imaging observations were seen to correlate highly with the pathological assessments of collected tissues, and imaging can be reliably performed using multiple FDA-cleared NIR imaging devices. Current results from evaluable patients in Part 3 demonstrate favorable sensitivity (100%) and specificity (92%) values for pegsitaciaine when used during head and neck cancer resections in the oral cavity. Conclusions Pegsitacianine continues to demonstrate its utility as a tumor-agnostic fluorescent nanoprobe for real-time surgical guidance in the operating room. To date, pegsitacianine has enabled fluorescence imaging of disease in 6 different tumor types using 4 different FDA-cleared imaging devices. The combination of the emerging tumor agnostic mechanism of detection and ease of integration into surgical workflows with existing clinical imaging systems make pegsitacianine is an ideal probe for oncologic surgery. These attributes can better aid surgeons in the real-time detection and removal of disease and overcome the limitations and challenges of other imaging approaches that rely on the expression of unique tumor biomarkers and customized imaging equipment. Country: United States τreformation = 3 ms. These results have notable ramifications for both encapsulation and MPI scan strategies. The asymptotic and long-term remanence of SFMIOs appear to be due to changing geometric alignment of SFMIO structures, which will depend on particle encapsulants. However, the time-varying decay of SFMIO signal is reassuringly mitigated by applied fields. Assuming scan speed is above a certain slew rate, SFMIO signal will be well maintained. In fact, this is consistent with previous investigations of SFMIO behaviour as a function of drive frequency [7] . Conclusion: This work investigated the signal evolution of SFMIO particles after polarization and structure formation, and found signal and remanence decay dependent on mechanical and mechanical agitation. Based on our results, SFMIOs should show minimal variability during standard MPI scans.

References: [1] Gleich B and Weizenecker J, Nat 2005; 435(7046) :1214-7 [2] Zheng B et al., Sci Rep 2015; 5:14055 [3] Chandrasekharan P et al., Nanotheranostics 2021; 5(2) :240-55 [4] Yu, E et al., Nano Letters 2017; 17 (3) :1648-54 [5] Yu, E et al., ACS Nano 2017; 11(12) :12067-76 [6] Tay ZW et al., Biomed Phys Eng Express, 2017; 3:035003 [7] Tay ZW, et al., Adv Mat. 2021;  in review [8] (B) ferucarbotran to (C) superferromagnetic iron oxide particles (SFMIOs). Superferromagnetism is thought to be due to (D) the positive feedback caused by local SFMIO interactions in tightly packed structures (E). Using (F) a home-built arbitrarywaveform relaxometer and (G) a custom pulse sequence that polarizes and reads out SFMIO structures with increasing delays, we characterized the evolution of these SFMIO structure after polarizations. (H) The particles were confirmed to be superferromagnetic with transmit amplitudes greater than 3 mT. (I) When read out using the pulse sequence from G, the SFMIO signal was observed to decay with increasing interpulse delays. When plotted against these interpulse delays (J) , this evolution was well fit by an exponential decay with a time constant of 120 ms. However, the signal was shown to asymptotically maintain SFMIO signal -even after 12 seconds (>> 5 decay constants) (K, top), an unshaken sample was observed to maintain superresolution behaviour. Only after agitation was the signal observed to return to SPIO like behaviour (K, bottom) . Finally, steady-state bias fields (L) were observed to greatly affect the decay constant and behaviour of the SFMIO structures. The slightest of fields parallel to the structure (assumed based on the most recent trapezoidal pulse) mitigated signal decay, and even slight fields anti-parallel to the structure greatly accelerated decay. This is thought to be due to the torque that anti-parallel fields yield on the structures, causing misalignment in similar manners to mechanical agitation. Abstract Body : Background: Prostate specific membrane antigen (PSMA) is a transmembrane protein in the cell membrane commonly upregulated in malignant and aggressive forms of prostate cancer (PC). Due to the overexpression of PSMA in PC, it has been extensively used as a target for diagnostic and therapeutic radiopharmaceuticals. The role and regulation of PSMA in PC are not entirely understood. Phosphatase and Tensin homolog (PTEN) is a phosphatase, a tumor suppressor gene that is frequently inactivated in aggressive PC. In the current study, we have explored the role of PTEN in regulating PSMA expression in PC cells. Methods: We studied prostate cancer cell lines LNCaP (PTEN-), LAPC4(PTEN+), and 22RV1 (PTEN+) using western blot and flow cytometry to determine the expression of PSMA and PTEN quantitatively. We generated 22RV1 PTEN CRISPR knockdown cell lines and analyzed PSMA uptake using a radiolabeled PSMA ligand ([177Lu]Lu-PSMA-11) compared to the controls. For in vivo studies, we xenografted 22RV1 PTEN shRNA knockdown cell lines into nude mice and analyzed the uptake of [68Ga]Ga-PSMA-11 ligand using PET imaging. Results: We observed an inverse correlation between PTEN and PSMA expression. LNCaP (PTEN -) has a high relative expression of PSMA compared to 22RV1 (PTEN +). PTEN knockdown in 22RV1 cells resulted in high PSMA expression at mRNA and protein level. PTEN loss also leads to a high uptake of [177Lu]Lu-PSMA-11, compared to the wild type control. In vivo PET imaging has shown a high uptake of radiolabeled PSMA-11 in 22RV1 PTEN shRNA tumor xenografts in mice compared to the control group. Conclusions: We found a strong correlation between PTEN loss and upregulation in PSMA in PC cell lines. These data indicate that PSMA imaging can be a potential biomarker to predict PTEN loss and aggressive PC. (1) . However, resistance to chemotherapy is the main mechanism for treatment failures. P-glycoprotein (P-gp) and Bcl-2 are major players in development of multi-drug resistance (MDR) in cancer cells (2) . P-gp acts as an efflux pump for a variety of compounds including some chemotherapies, while Bcl-2 helps cancer cell evade apoptosis. 99mTc-MIBI is a known transport substrate for P-gp in a variety of tumor cells (3) . It was hypothesized that the low avidity of breast lesion on early 99mTc-MIBI imaging could reflect a defective apoptotic signaling pathway, while an enhanced/fast tracer washout, after initial positive uptake, reflects the overexpression of membrane transporters such as P-gp (4) . The aim of the study is to histopathologically validate the correlation between 99mTc-MIBI uptake in LABC and molecular expression of P-gp and Bcl-2 before and after NAC. Methods Thirty-one female patients with biopsy-proven LABC (mean age: 45.7±11.6 yrs., range:23-70) underwent 99mTc-MIBI breast SPECT/CT before starting their scheduled NAC (injected dose: 813±48 MBq, prone position, early scan 30±6 min post-injection, late scan 117±15 min afterwards). 99mTc-MIBI breast SPECT/CT was repeated after finishing NAC and within 30 days before scheduled breast surgery (n=24). Different metrics of the lesion/non-lesion volume of interest (VOIs) were calculated for early and late images in addition to retention index ((late-early)/early*100). All quantitative metrics were transformed into percentile rank. Response to NAC was classified according to RECIST criteria. Evaluation of P-gp and Bcl-2 expression was graded on the pre-NAC biopsy and the surgical specimen post-NAC. Pathological response was evaluated using Miller-Payne system. Results On pretherapy studies, MIBI retention indices were significantly lower when P-gp was expressed (25±13 vs. 75±20, p = 0.008). The corresponding metrics from post-NAC study where not associated with P-gp expression. On the other hand, higher MIBI uptake on post-NAC studies was seen with higher Bcl-2 expression. Pgp intensity scores were significantly higher in the post-NAC specimens while Bcl-2 was generally downregulated after chemotherapy ( Figure 1 ). MIBI metrics on post-NAC scans were significantly higher in patients categorized as clinically progressed or stable disease compared to those with complete or partial response (75±17 vs. 46±29, respectively, p = 0.04) or pathologically grade 1-4 on Miller score compared to grade 5 (complete pathological response, 56±28 vs. 13±6, p = 0.04) Conclusions 99mTc-MIBI breast SPECT/CT could represent a useful in-vivo molecular imaging probe for non-invasive evaluation of important molecular markers related to multidrug resistance developing against neoadjuvant chemotherapeutic agents. Larger studies are warranted to further evaluate the utility of this tool.

Wei Wu, Stanford University, vvwu@stanford.edu Category: Oncology Abstract Body : INTRODUCTION: Glioblastoma multiforme (GBM) is a WHO grade IV brain tumor with 5-year survival of 7.2% in the United States1. The cancer is highly diverse thus effective therapies have not been forthcoming. Chimeric Antigen Receptor (CAR) T-Cells can be genetically modified to express surface ligands that target molecular surface markers on brain cancers2. CAR T-Cell Therapy has induced measurable response in patients with leukemia and lymphoma3, 4. However, CAR T-cell therapy alone has been ineffective in GBM due to its highly immunosuppressive microenvironment5. X-ray irradiation can render GBM receptive to immunotherapy6, 7. The absence of a clinically viable tracking technique for CAR T-cells has been recognized as a main hurdle to optimize CAR T cell therapy for GBM. MegaPro is an iron oxide nanoparticle which has passed a phase 2 clinical trial as an MRI contrast agent. By exploiting clinically translatable iron oxide nanoparticles, such as MegaPro, this study employs the modalities of magnetic resonance imaging (MRI) and magnetic particle imaging (MPI) for the in vivo tracking of CAR T-cells into preclinical models of glioblastomas. METHODS: Human U87-MG/eGFP-fLuc GBM were intracranially implanted into 7 NSG mice. Growth of tumor was monitored by Bioluminescence imaging (BLI). When the tumors had reached a BLI signal of ~108 photons/second, animals received two fractionated irradiations (4.5Gy each) of the whole brain. CD70CAR-CXCR2 T-cells and untargeted T-cells were labeled with MegaPro iron oxide nanoparticles. At day 7 after the irradiation, 4 mice were intracardiacally injected with nanoparticle labeled of CD70CAR-CXCR2 T-cells and 3 mice were intracardiacally injected with nanoparticle-labeled untargeted T cells, followed by serial BLI, MRI and MPI on day 1, 3 and 5 after the injection. RESULTS: After administration of therapeutic cells, MRI scanning showed a significant decline of the tumor T2-signal after treatment with nanoparticle labeled CD70CAR-CXCR2 T-cells ( Figure 1A ). The T2* relaxation time of GBM treated with ironlabeled CD70CAR-CXCR2 T-cells significantly decreased from 35.17 ± 3.31 ms at baseline (i.e. after irradiation but before treatment) to 17.35 ± 4.05 ms on day 5 post-treatment (P 0.05) ( Figure. 1B) . Similarly, MPI demonstrated a significant increase in MPI signal of GBM on day 5 (17.66 ± 1.29ug) after injection of iron oxide labeled CD70CAR-CXCR2 T-cells compared to baseline values (0.74 ± 0.36 ug) (P CONCLUSION: This study demonstrates the successful and specific tracking of CD70CAR-CXCR2 T-cells in glioblastoma through clinically translatable imaging technologies (MRI and MPI), which can be significant tools in the development and monitoring of effective CAR T-cell therapy.

Shanshan Tan, Johns Hopkins University, tanshanshan0425@gmail.com Category: Oncology Abstract Body : Introduction As gene-silencing agents, siRNA have significantly expanded the specificity and range of 'druggable' targets making them promising agents for precision medicine in cancer [1] . Effective delivery and cellular uptake, the major challenges in siRNA nanoparticle (NP) therapeutics, become even more challenging in cancer because of the complexities of the tumor microenvironment (TME) such as the abnormal vasculature. Studies directly relating NP delivery to function are necessary to understand how these NPs navigate through the TME, and to understand the impact of the TME on siRNA delivery and function [2] . Here we have used triple negative MDA-MB-231 human breast cancer xenografts derived from cells engineered to overexpress VEGF to understand the role of VEGF and vascularization in NP delivery and function. VEGF overexpression increases vascularization in these tumors [3] . We used polyethylenimine (PEI) NPs to deliver siRNA to downregulate choline kinase-alpha (Chka), an enzyme that is associated with malignant transformation and progression [4] . Methods Tumors were obtained by inoculating 1×106 MDA-MB-231 wild type cells, or MDA-MB-231 cells engineered to stably express VEGF, orthotopically in female SCID mice. PEI NP were labeled with Cy5.5 dye for optical imaging with a Pearl® Trilogy Small Animal Imaging System (LI-COR, Lincoln, NE). PEI NPs delivering Chka siRNA were administered intravenously with two doses of 3 nmol Chka siRNA given 24h apart, once tumors were ~ 300-400 mm3. In vivo and ex vivo optical imaging was used to track NP delivery and distribution within 6 wild type and 6 VEGF overexpressing tumors at 24h following injection of the second siRNA NP dose. RT-PCR and immunoblotting were used to evaluate Chkα levels in tumors excised at 24h after the injection of second dose. Results and Discussion Significantly higher Cy5.5 fluorescence intensity was observed in VEGF overexpressing MDA-MB-231 tumors compared to wild type MDA-MB-231 tumors as shown in the representative in vivo (Fig. 1A ) and ex vivo (Fig. 1B) images. Analysis of the tumor/muscle ratio demonstrated a significant increase of the intensity ratio in VEGF overexpressing tumors (Fig. 1C) . Representative ex vivo images of Cy5.5 intensities in organs (Fig. 1D ) that are summarized in Fig. 1E demonstrated that VEGF overexpression in tumors did not alter the biodistribution of the PEI NPs in these organs. RT-PCR analysis (Fig. 1F ) and immunoblots of tumors (Fig. 1G ) confirmed that the improved NP delivery in VEGF overexpressing tumors resulted in a significantly improved downregulation of Chka mRNA and protein. These data demonstrate the importance of vascular delivery in achieving successful target downregulation, and highlight the role of imaging in evaluating NP delivery. Our data indicate that strategies to improve vascular delivery of NPs in tumors are important in the use of siRNA to achieve gene-specific downregulation. is a clinically translatable PET (Positron Emission Tomography) biomarker for cell proliferation1. 18F-FLT-PET imaging has been extensively utilized to assess changes in tumor cell proliferation during chemotherapy, radiotherapy, or tyrosine kinase inhibition in pre-clinical models and clinical studies2. Here we demonstrate the utility of 18F-FLT-PET imaging in evaluating the pharmacodynamic effects of PF-07104091, a novel cyclin-dependent kinase 2 (CDK2) selective inhibitor in palbociclib-sensitive (MCF7) and -resistant (OVCAR3) xenograft tumor models. Specifically, we asked whether 18F-FLT PET imaging could differentiate between responsive and non-responsive tumor models. Methods: In vivo PET/CT imaging and/or ex vivo gamma counting was conducted in MCF-7 or OVCAR-3 tumor bearing NSG mice. Mice were treated with CDK inhibitors: Palbociclib (PD-0322991, a CDK 4/6 inhibitor) and PF-07104091 (a CDK2 inhibitor) for 4 days. On the 4th day, at 120 minutes post-dosing, 80 µCi 18F-FLT was dosed intravenously, and a 60-minute uptake period was allowed prior to imaging (conscious, ambient temperature). 18F peak-calibrated 10-minute PET scan was collected followed by 2minute co-registered CT scan (50 kVp, 200 µA). Gamma Counting was taken for ex-vivo tumor tissues. PET data analysis was performed using VivoQuant Software. Results: The Palbociclibsensitive MCF7 model demonstrated significant reduction of 18F-FLT uptake in both Palbociclib (CDK4/6i) (3.21 ± 0.58 vs 4.62 ± 0.31 %ID/cm3; p = 0.003) and PF-07104091 (CDK2i) (2.64 ± 0.47 vs 4.62 ± 0.31 %ID/cm3; p Palbociclib-resistant OVCAR3 model demonstrated significant reduction of 18F-FLT uptake only in the PF-07104091 (3.72 ± 0.77 vs 5.01 ± 0.81 %ID/g; p=0.0004) treated group. As expected, no significant inhibition was observed with palbociclib (4.5 ± 0.44 vs 4.64 ± 0.59 %ID/g) compared to the vehicle group (Data not shown). Furthermore, these data were well correlated with the immunohistochemistry biomarkers: pRb1 and Ki67. Conclusions: Together, these results demonstrate the utility of 18F-FLT-PET imaging as a noninvasive pharmacodynamic biomarker for CDK inhibition and can be used to differentiate responsive vs non-responsive tumors. These results also provide a motivation to evaluate 18F-FLT-PET imaging as a translational biomarker in the clinical evaluation of CDK inhibitors. Figure 1 : 18F-FLT-PET as a Biomarker for Tumor Proliferation for CDK inhibitors in MCF-7 (Breast Cancer) Xenografts (A)Representative in vivo 18F-FLT-PET images of MCF-7 tumor-bearing NSG mice. Tumors are indicated by red arrow. (B) Quantitative analysis of uptake in tumor Volumes of Interest (VOIs). Significantly reduced tumor 18F-FLT uptake (indicative of cell cycle inhibition) was observed 4 days post-treatment with PD-0322991 (Palbociclib: CDK4/6i) (p=0.003) and PF-07104091 (CDK2i) (p < 0 .001) compared to Vehicle.

Alessia Volpe, Memorial Sloan Kettering Cancer Center, VolpeA1@mskcc.org Category: Immunology: Inflammation & Infection Abstract Body : Introduction Non-invasive CAR-T cell-based immunotherapies can inform on in vivo distribution, fate and reasons for therapy success and failure in solid tumors. Endogenous reporter genes (such as hNIS, hNET and hSSTR2) are well suited for this purpose1 as they overcome potential immunogenicity of foreign reporters (HSV1-tk and mutants). However, their endogenous expression pattern as well as the distribution and in vivo clearance of their paired radiotracers could restrict the monitoring of the cell population of interest only to selected organs. Antibody fragments can be raised against radiolabeled DOTA derivatives and serve as artificial reporter genes.2 Here we describe the feasibility of a novel cell-surface anchored humanized antibody fragment as an artificial reporter gene with nanomolar affinity to 68Ga-and 64Cu-DOTA radiometal chelates, with the latter acting as reporter probes. Methods IgG-based humanized scFv antibody fragments with different specificity to DOTA derivatives of 68Ga-and 64Cu radionuclides were engineered using a yeast surface-display methodology. Selected membrane-anchored scFvs were subcloned into an SFG-retroviral vector to be stably transduced in the desired cell population. Reporter gene function was assessed by in vitro radioactive assays in C6 rat glioma (1.1uCi/106cells). Selected scFvs-based reporters were validated for in vivo radioactive uptake using 68Ga-DOTA/PET-afforded whole-body imaging in NSG males bearing subcutaneous C6 tumors. Ex vivo biodistribution and gamma counting of relevant organs was performed after the imaging session. Results Retrovirally transduced C6 cells stably expressing a panel of membrane-anchored scFv antibody fragments were incubated with 68Ga-(A) and 64Cu-DOTA (B) radiotracers for 30 min. Radiotracer uptake revealed that clones 18 and 22 have a higher binding affinity for 68Ga-DOTA, while clone 16 for 64Cu-DOTA. Specificity was demonstrated by using DOTA chelator, which does not have binding capabilities to any of the clones. Cell-surface scFv 18 and 22 reporters enabled in vivo tracking of engineered C6 glioma cells by 68Ga-DOTA-based nanoPET-CT (C). In vivo imaging showed an increase in tumor uptake (%ID/g: 1.85±0.07 SD for scFv 18; 0.26±0.08 SD for scFv 22), whereas no uptake was reported in wild-type C6 cells. As 68Ga-DOTA is rapidly cleared by renal excretion, the in vivo imaging resulted in high contrast in organs close to the tumor (e.g. 52-fold in heart and 37-fold lower SUV in lungs compared to C6 tumor expressing clone 18). Conclusions Our data suggest that the cell-surface antibody fragments 18 and 22 allow successful in vivo long-term tracking in a C6 tumor model. The scFv reporters act as artificial receptors for selective and irreversible binding to 68Ga-and 64Cu-radiolabeled DOTA derivatives. Further in vitro and in vivo characterization of tumor-specific T cells engineered to express the scFvs is required to confirm their suitability for in vivo tracking of cell-based immunotherapies. Comparison with existing endogenously expressed reporter genes will be also required to assess performance. Aknowledgements This work was supported by an NIH/NCI grant.

Akiva Mintz, Columbia University, am4754@cumc.columbia.edu Category: Neuroscience Abstract Body : Microtubules play a central role in brain physiology and in the pathogenesis of various central nervous system (CNS) disorders, including ALS, Alzheimer's Disease and psychiatric diseases. Microtubules are also a target for cancer chemotherapy. Thus, microtubules are a logical biomarker for imaging and pharmacological targeting, especially because the alterations in the cytoskeleton can occur at early stages of neurodegeneration. However, the lack of a central nervous system (CNS) microtubule imaging tracer that can penetrate the blood brain barrier (BBB) limits our understanding of the role of microtubules in disease progression and limits drug development. MPC-6827 is a high affinity small molecule (Ki 1.5 nM) that binds to the colchicine site of tubulin αβ heterodimers and is not a substrate for Pgp transporters. In preclinical studies, we radiolabeled MPC-6827 with 11C and demonstrated significant BBB penetration in rodents and non-human primates.

[11C]MPC-6827 manifested lower uptake in multiple preclinical models of brain diseases that involve perturbed microtubule dynamics, including ALS, Alzheimer's disease and alcohol use disorder. We hypothesized that [11C]MPC-6827 crosses the BBB in humans and has the potential to image early changes in human CNS disease. To test the potential of using [11C]MPC-6827 in humans, a first-in-human PET study was performed to validate BBB penetration and establish human dosimetry of [11C]MPC-6827. We successfully synthesized, optimized, and automated [11C]MPC-6827 production in a TRACERlab FX C Pro Chemistry Synthesizer under cGMP conditions. Preclinical dosimetry studies revealed hepatic clearance and robust brain uptake (SUVmax ~5). Based on the preclinical dosimetry and 3 manufacturing validation trials, an exploratory IND was obtained and 2 healthy controls were injected with 5-15 mCi of [11C]MPC-6827. Subjects were scanned continuously over a period of 90 minutes and dosimetry was calculated for all organs using OLINDA/EXM2.0 (Hermes). Scans revealed high brain uptake of [11C]MPC-6827, similar to what was seen in the preclinical studies. Clearance was hepatobiliary, and subsequent bowel activity detected. No adverse effects were reported. In conclusion, [11C]MPC-6827 demonstrated robust BBB penetration in humans and is therefore a promising PET tracer for diseases that involve altered microtubule dynamics, especially in the CNS. Abstract Body : Introduction: Integrin, a group of heterodimeric glycoproteins containing αVβ3 receptors are overexpressed on tumour cells and activated endothelial cells. It plays an important role in tumour growth, tumour mediated angiogenesis, inflammation etc. It is a suitable marker for angiogenesis because it is absent in resting endothelial cells and most normal organ systems. Tripeptide sequence containing Arg-Gly-Asp(RGD) shows high affinity and specificity towards αVβ3 receptors [1, 2, 3] . It has been shown that cyclization of linear RGD peptides and multimerization improved the binding affinity of RGD ligands for αVβ3. Radiolabelled RGD derivative plays an essential role in tumour angiogenesis imaging [4] . DOTA as a chelator provides thermodynamic as well as kinetic stability. It efficiently forms complexes with trivalent radiometals such as (68)Ga, (44)Sc, (90)Y, (177)Lu, (213)Bi, (225)Ac etc. Hence from a theranostics perspective DOTA should be the ideal chelator of choice [5] . This study was carried out to optimize radiolabelling procedure of dimeric cyclic RGD[c(RGD)2], using DOTA as bifunctional chelator with (68)Ga to obtain high labelling efficiency and study its in-vitro performance parameters. Materials and Methods: (68)Ga was obtained from ITGs (68)Ge/(68)Ga generator. Labelling was performed using 25 and 50 micrograms of peptide DOTA-[c(RGD)2] dissolved in 0.25M sodium acetate to obtain a total volume of 1mL. Peptide was heated at 95 C for 5 minutes followed by elution of (68)Ga with 4mL of 0.05M HCl. Peptide and eluate were heated for 10 minutes for 95 C. It was later passed through C-18 cartridge preconditioned with 70% of ethanol and normal saline and the cartridge was eluted with 50% ethanol. Labelled product was passed through 0.22µ millipore filter. Colour, appearance, pH of labelled product was checked. Radiochemical purity, stability and in-vitro serum stability were evaluated. Radiochemical Purity was determined in 0.1M trisodium citrate using ITLC-SG strips and 50% acetonitrile in Whatman3-MM chromatography paper at 30 minutes, 2 hours and 4 hours for 25 and 50 microgram of peptide. Serum stability of radiolabelled peptide studied for 1 hour and 2 hours for 25 and 50 microgram of peptide by adding (68)Ga-DOTA[c(RGD)2] into the blood sample. Serum was separated by centrifugation of the blood sample and protein precipitation was done by adding 50% acetonitrile after which it was again centrifuged. ITLC of supernatant was performed in 0.1M trisodium citrate using ITLC-SG strips. Result: The product yield in the labelling module was found to be 92. 825%±8.58(n=16) . Labelled product (68)Ga-DOTA[c(RGD)2] was colourless and non-turbid. pH of the product was 5.5 and of waste was 4. Labelled product remained at PS(Rf=0) with 0.1M trisodium citrate and at SF(Rf=0.8-0.9) using 50% acetonitrile. Radiochemical purity was greater than 97% for 25 and 50 microgram of peptide in both the solvents. Stability upto 4 hours was more than 92% for 25 and 50 microgram of peptide. Serum stability was greater than 90% upto 2 hours for 25 and 50 microgram of peptide. Conclusion: Theoretically,the ionic radius of gallium ion is too small to fit optimally in the DOTA cage and is said to make less stable complexes with (68)Ga. Inspite of this hypothesis, our results showed excellent stability upto 4 hours and good in-vitro serum stability which makes DOTA a stable chelating agent for RGD. Other in-vivo studies showed good blood clearance and tumour uptake with DOTA-RGD. Since the bifunctional chelator of choice for labelling RGD peptide with therapeutic radionuclides like (177)Lu, (90)Y, (213)Bi, (225)Ac etc. is DOTA. Using the same bifunctional chelator for (68)Ga labelling would give more meticulous and detailed biodistribution which will be beneficial for theranostic purposes especially for dose determination.

References: [1] Eliceiri BP, Cheresh DA. The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest. 1999 May;103 (9) Table 1 : % RCP for 68Ga DOTA RGD in 0.1M Trisodium Citrate at different time points using 25 micrograms of peptide Table 2 : % RCP for 68Ga DOTA RGD in 50% Acetonitrile at different time points using 25 micrograms of peptide Table 3 : Serum Stability in 0.1M Trisodium Citrate at different time points using 25 micrograms of peptide Table 4 : % RCP for 68Ga DOTA RGD in 0.1M Trisodium Citrate at different time points using 50 micrograms of peptide Table 5 : % RCP for 68Ga DOTA RGD in 50% Acetonitrile at different time points using 50 micrograms of peptide Abstract Body : Cerebrospinal fluid (CSF) plays an essential role in maintaining the homeostasis of the central nervous system, providing buoyancy to the brain, serving as an important route for the removal of a variety of waste products produced by cellular metabolism. The classic model believes that the choroid plexuses, provided by the anterior choroidal arterial blood inside the brain secrete CSF. After formation, CSF flows unidirectionally alongside subarachnoid spaces and is absorbed into venous sinuses. Despite its popularity, many experimental results are not consistent with this hypothesis. The lack of non-invasive techniques prohibits a detailed understanding of CSF flow and formation. Here, we present the first noninvasive magnetization transfer indirect spin labeling (MISL) MRI method to quantify in vivo ISF-CSF (ICF) flow in the mouse brain, giving revelational insights on CSF secretion and circulation. The principle of the MISL method is illustrated in Fig. (a) . The abundant macromolecules in the parenchyma were labeled, while the CSF signal was not attenuated due to the trace protein concentration (200 times lower than blood plasma). Protons in the macromolecules and water molecules constantly exchange in the parenchyma, through which water in the ISF was labeled by the magnetization transfer (MT) method. The ISF-CSF exchanging process was monitored by subtracting the label MRI at -3.5 ppm from the control MRI at 200 ppm, ∆Z. Two MISL sequences were studied. One focused on kinetic curve parameters (pulsed-MISL), while the other focused on high sensitivity imaging (continuous-MISL). In the pulsed MISL, a short selective pulse followed by a post-labeling delay before an MRI acquisition with a long echo time was implemented; in the continuous MISL, a train of saturation pulses was applied in the place of the selective pulse. MISL offered multi-slice ICF images with high sensitivity and quality. Fig. (c) is corresponding maps of a representative slide acquired with the continuous-MISL. The Virchow-Robinperivascular space (PVS), glymphatic vessels, and CSF distribution in the mouse brain were revealed with a high-resolution whole-brain turbo spin-echo (TSE) sequence in conjunction with a cryogenically cooled coil. Fig.(b) ICF (∆Z) Comparison between wild-type (WT) and aquaporin-4-knockout (AQP4-/-) mice were performed to examine the contributions of ICF, while the age-dependent ICF was investigated by comparing the adult and young WT mice. The pulsed MISL method observed rapid occurrence of ICF during the saturation pulse, and the ICF signal reached the maximum at 1.5 s. Region of interests is labeled in Fig.(b) . The continuous MISL method showed the highest ICF in the fourth ventricle (∆Z =13.5±1.4%), while the third ventricle and the lateral ventricles had similar ICF ∆Z values (∆Z =12.0±1.8%). The current study showed an evident reduction of CSF recirculation related to aged brain ventricles. A significantly lower ∆Z (9.3-18.7% reduction) was found in all ventricles for the adult mice (9-10 months) than those of the young mice (2-3 months) (pWe presented magnetization transfer indirect spin labeling (MISL) as a new translational MRI scheme to quantify in vivo ISF-CSF flow in the mouse. MISL offered multi-slice ICF images with high sensitivity and quality. We demonstrated the feasibility of using MISL to study age-dependent and AQP4-dependent ICF differences. MISL is an applicable tool to study CSF and ISF exchange in the brain. The results also suggested that the novel MISL method has a far-reaching impact on studying, diagnosing, and treating a range of brain diseases, given their association with CSF.

References: 1. Abate O, Bollo E, Lotti D, Bo S. Cytological, immunocytochemical and biochemical cerebrospinal fluid investigations in selected central nervous system disorders of dogs. Zentralbl Veterinarmed B 1998; 45 (2) (7) Abstract Body : Introduction Pleural and peritoneal mesothelioma are the most common types of mesothelioma in the US, accounting for more than 150,000 new cases each year. Mesothelin (MSLN) expressing mesothelioma is less likely to respond to conventional therapies and is associated with poor survival. MSLN-targeted chimeric antigen receptor (CAR)-T cell therapy proved to be effective both alone or as a combinatorial treatment.1 However, the therapeutic effect is only restricted to MSLN+ tumors. The TNF-related apoptosis-inducing ligand (TRAIL) exhibits a strong anti-tumor activity in several mouse xenograft models of human cancers and in clinical trials.2 Here we propose a new strategy for tumor sensitization to adoptive T cell immunotherapies based on membrane bound (overexpressed) TRAIL or secreted (soluble) TRAIL by MSLN-directed CAR-T cells to augment targeting and effector function in a model of MSTO-211H human metastatic pleural mesothelioma. Methods A membrane-bound (MB-) and a series of soluble (s-) TRAILs with active trimerization motifs coupled with a MSLN-directed CAR (M28z) were retrovirally transduced in human T lymphocytes. The transduced CAR-T cells were characterized in vitro for IFN-gamma release and tumor cell killing. CAR-T cells and MSLN+ and MSLN-cancer cells were engineered with maCluc, CBG and RLuc independent bioluminescence reporters, respectively, thereby enabling long-term in vivo whole-body bioluminescence imaging (BLI) of all three transduced populations within the same animal.3 MSTO-211H human metastatic pleural mesothelioma tumors with heterogeneous expression of MSLN were established in young adult male NSG mice by intra-peritoneal injection. 5x105 CAR-T cells was regionally administered at day 9 post tumor establishment. In vivo BLI imaging of MSLN+ and MSLN-tumors allowed a reliable assessment of the therapeutic efficacy of TRAIL-MSLN-directed CAR-T cells and correlated that to CAR-T cell kinetics. Ex vivo histology validated the in vivo imaging findings. Results All CAR-T cells showed an in vitro tumoricidal activity against MSLN+ cells (Figure 1 -A) due to anti-MSLN CAR::MSLN engagement. However, only MB-and s-TRAIL M28z CAR-T cells resulted in a progressive and highly statistically significant depletion of MSLN-cells (B) due to TRAILinduced apoptosis (at 72h: M28z p = 0.001; MB-TRAIL p The triple BLI reporter imaging approach allowed visualization of MSLN+ tumor regression, followed by complete eradication 21 days post CAR-T cells administration (C/green). The response was durable and with no sign of relapse in all groups (D). In vivo CAR-T cell imaging confirmed that the robust and early antitumor activity at the MSLN+ tumor correlates with CAR-T cell accumulation (C-bottom/blue and C-top/green). M28z CAR-T cells failed to cure the non-antigen expressing tumor cells (C/orange, left panel), resulting in tumor progression and death (E/grey). Only animals treated with MB-and s-TRAIL M28z CAR-T cells showed a progressive reduction of MSLN-tumor burden due to the TRAIL-mediated tumor targeting and proapoptotic effect (C/orange, middle and right panel; D). MB-and s-TRAIL-mediated M28z CAR-T cells show an increase in animal median survival compared to mice that received only MSLN-targeted CAR-T cells (46 and undefined vs 40 days; p = 0.1048 and Conclusions We proved that our new TRAIL-mediated mesothelin-specific CAR-T cell strategy is superior to the already therapeutic MSLN-targeted CAR-T cells by providing additional proapoptotic stimuli to both antigen positive and negative tumor targets, thereby enhancing anti-tumor targeting and improving overall response. The TRAIL-MSLN CAR-T cell approach could provide a readily translatable treatment opportunity to patients with mesothelioma. Acknowledgements This work was supported by an NIH/NCI grant and by the EIO Fellowship Award from the Center for Experimental Immuno-Oncology (FP00001443, MSKCC). Abstract Body : Introduction Cadherin-17 (CDH17) is a calcium-dependent adhesion protein that is over-expressed by a variety of malignancies, including gastrointestinal, pancreatic, and colorectal cancers. Critically, high levels of CDH17 have been linked to metastatic spread and poor prognosis in patients with these three cancers. In addition, CDH17 has also recently attracted interest as a therapeutic target.1,2 In this investigation, we have leveraged a CDH17targeted monoclonal antibody -D2101 -to create a radioimmunoconjugate for the PET imaging of CDH17 expression in pancreatic ductal adenocarcinoma (PDAC). More specifically, we report the modification of D2101 with the chelator desferrioxamine (DFO), the radiolabeling of DFO-D2101 with the positron-emitting radiometal zirconium-89 (89Zr), and the functional characterization of the resulting radioimmunoconjugate, [89Zr]-Zr-DFO-D2101. Finally, we have used PET imaging and biodistribution experiments to validate the in vivo performance of [89Zr]-Zr-DFO-D2101 in a murine model of PDAC. Methods The CDH17-targeting mAb D2101 was modified using a stochastic approach with p-SCN-Bn-DFO. The resulting immunoconjugate -DFO-D2101 -was then radiolabeled with zirconium-89 (t1/2 ~3.3 days) and purified with size-exclusion chromatography to produce [89Zr]Zr-DFO-D2101. The stability of this radioimmunoconjugate in human serum was interrogated via radio-instant thin layer chromatography and size-exclusion HPLC, and the immunoreactivity of the construct was determined using Ni-NTA beads coated with CDH17. For the in vivo validation experiments, [89Zr]Zr-DFO-D2101 was administered to athymic nude mice bearing subcutaneous AsPC-1 human PDAC xenografts, and PET images were acquired at 24, 48, 72, 96, and 120 hours postinjection. After the final imaging time point, the mice were euthanized, and the xenografts and other selected tissues were harvested, washed, dried, and analyzed on a gamma counter to generate quantitative biodistribution data. [89Zr]Zr-DFO-huIgG was employed as a non-specific isotype control radioimmunoconjugate for all in vivo studies. Results DFO-D2101 was prepared with a degree of labeling of 1.1 DFO/mAb. Subsequently, [89Zr]Zr-DFO-D2101 was synthesized with >95% radiochemical yield and >99% radiochemical purity. This radioimmunoconjugate remained >80% intact over 6 days in human serum at 37°C and exhibited an immunoreactivity of >89% with CDH17 coated beads. PET imaging experiments using mice bearing subcutaneous AsPC-1 xenografts revealed that [89Zr]Zr-DFO-D2101 is capable of delineating CDH17-expressing tumor tissues with high tumor-to-background contrast. By 120 hours post-injection, the radioimmunoconjugate produced a tumoral uptake of >21 %ID/g, while the blood and liver were the healthy tissues with the highest activity concentrations. In contrast, [89Zr]Zr-DFO-huIgG displayed low tumoral accretion throughout the experiment. Conclusion The data suggest that [89Zr]Zr-DFO-D2101 could be an effective agent for the diagnostic and theranostic PET imaging of CDH17-expressing malignancies. We are currently working on the validation of [89Zr]Zr-DFO-D2101 in more advanced models of pancreatic and gastric cancer as well as the development of D2101-based radioimmunoconjugates for radioimmunotherapy. Abstract Body : Introduction: Spinal cord injury (SCI) caused by trauma to the vertebral column affects motorsensory, cognitive, and emotional functions. Although current clinical anatomic imaging methods such as X-ray, CT, and MRI provide valuable information on the integrity of the spine, the critical physiological and pathological information on the spinal cord (SC) is missing, and disease severity can only be estimated by subjective functional tests. PET imaging of synaptic vesicle glycoprotein 2A (SV2A), a synaptic biomarker, has been used in measuring synaptic density changes in neuropsychiatric diseases.1 Because SCI affects synaptic plasticity in both SC and brain,2-5 in this study, we explored the uptake of the novel SV2A tracer [18F] SynVesT-1 in SC and relevant brain regions in a rat model of sub-acute SCI, for the first time. Methods: SCI was generated at T7 in female Sprague-Dawley rats (sham vs. SCI, n=4/group) using MASCIS impactor (10 g, 25 mm). All the rats were assessed daily for locomotor performance and underwent a PET/CT scan on an Inveon PET/CT scanner at day 10-11 post injury as illustrated in Fig.1A . A 60 min-PET scan was performed after intravenous injection of [18F] SynVesT-1 (15~22 MBq) with/ without the blocking drug levetiracetam (30 mg/kg), followed by a 10-min CT scan for attenuation correction and spinal region of interest (ROI) definition. After imaging, SCs were procured with/without paraformalydehyde perfusion. Confocal immunofluorescence staining and capilary electrophoresis western blotting (WES) of SV2A were applied to detect synaptic changes. The reconstructed PET data were analyzed using IDL software to generate standardized uptake values (SUVs) for the ROIs. Four ROIs (1) (2) (3) (4) representing SC regions of C1-C7, Th1-Th5, Th6-Th10, and Th11-L2 were drawn by referencing the individual CT. The SUVs of ROIs were normalized by the SUVs of ROI-1 to generate SUV ratio (SUVR). SUVRs from 0-10 min and 30-60 min post tracer injection were chosen to evaluate blood flow and SV2A levels, respectively. Brain regions including amygdala, brainstem, hippocampus, limbic insular cortex, motor sensory cortex, striatum, and cerebellum were defined using a rat brain atlas and analyzed to determine mean SUVR(30-60 min) with brain stem and spinal ROI-1 as the reference region, respectively. Results: Compared to sham controls, SCI caused the loss of motor/sensory functions below the injured site. No visible lesion was observed on SC of SCI rats. [18F] SynVesT-1 exhibits high specific uptake in the SC secondary to the brain, as demonstrated by levetiracetam blocking experiments. Interestingly, the uptake of [18F] SynVesT-1 is heterogenous across SC, with ROI-3 the lowest (Fig.1B) , suggesting the uneven synaptic densities along the entire SC. The SUVRs of both 0-10 min and 30-60 min show 30-35% decrease in ROI-3 in SCI rats compared to sham rats (Fig.1C, D) . WES results indicate a substantial decrease of SV2A in the injury epicenter. Importantly, the decrease of SV2A is also seen in lower thoracic and lumbar regions of SCI rats compared to sham controls. Using confocal immunofluorescence staining of SV2A, we found decreased SV2A in the laminae of dorsal horn (Fig.1E) , corroborating the PET imaging and WES results. The SUVRs of selected brain regions are consistent between using brain stem and spinal ROI-1 as reference region. Amygdala, limbic insular cortex, and motor sensory cortex exhibited a trend of decreased SUVR, while no difference was seen in the hippocampus, striatum, and whole cerebellum. Conclusions: Using [18F] SynVesT-1 and PET/CT imaging, we have, for the first time, detected synapse loss in SCI rat model, with certain brain regions showing lower tracer uptake as well. A larger scale study with various clinical stages of SCI is under way. Our results indicate that SV2A PET imaging may track the synaptic plasticity after SCI and may provide guidance for the clinical interventions. Spinal cord contusion injury was made on day 0, animals were scanned on day 10-11, and spinal cord tissues with injury site were collected on day 11-12. (B) Representative [18F] SynVesT-1 PET images of SCI rat compared to sham control with an intact spinal cord. Images were generated using maximum intensity projection method. Uptake at 30-60 minute is illustrated. Regions of interest (ROI 1-4) were drawn by referencing the corresponding CT image. ROI-1: C1-C7; ROI-2: Th1-Th5; ROI-3: Th6-Th10; ROI-4: Th11-L2, as indicated in the figure. C: cervical; Th: thoracic; L: lumbar spine. The reduced uptake in the thoracic cord (ROI-3: Th6-Th10) is indicated by the blue circle. (C, D) The SUV ratios (SUVR) of 0-10 min (C) and 30-60 min (D) were obtained from four ROIs normalized to ROI-1 of each rat as indicated in panel A. Data were from two rats for each experimental paradigm. (E) SV2A immunofluorescence staining in the spinal cords of SCI and sham control rats. Decrease in SV2A staining signals can be seen in the SCI spinal cord compared to the control. The SV2A signal is substantially lower in the dorsal laminae, as pointed by the blue arrows. Contusion injury on the dorsal side also caused inflammation and necrosis as indicated by the red arrows. Spinal cord sections (30 um) are from rostral, lesion, and caudal site of the spinal cord. Rostral and caudal sections were from either 6 mm above or 6 mm below the lesion site. Pictures were taken from Leica confocal microscope. 10x. Abstract Body : Introduction: The enzyme poly(ADP-ribose) polymerase-1 (PARP1) is overexpressed in glioblastoma and its levels show positive correlation with tumor grades in gliomas, such as proneural and classical glioblastoma multiforme (GBM) subtypes [1] . PARP1 inhibitors (PARPis) are actively pursued as treatments for brain tumors [2] . It is key to stratify glioma patients who will potentially benefit from PARPi-based therapeutics from others. The noninvasive quantification of PARP1 expression using Positron Emission Tomography (PET) may fulfil this need and facilitate the implementation of PARPi based clinical trials. Currently, there is no PARP1 imaging agent available that is brain penetrant, making the in vivo quantification of PARP1 in the brain challenging. Herein, we report the pharmacokinetic modeling and correlative analyses of the novel PARP1 radioligand [11C]PyBic in an RG2 glioma rat model and in a healthy nonhuman primate (NHP). Methods: [11C]PyBic is derived from the PARP1 veliparib and synthesized from its desmethyl precursor by radiolabeling with [11C]Mel. RG2 glioma bearing Fischer 344 rats underwent 60-90 min dynamic scans on the FOCUS -220 scanner after intravenous injection of [11C]PyBic (20.7-35.1 MBq) with or without blocking drug veliparib (5 mg/kg), followed by ex vivo biodistribution (BioD) and PARP1 immunostaining and western blotting analyses (baseline, n = 4/5; blocking, n = 3/4), as described before [3] . Distribution volume ratio (DVR) was calculated by kinect modeling using the simplified reference tissue (SRTM) method, with brain stem as the pseudo reference region, and the correlaton analysis between DVR and western blotting and BioD results was carried out to verify the imaging findings. In addition, a healthy rhesus monkey was injected with [11C]PyBic (159 MBq) and scanned for 2 h , with arterial blood samples collected at 5, 15, 60 min after radiotracer injection for radiometabolite analysis. Summed images of standardized uptake value (SUV) were derived to evaluate the brain penetration of the tracer in NHP. Results: Among tumors and the selected brain subregions, [11C]PyBic showed highest uptake in tumor (DVR: 3.07 ± 0.15, n = 4) (Fig. 1A) . The averaged tumor DVR was decreased significantly (1.73 ± 0.14, n = 4, p = 0.049) in blocking scans. Biodistribution analysis indicates that [11C]PyBic had the highest uptake in tumor (0.85 ± 0.3%ID/g, n = 4) and spleen (2.85 ± 0.3%ID/g, n = 4), which was reduced by 75% (n = 3, p = 0.020) and 74% (n = 4, p = 0.0004), respectively, with preadministration of veliparib (Fig. 1B) . The in vivo PET imaging results were corroborated by ex vivo biodistribution data (Y=0.4028*X-0.2594, R2 = 0.9413, Fig. 1C ) and western blotting results (Y=167536*X-58717, R2 = 0.5853, Fig. 1D ). In the rhesus monkey, summed PET SUV images from the early time (10-20 min) and late time (60-90 min) windows showed fast tracer entrance to the brain and sustained retention in the cerebrum (Fig. 1E ). All brain regions showed similar levels of uptake of the tracer (SUV ~ 1), with cerebellum being the highest, followed by occipital cortex, frontal cortex and globus pallidus showing the lowest tracer uptake. Conclusions: We have developed a novel brain penetrant PARP radiotracer and demonstrated its entry into the brain and elevated uptake in tumor. This is the first report of a brain penetrant PET radioligand suitable for glioma imaging. Abstract Body : The early stage of oral cancer is mainly treated with surgery and radiotherapy1, compared to facial disfigurement, radiotherapy brings reversible side-effects like xerostomia, making it a more favored treatment. However, radiotherapy-induced radioresistance often contributes to treatment failure and we shall seek methods to increase the tumor radiosensitivity. Gold nanoparticles (AuNPs) have been applied to multiple biomedical fields like drug delivery and radiosensitivity elevation2,3. Hence, tumor-specific AuNPs delivery should enhance the efficacy of radiotherapy. In the current study, macrophages are chosen as tumor-specific carriers to deliver AuNPs to the tumor microenvironment based on their excellent endocytosis ability4 and tumor-homing nature5.AuNPs ( 6, particles remained stable for at least three months under cold storage. Co-incubation of murine macrophage cells Raw264.7 with AuNPs (Raw_AuNPs) verified the uptake of AuNPs. Raw_AuNPs retained the migratory ability toward cancer cells as shown by transwell assay. With clonogenic assay, AuNPs exerted a modest radiosensitization effect on murine OSCC cell line MTCQ1. Before animal experiments, macrophages were intravenously injected into C57BL/6 mice for safety evaluation. By fluorescence-labeling and imaging with an optical imaging instrument, we found that a max amount of macrophages accumulated at the tumor site within six days after injection. The tumor tissues were analyzed with flow cytometry -control group, radiotherapy only, and Raw cell injected showed gradually elevated T cell infiltration. We are now working on the therapeutic efficacy of combining radiotherapy with Raw_AuNPs injection. The tumor-draining lymph node and spleen will also be analyzed to get more information about the impact on the immune system with macrophage injection. To be more clinically translatable, we have isolated bone marrow cells from C57BL/6 mice and differentiated them into bone marrow-differentiated macrophages (BMDMs). So far, we confirmed that BMDMs showed superior AuNPs uptake(BMDM_AuNPs) and tolerance to AuNPs with the MTT assay. In future experiments, we will investigate the influence of BMDM_AuNPs on tumor progression combining with radiotherapy in vitro and in vivo. Abstract Body : Background: Neuroinflammation is mediated by activated microglia and astrocytes and is a key determinant of pathophysiology of many neurological disorders, including cerebral palsy, traumatic brain injury and meningitis. Targeting neuroinflammation is difficult due to challenges overcoming the blood brain barrier to achieve therapeutic brain concentrations. Additionally, the ability to monitor response to treatment is urgently needed for novel therapeutic target investigation and future clinical translation. Hydroxyl polyamidoamine (PAMAM) dendrimers, small nanoparticles with tree-like structures and multifunctional terminal branches, deliver conjugated drugs directly to activated microglia/astrocytes proportional to disease severity (Nance et al 2016). In several models of neuroinflammation, such as cerebral palsy, dendrimers conjugated to N-acetyl-cysteine (D-NAC) have improved survival and neurological outcomes (Kannan et al 2012). Additionally, dendrimer's flexible terminal groups are ideal for conjugation of imaging ligands, such as positron emission tomography (PET) radiotracers, to create a theranostic dendrimer that simultaneously delivers therapy and monitors response to treatment. We radiolabeled the PAMAM dendrimer and performed 124I-Dendrimer PET/computed tomography (CT) imaging of rabbits with and without cerebral palsy to noninvasively monitor pharmacokinetic biodistribution of dendrimer as the first step in creating a theranostic dendrimer. Objective: To noninvasively monitor the pharmacokinetic biodistribution of radiolabeled dendrimer in young rabbits, both healthy and those with neuroinflammation secondary to cerebral palsy. Methods: The synthesis of radiolabeled 124I-Dendrimer was carried out by reacting 124I-benzamide-tetraethyleneglycol-azide with alkyne terminating dendrimer (Dhexyne) using a highly efficient copper (I) catalyzed alkyne-azide click chemistry approach. Young healthy (n=2) and experimentally-induced cerebral palsy (i.e., lipopolysaccharide intrauterine exposure, n=5) rabbits were imaged noninvasively with PET/CT at 1, 4 and 24 hours after intravenous injection of 124I-Dendrimer. Dynamic PET imaging was performed for 60 mins in one cerebral palsy rabbit. Regions of interest for all organs, including several compartments within the brain (i.e., periventricular region, cerebellum and brainstem), were calculated and brain regions were corected for cerebral blood volume. Data were presented as tissue/plasma ratios (median ± IQR). Results: Young rabbits tolerated intravenous injection with 14.02 ± 7.23 MBq of 124I-Dendrimer. Serial PET imaging demonstrated that radiolabeled PAMAM dendrimer had similar biodistribution as fluorescently labeled dendrimer, and remained radiolabeled for at least 24 hours. There was no difference overtime between healthy and cerebral palsy rabbits in kidney, liver or spleen biodistribution with rapid renal accumulation and excretion into the bladder. As expected, all 124I-Dendrimer brain/plasma ratios increased overtime, reflecting the accumulation of dendrimer within in the brain and decreasing levels in the plasma via renal excretion. Additionally, there was a trend toward increased accumulation in brains with neuroinflammation (cerebral palsy rabbits), especially the brainstem at 4 hours (P = 0.059, unpaired t-test), although this did not reach statistical significance. Conclusions: Highly efficient click chemistry technique was used to synthesize radioiodinated dendrimer that could be visualized noninvasively with PET imaging up to 24 hours after radiotracer injection. 124I-Dendrimer had similar pharmacokinetic biodistribution compared to unlabeled dendrimer, with increased accumulation in the brain regions overtime. Successful radiolabeling and noninvasive PET imaging of the dendrimer biodistribution is an important step toward synthesis and utilization of a theranostic dendrimer that could simultaneously deliver therapy and monitor response to treatment. Future studies will work to combine radiolabeling and drug conjugation of the dendrimer to build the theranostic dendrimer. representative rabbit with cerebral palsy demonstrate rapid renal accumulation and excretion into the bladder as well as accumulation in the spleen. Quantification of radioactivity (Bq/mL) in tissues of the same rabbit is shown overtime (right). C) Representative MIP with regions of interest is shown on the left. Tissue-to-plasma ratios were calculated based on these regions of interest, demonstrating 124I-Dendimer accumulation in the kidneys and spleen. There are no apparent differences in biodistribution to kidneys, spleen or liver between healthy and cerebral palsy rabbits. D) Representative MIP with regions of interest is shown on the far left. Brain/plasma ratio in the periventricular region (left), cerebellum (middle) and brainstem (right) demonstrate accumulation in the brain overtime, with a trend toward increased accumulation in cerebral palsy rabbits. Data are represented as median ± IQR. Abstract Body : Background: Epilepsy is one of the most common neurological disorders in children, 20% of which are drug-resistant and should be considered for epilepsy surgery. Statistical Parametric Mapping (SPM) has been used to assist visual assessment of 18F-FDG PET in epileptogenic focus localization. However, the standard SPM process depends on adult template for spatial normalization, which is not appropriate for pediatric image analysis due to large anatomical and metabolic differences between pediatric and adult brains. Objective: This study aimed to develop pediatric age-specific 18F-FDG PET template to improve epileptogenic focus localization in pediatric patients with epilepsy. Methods: We retrospectively recruited 40 pediatric patients (19 girls and 21 boys, age 12.5 ± 3.4 years) who underwent epilepsy surgery in our hospital. These patients were postsurgical seizure-free according to Engel classification criteria (mean follow-up = 2.26 y). Sixty-seven age-matched children with normal brain metabolism (21 girls and 46 boys, age 13.1 ± 3.4 years) were retrospectively included as pseudocontrols. All subjects fasted at least 6 h before PET examination. Subjects were injected with a standard dose of 18F-FDG PET (3.8 MBq/kg) followed by a 40-mins glucose uptake period, and then underwent 5-mins three-dimension brain scan. Pediatric age-specific 18F-FDG PET templates were created for two age ranges (6 -10 y and 11 -18 y) by using an iterative registration-averaging optimization approach. This optimization approach iterated between registration and averaging steps. The registration step transformed all control PET images into an approximated template space. The averaging step computed average non-rigid components of inverse transformation as residual error, corrected transformations by composing the residual error, and averaged transformed images as approximated template in the next iteration. All 18F-FDG PET images of epilepsy patients were spatially normalized to the age-specific PET template, and smoothed by using a 4-mm full-width-half-maximum Gaussian kernel. Standardized uptake value ratios (SUVRs) were determined by using the cerebellum gray matter as the reference. Metabolic abnormalities were detected by SPM voxel-wise analysis. Clusters of contiguous voxels with P Results: Figure A showed the pediatric age-specific 18F-FDG PET template we developed for the two age ranges. The age-specific template-based analysis achieved a substantial agreement with surgical resection areas (Kappa = 0.743), while that based on adult template achieved only moderate agreements (Kappa = 0.469). Analysis based on the pediatric template accurately localized epileptogenic foci in 80% (32/40) of patients, significantly better than that based on the adult template (55.0%, P = 0.004) ( Figure B ). Figure Abstract Body : Bioluminescence imaging is a versatile technique for examining cellular and molecular features in preclinical models. The scope of this technology has grown in recent years with advances in luciferase engineering and luciferin probe design. Several of these advances will be highlighted, including the development of tools for multi-component imaging and metabolite sensing. This talk will further showcase new discoveries and research pursuits enabled by the expanding bioluminescent toolkit.

Last Name: Prescher Email: jpresche@uci.edu

Haris Smailovic, Lawson Health Research Institute, hsmailov@uwo.ca

Abstract Body : Introduction: Currently, PET imaging, using the tracer 18F-fluorodeoxiglucose (FDG), a glucose analogue, is the standard for assessment of myocardial inflammation. FDG is taken up by invading macrophages in response to myocardial injury and is increasingly used for the detection of cellularly-mediated cardiac inflammation, particularly in sarcoidosis and, more recently, in myocardial infarction1. However, FDG is also taken up by cardiomyocytes. To differentiate between myocyte and inflammatory cell uptake, suppression of myocyte glucose uptake is needed. Suppression of glucose uptake is accomplished through a combination of dietary modification, fasting, injection of heparin and sometimes lipid infusion. Restrictions of diet and management of blood glucose levels are especially important and challenging in diabetic patients and requires meticulous patient preparation. However, despite the best efforts of the patient this technique is not without problems and may still result in inadequate myocardial glucose suppression2. The development of a specific agent to assess inflammation, without the confounding effects of myocardial uptake, would be a significant improvement. 18F-FEPPA is a ligand for the mitochondrial translocator protein of 18 kDa (TSPO) expressed in various mitochondria-rich cells, including activated macrophages and neutrophils. Elevated levels of 18F-GE180, an alternative TSPO tracer, has been shown to have increased uptake in the infarct 1-week post myocardial infarction (MI)3. It is our hypothesis that 18F-FEPPA will allow quantitative imaging of inflammatory cells within the myocardium without the need for the extensive suppression techniques. Methods: 8 healthy canines were imaged with hybrid PET/MRI using a Siemens Biograph mMR twice at baseline with FDG and 18F-FEPPA, four days post-MI with FDG, and five days post-MI with 18F-FEPPA. For FDG scans, glucose suppression was achieved with fasting, heparin injection, lipid infusion and animals were imaged for 60 minutes. FEPPA scans were conducted for 60 minutes following the bolus injections. An MI was generated by an occlusion of the left anterior descending artery, followed by reperfusion after 3 hours. 3D Slicer was used to quantify the standardized uptake value (SUV) in specific regions of interest for both 18F-FEPPA and FDG. Blood samples were taken and analyzed for parent 18F-FEPPA and metabolites. Animals were euthanized and myocardial tissue samples were taken for histology. Results: For FDG, suppression was successful, and as expected, shows the highest mean SUV in the infarcted tissue. For 18F-FEPPA, mean SUV in the baseline heart tissue rises slowly over time throughout the duration of the scan. Interestingly, 5 days post-MI, 18F-FEPPA concentration quickly rises until it reaches a peak in remote and infarcted myocardium at 20 minutes into the scan and then decreases for the remaining 40 minutes. At 20 minutes, for 18F-FEPPA: remote non-infarcted tissue is higher than both infarcted (p Conclusion: These results are the first to test 18F-FEPPA in a canine model of myocardial infarction. In the heart, there is high TSPO expression by mitochondria-rich cardiomyocytes and so loss of these myocytes may explain the lack of uptake in the infarct. Thackeray et. al, showed in a mouse model of MI an elevated myocardial TSPO signal 8 weeks post-MI in the remote myocardium in the absence of inflammatory cells3. Their study and ours may suggest myocyte mitochondrial changes occurring due to myocyte insult. Overall, it suggests that the results from FEPPA are not equivalent to those from FDG, rather that these tracers are complementary. Next steps include a) kinetic analysis with a suitable compartment model, b) tissue analysis for TSPO and macrophage presence and c) validation in humans. Abstract Body : Introduction: The extracellular pH (pHe) of solid tumors is often acidic, as a consequence of the Warburg effect, an altered metabolic state often associated with malignancy. It has been shown that acidosis can promote tumor progression, thus neutralization of the pHe is a therapeutic strategy that has been explored to inhibit invasion and metastasis, improve immune surveillance and overcome resistance to chemotherapies [1] . Chemical exchange saturation transfer magnetic resonance imaging (CEST MRI) is a noninvasive technique that can accurately measure pHe in vivo using contrast agents that contains amide group protons, such as Iopamidol. Those amide protons resonate at 4.2 and 5.5 ppm with pH dependent exchange rates, which provides a basis for establishing the ratiometric approach to determine pH [2] . Iopamidol is clinically used as a contrast agent in Computed Tomography (CT) and safely administered intravenously (IV). However, repeated IV catheterization that are necessary for longitudinal measurements in pre-clinical studies frequently cause venous thrombosis and wounds of the tail interfering with further injections. In this study we have optimized the intraperitoneal (IP) delivery of iopamidol to facilitate longitudinal assessments of orthotopic pancreatic tumor pHe by CEST MRI. Methods: Pancreatic tumor models were developed by injecting KPC961 tumor cells orthotopically in B6.129 mice. CT in vitro studies with different concentrations of iopamidol were performed to establish a linear calibration of signal versus concentration. Preand post-contrast CT time course imaging was used to evaluate the uptake and intratumor concentration of iopamidol, following IV-infusion and IP bolus injection protocols. Intensity mean values were extracted by drawing a region of interest (ROI) around the tumor in the CT images and pre-contrast images were used as background. In vivo CEST-MRI was performed following IV-infusion and IP injection protocols, on a Bruker 7T MRI scanner using a 1H 30 mm M2M coil, using the protocol described in [2] with modifications. The acquisition time for a single Z-spectrum was 4 min 36 sec, and it was acquired once before contrast and up to 8 times post-contrast. CEST images were analyzed using MATLAB with a handmade script based on a multipool Lorentzian fitting to establish iopamidol contribution at 4.2 and 5.5 ppm. pH values were determined interpolating the ratio between the two frequencies to a calibration curve obtained from in vitro experiments performed with 20 mM iopamidol solution at different pHs. Results: CT results showed that an IV bolus (200 µl) followed by infusion at 400 µl/hr provided a continuous uptake increase, delivering up to 10 mM of iopamidol within tumors, 25 min postinjection ( Fig. 1A) , while the IP injection delivered concentrations around 7 mM, 40 min postinjection (Fig. 1B) . CEST MRI results showed that these time points (25 min for IV-infusion and 40 min for IP) showed the lowest standard deviation (STD) of the pHe values between mice (0.08 pH units for IV-infusion and 0.07 pH units for IP). When comparing the average pHe values measured at these time points between IV-infusion and IP, the difference was 0.07 ± 0.06 pH units (pHe = 6.79 for IV-infusion vs pHe = 6.87 for IP; p = 0.30), indicating that both injection protocols produced comparable measurements of tumor pHe ( Fig. 1C-D) . In conclusion, this study shows the capability to measure pHe using an IP delivery of iopamidol into orthotopic pancreatic tumors, which is being explored to monitor the response to alkalinizing treatments longitudinally in pre-clinical models. Abstract Body : Background Antibody drug conjugates (ADCs) combine the precision of monoclonal antibodies (mAbs) and the potency of small molecule therapeutics.1 The rapid translation of these agents highlights the significant potential of these strategies. Nevertheless, the clinical implementation of ADCs has encountered significant toxicity, which is often due to off-target release of the small molecule payload. As a consequence, there remains significant need for strategies to optimize and evaluate novel antibody small molecule conjugates. In particular, near-infrared (NIR) optical imaging strategies that use triggered turn-on events can provide insight into the activation and uptake of antibodies in model organisms. The sensitivity and accuracy of fluorescence imaging can be further improved by employing a ratiometric imaging strategy based on two distinct fluorescent signals with differing responses to the analyte of interest. In the context of fluorescence microscopy, this type of imaging strategy can provide quantitative maps of specific variables such as pH, local ion concentration or protein activity. To date, this technique has found limited success in live animals due to the relatively narrow optical window for multiplexing with conventional silicon-based imaging detectors. With the increased availability of InGaAs-based fluorescence detectors, imaging in the much wider shortwave infrared (SWIR) region (1000-1700 nm) can readily be performed, opening up the possibility for multiplexed imaging in live animals. Although always-on NIR dyes such as the heptamethine cyanine fluorophore indocyanine green (ICG) have been demonstrated to be efficient SWIR emitters, suitable stimuli responsive probes with emission maxima in this wavelength range remain rare. Design and Objective

For this study, we designed a novel bioconjugatable SWIR fluorescent probe with turn-ON emission at low pH. The pH-responsive nature of this probe comes from protonation of an indolenine nitrogen, generating a nonamethine cyanine chromophore with λmax,abs of 1060 nm and λmax,em of 1080 nm ( Figure 1A ). We hypothesized that these probes could be used in a ratiometric imaging scheme alongside an always ON NIR dye by exciting each dye at their respective absorbance maxima and collecting the SWIR emission using 1150 nm longpass filters. For the always on NIR dye, we chose to use FNIR-Tag, a bioconjugatable NIR heptamethine cyanine dye that produces bright, nonaggregating antibody fluorophore conjugates (AFCs).2 To characterize these novel dyes for ratiometric imaging, we performed ex vivo imaging experiments of mixed solutions and of mAbs dual labeled with FNIR-Tag and pH-FNIR-1060 at different pH values. Finally, we evaluated the ability of this system to generate quantitative tumor uptake kinetic data in vivo by intratumoral injection of the dual labeled AFCs in athymic nude mice bearing MDA-MB-468 xenograft tumors. Results We successfully prepared the novel SWIR fluorescent turn-ON probe, pH-FNIR-1060, in 4 steps from commercially available materials in good yields. We demonstrated that this novel probe had pH dependent turn-ON emission in the SWIR region with a λmax,em of 1080 nm and a pKa of 5.3 ( Figure 1B ). Next, we performed ex vivo imaging of this probe in mixed solutions with FNIR-Tag with different stoichiometry and demonstrated a ratiometric response with linearity between pH 5.5 and pH 7 (R2 = 0.99). Finally, we prepared and characterized dual labeled AFCs using the anti-EGFR mAb Panitumumab and demonstrated the use of this construct to generate kinetic curves of AFC uptake (t1/2 = 2.97 h, R2 = 0.99) in living MDA-MB-468 tumor-bearing mice after intratumoral administration ( Figure 1C ,D). In total, these studies establish a framework for studying the uptake kinetics of mAbs and related systems in living animals with optical imaging. Abstract Body : Systemic amyloidosis is a severe disease which is difficult to assess as no radiotracers are approved in the US for detection and tracking of the disease. Additionally, systemic amyloidosis is extremely heterogeneous, with approximately 17 different proteins potentially accumulating in any tissue throughout the body. We have developed a peptide radiotracer, 124I-p5+14 (AT-01), for the detection of diverse forms of systemic amyloid by PET/CT imaging, which has been evaluated in a Phase 1/2 imaging study of patients with transthyretin (ATTR) and monoclonal immunoglobulin light chains (AL) amyloidosis (NCT 03678259). Here, we present preliminary findings of patients who underwent AT-01 PET/CT imaging and were evaluated using a recently developed application of AIQ Solutions' TRAQinfom IQ software that fully automates 3D quantification of radiotracer uptake in the major abdominothoracic organs. We compare this method with our current standard of quantification using 2D regions of interest (ROIs) manually placed by an experienced reader. Subjects >18 years with a diagnosis of AL or ATTR amyloidosis were enrolled. Subjects received < 2 mg of AT-01 (≤2 mCi I-124) administered as an IV infusion. Images were acquired 5-6 hours post-injection using a Biograph PET/CT scanner. The entire liver, spleen, kidneys, heart, and aorta were automatically segmented on the CT image using a 3D U-net convolutional neural network. The network was pre-trained using 533 CT images and externally validated in 170 CT images from PET/CT imaging datasets using physician contours as ground truth. Automated contours generated from the CT images were applied to the AT-01 PET data for quantitation of mean standardized uptake value (SUVmean). SUVmean was normalized using the mean aorta lumen radioactivity, resulting in automated 3D SUVRmean outputs for all four organs. Separately, the fully manual 2D ROI analysis was performed on a single representative slice of each organ and again normalized using the thoracic aorta lumen as the reference, resulting in 2D SUVRmean outputs. Pearson's correlation coefficients (r) were calculated between automated 3D SUVRmean and manual 2D SUVRmean values. Validation of automated segmentation showed a median (interquartile range) dice similarity coefficient for liver: 0.95 (0.94-0.96), spleen: 0.94 (0.92-0.95), kidneys: 0.93 (0.91-0.94), heart: 0.92 (0.91-0.94), and aorta: 0.92 (0.90-0.93) in the 170 external CT images. In the ATTR and AL patients, automated 3D SUVRmean and manual 2D SUVRmean yielded excellent positive correlations in all organs: for AL, r=0.99 and p < 0 .0001 and for ATTR, r=0.90 and p < 0 .0001. Linear regression analyses for AL and ATTR data resulted in gradients of 1.4 and 1.6, respectively, indicating the single slice quantitation was generally higher than the whole organ quantitation. When combining AL and ATTR patients and assessing organs separately, the liver, kidney, and spleen, showed highly significant correlations between methods (p < 0 .0001). For the heart, r=0.84 with p=0.002, likely reflecting the heterogeneity of amyloid deposition or the quantitation efficient for organ notably for the ATTR patients. Conclusion: Detection and quantitative analysis of amyloid burden is an unmet clinical need for patients with systemic amyloidosis. Given the novelty of the AT-01 radiotracer and the heterogeneous presentation of disease in this patient population, this automated approach to image analysis of AT-01 PET/CT data would be an invaluable tool for novice readers and those seeking to quantify amyloid burden longitudinally without introducing reader bias. This approach will significantly impact the ease of use and improve accuracy of image interpretation that will ultimately benefit clinical management of patients with amyloidosis. This study was supported in part by the National Heart Lung and Blood Institute, National Institutes of Health, through the Science Moving TowArds Research Translation and Therapy (SMARTT) program via the following contract(s) HHSN268201600011C, HHSN268201600012C, and HHSN268201600014C, as well as Image/ Figure: Image/Figure Caption: Exemplary quantitation of amyloid-binding radiotracer 124I-p5+14 in abdominothoracic organs using a fully 3D automated segmentation method. A) PET/CT imaging of amyloid in a patient with AL showing uptake in the liver, spleen, heart and kidneys (MIP, coronal and sagittal aspects). B) Automated segmentation defines 20 individual organs and tissues in 3D that are applied to the PET data for quantitation of radioactivity. C) Standard 2D analysis by positioning ROIs on "representative" single slices (arrows). D) Correlation between SUVRmean values calculated using automated 3D and single slice 2D methods for the heart, liver, spleen and kidney in a subset of 5 AL (Pearson r = 0.993, p = p = < 0 .0001) patients. Abstract Body : Objective(s): Historically, one of the main challenges unique to radiopharmaceutical manufacture involving radiolabeled proteins has been the automation of a radiolabeling process that includes gravity-based desalting gel purification step, which is almost universally used as a manual process in early clinical manufacturing setting. To our knowledge, a fully automated gravity-based purification process that faithfully mimics the manual process has not been developed. Previously reported methods have been either pressure-based, resulting in column gel compression and unreliable purification, or have taken the form of "open air purification column" systems that preclude the collection of isolated eluted product fraction, exclude the possibility of bioburden control, and increase the risk of surface radioactive contamination.1,2 The goal of this work was to develop and validate a fully automated, gravitybased method for the radiolabeled antibody purification using desalting gel columns that addresses the current challenges described above and that could easily be incorporated into cassettes of most of the commercially available synthesis modules. Methods: Working with a medical plastics manufacturer, a single-use plastic enclosure that could house the PD-10 desalting gel column was designed. The column housing design, depicted in Figure 1 , allows for control of the internal pressure during automated delivery of the product onto the column, removal of the initial unneeded column eluate fraction, elution of the gravity-based product, and subsequent transfer to the final drug product vial. To validate the developed solution, a series of radiolabeled antibody productions were performed, including a representative automated radiolabeling of the monoclonal B7-H3 antigen targeting antibody, omburtamab (provided by Ymabs Therapeutics, NY, USA), with 131I (provided by CMR, Russia), reported herein. The key manufacturing process characteristics such as the overall radioactivity and protein yields, as well as critical specifications of the final drug product, such as radio-immunoreactivity and radiochemical purity, were evaluated and compared to those obtained using the manual radiolabeling process. The synthesis sequence was developed for a Trasis All-in-One Mini synthesizer, and included reacting 145mCi (0.4mL) of 131I-sodium iodide solution with 0.8ml of 0.2M phosphate buffer, and 0.7ml (1.4mg) of omburtamab solution in an iodogen reaction vial at ambient temperature for 15 minutes. The reaction mixture was then withdrawn and transferred to the top of the enclosed PD-10 column usinge the synthesizer cassette transfer syringe. Once the reaction mixture fully permeated the gel by gravitational force, the eluate fraction collected at the enclosure's bottom reservoir was pushed into waste by applying air pressure from the transfer syringe. The second syringe was then used to elute the product off the purification gel column with 4ml of the formulation buffer. Once the eluate fraction containing the drug substance was collected at the enclosure's bottom reservoir, syringe pressure was applied to transfer the final drug product through the sterilizing-grade filter into sterile glass vial. The synthesizer schema is depicted in Figure 2 . Results A total of 83.1mCi of 131I-Omburtamab final drug product was produced, representing 57% overall radioactivity yield. The radionuclide incorporation prior to purification was measured by iTLC and determined to be 80%, and the overall protein loss during synthesis was determined by UV spectrophotometry to be ~30%. The final drug product did not contain any unincorporated 131I when measured by radio-TLC; the radio-monomer content was 96%, as determined by radio-SEC-HPLC; and the radio-immunoreactive fraction was 95.5%, as determined by the previously described stationary antigen assay3. All obtained results agreed with the corresponding parameters obtained historically using the manual synthesis process. Conclusions Our developed a solution can be applied to a variety of synthesis modules, radionuclides, and macromolecule ligands, facilitating the pharmaceutical development of macromolecule-based radiopharmaceuticals beyond the early clinical investigational stages. Abstract Body : Background: Prostate-specific membrane antigen (PSMA)-PET is a very sensitive molecular imaging technique that targets the PSMA protein overexpressed on most prostate cancer (PCa) cells. In combination with multiparametric MRI, which is a standard clinical procedure for localizing and characterizing PCa, PSMA-PET offers very high lesiondetection specificity (1, 2) . However, limited accessibility, cost, and repeated dose of the radioactive tracer limits the utility of a combined PSMA-PET/MRI system for PCa imaging. To address these challenges, this study focuses on the development of single modality assay based on multiparametric MRI and sodium-MRI. Tissue sodium concentration in human PCa with sodium-MRI was recently shown to significantly correlate with histological lesion grade (3). The addition of sodium-MRI to multiparametric MRI may provide similar lesion characterization as PSMA-PET and find wider clinical adoption in the management and active surveillance of PCa. Hypothesis: A combined multiparametric MRI and sodium-MRI imaging assay will improve the discrimination between low-and high-grade lesions throughout the entire prostate. Methods: The imaging assay was evaluated in the first patient (62 years old, 95.2 kg, Gleason score=7) from a planned cohort of 45 men with biopsy-proven PCa prior to prostatectomy using a 3 Tesla PET/MRI scanner (Siemens Biograph mMR). The radiofrequency system was PET-compatible and consisted of a custom-built 23Na RF transmit body coil (32.6 MHz), a 16-channel flexible array for 1H imaging, and a rigid dual-tuned receive endorectal coil for 23Na/1H imaging (4). The MR imaging panel included 23Na MRI (TE=2.3ms, TR=218ms, FOV=20cm2, in-plane resolution=3mm2, flip angle=50˚, scan time=32min), followed by T2-weighted MRI (TE=101ms, TR=1700ms, FOV=22.6cm2, in-plane resolution=0.70mm2, flip angle=115˚), dynamic contrast-enhanced (DCE) MRI (TR=5.02ms, TE=1.95ms, in-plane resolution=1.1250mm2, 0.1mmol/kg Gadovist), and diffusion-weighted MRI (DWI) (TE=96ms, TR=5200ms, in-plane resolution=1.625mm2, b-values=0-800s/mm2). An apparent diffusion coefficient (ADC) map was generated by fitting DWI data with a monoexponential model. PSMA-PET (3D mode, resolution=4.1725×4.1725×2.0313mm3, frame duration=20min) was acquired 134 minutes after the administration of 410 MBq of [18F] PSMA-1007. The boundary of the primary lesion was defined by 40% of the maximum standardized uptake value (SUVmax) (5) . After prostatectomy, intrinsic and extrinsic strand-shaped fiducials were applied to the specimen and T1 and T2-weighted MRI was performed. The specimen was then processed for digitized whole-mount histopathology and annotated (6, 7) . Results and Discussion: High [18F] PSMA-1007 uptake localized the primary intraprostatic lesion in the left transition zone (SUVmax = 7.76). Histopathology confirmed the presence of a Gleason 7 cancer in this region. Disease was also visible outside of the prostate. The primary lesion defined by the boundary threshold of 40% SUVmax (volume=2.5 cm3) corresponded to mildly hypointense regions on the T2-weighted image and ADC map, and early, mild enhancement on DCE. From the raw 23Na MRI data, the primary lesion corresponded to a lower sodium signal relative to that observed 1cm from the endorectal coil. Based on these preliminary results, PET of [18F] PSMA-1007 may be superior in detecting PCa lesions in the transition zone and distant metastases, while, using this experimental setup, 23Na MRI may be more sensitive to lesions in the peripheral zone where majority of PCa originates. Future work includes 1) correction of the sodium signal for RF coil sensitivity to create absolute tissue sodium concentration maps, 2) registration of the Gleason-graded whole-mount sections with the PET/MRI images using the fiducials and tissue features, and 3) statistical analysis of the annotated histopathology with imaging data (sodium concentration from 23Na, ADC from DWI, kinetic parameters from DCE), comparing clinically significant and insignificant regions. (a-c) Whole brain and cerebellum TACs for wild type mice (a), β2-knockout mice (b), and acute nicotine-administered mice (c) measured using 2FA PET SUVs. Significantly higher brain uptake of 2FA was observed in female mice compared to male mice for all groups (all p β2-knockout mice (e), and acute nicotine-administered mice (f) measured using nifene PET SUVs. Significantly higher brain uptake of nifene was observed in female mice compared to male mice in the wild type group (p β2-knockout and nicotine-administered groups. For both the β2-knockout and nicotine-administered groups, 2FA and nifene uptake across the whole brain was not significantly different from the cerebellum, which is representative of nondisplaceable signal. (g-f) Logan DVR values for the thalamus and midbrain of male and female mice in the wild type (g), β2-knockout (h), and nicotine-administered (i) groups. No significant difference in regional 2FA and nifene binding was observed between male and female mice following signal normalization to the cerebellum, indicating that female mice have greater nondisplaceable binding signal. Abstract Body : Triple Negative Breast Cancer (TNBC) has a lower survival rate than receptor positive breast cancers (77% compared to 93%), and no targeted treatment options are currently available for this kind of cancer [1] . Our goal is to find viable treatment options for TNBC by developing a microRNA (miRNA) mediated reprogramming approach, which improves TNBC therapy by sensitizing cancer cells to currently used chemotherapies. We hypothesized that targeting a selected panel of miRNAs using miRNA mimics and/or antisense-miRNAs could counteract the differential expression and, consequently, alter the chemo-resistant phenotype of TNBC cells through normalization of the expression of target genes associated with important therapeutic pathways (apoptotic and growth signaling, stemness, invasion and metastasis, and cytokine signaling) of cancer. In this study, we identified 37 differentially expressed miRNAs (19 downregulated and 18 upregulated) from human TNBC datasets taken from Genomic Data Commons Portal (GDC) and Gene Expression Omnibus (GEO). MiRNA expression data from GDC was analyzed using the DESeq2 package in R, and expression data from GEO was analyzed on the GEO2R platform. We then identified potential target genes of these miRNAs by researching existing literature and searching on TargetScan and correlated the expression of those target genes with miRNAs. Three upregulated miRNAs (miR-21, miR-203, and miR-19b) and two downregulated miRNAs (miR-218 and miR-10b) were selected based on target gene association with predetermined therapeutic pathways as schematic workflow shown in Fig 1A. We then analyzed the effects of treatment of the selected miRNAs on the chemosensitivity of TNBC cells. The miRNA mimics and antisense-miRNAs were loaded into PLGA-PEG nanoparticles for delivery into TNBC cells. The cells were co-treated with chemotherapeutic drugs (doxorubicin, paclitaxel, or etoposide) to measure the improved treatment response. After treatment, we used Guava FACS analyzer to identify apoptotic populations, a Tecan plate reader to quantify cell viability via MTT assay, and the IVIS-Lumina Imaging system to measure target gene expression via immunoblot analysis. Overall, as expected, an inverse relationship between miRNA to respective target gene expression was observed based on expression data analysis in R, and western blot results shown in Fig. 1D . These results suggest that inhibition of therapeutic target genes expression as the mechanism of miRNA-mediated enhancement in chemosensitivity. In addition, combinations of multiple miRNAs resulted in lower cell viability and higher rates of apoptosis in comparison to treatment with single miRNA as target. The combination of miR-218, AmiR-21, AmiR-19b and AmiR-10b showed the most promising therapeutic outcome compared to other combinations. As shown in Fig. 1B , cotreatment of this panel of miRNAs in combination with a low dose paclitaxel yielded a 21.2% decrease in cell viability compared to the control nanoparticle. Similarly, cotreatment with low dose etoposide yielded a 19.9% decrease in cell viability. Cotreatment of this combination with 0.5 μM of Dox increased the apoptotic population by 4% in comparison to the control nanoparticle (10.8% for control nanoparticle and 14.8% for miRNA cotreatment) in Fig. 1C . In addition, our cell cycle analysis showed that when cells were cotreated with this miRNA combination and any of the three chemotherapy drugs used in this study, G2 cell cycle arrest was increased (persuasive file). Furthermore, treatment with miRNA alone (in the absence of drugs) significantly decreased cell viability without significant increase in cell apoptosis. This result suggests that the miRNA alone treatment has a primary cytostatic effect rather than a cytotoxic effect on the TNBC cells. However, the decrease in cell viability 72 hr post-treatment in comparison to 24 hr posttreatment indicates that the cytotoxic effect may increase slightly over time. Further studies are needed to test the effectiveness of this miRNA combination therapy in an in vivo setting. Expression Omnibus (GEO) databases were used for identification of 80 differentially expressed miRNAs by cross referencing and selecting for |log2FC|>1, adjusted p-value < 0 .05, and SME < 1 (Due to repeated expression results per miRNA coming from multiple oligonucleotide probes in the GEO dataset, representative probes were determined based on minimum adjusted pvalue). This pool was then selectively filtered by cross referencing with GEO results using the criteria of median p-value to determine the representative probe. The 37 filtered miRNAs are presented in a Venn diagram of various therapeutic pathways. The miRNAs labeled "Not Identified" lacked sufficient studies and could not be successfully categorized into any of the four therapeutic pathways based on the current literature. The final 5 miRNAs were selected based on a literature review to determine associated pathways of the miRNAs. Red color shows the down-regulated miRNA while green shows the up-regulated miRNAs. (B) MTT assay evaluating percent cell viability in cells co-treated with the selected miRNA combination (miR-218, AmiR-21, AmiR-19b, and AmiR-10b) and varying drug types and concentrations. Error bars present standard deviations. Cells were collected for analysis 48 hr after cotreatment. (C) PIstaining-based FACs analysis to measure apoptotic populations of TNBC cells after miRNA and doxorubicin co-treatment. Percentage of apoptotic cells shown in red. *Indicates cells collected 48 hr (rather than 72 hr) after plating to avoid effects of cell starvation. (D) Western blot (immunoblot) analysis evaluating the expression of therapeutic target proteins (PTEN, BIRC5, HOXD10) in cells transfected with different combinations of miRNAs. Doxorubicin-treated and no drug conditions were also shown. Average fluorescent counts normalized to GAPDH measurements are shown below to each band. Cells were collected for western blotting analysis 48 hr after drug treatment. Abstract Body : Objectives: Metastatic castration resistant prostate cancer (mCRPC) is a generally fatal and currently non-curable form of cancer. However, the recent irruption of radiopharmaceuticals, in particular the beta-minus (β-) emitting [177Lu]Lu-PSMA-617, has greatly improved clinical outcomes for mCRPC patients.1 As approx. 25% of patients do not respond to beta-minus based mCRPC radionuclide therapy, alpha-based approaches have been postulated to circumvent treatment resistance.2 Due to its favourable decay properties and upscaling feasibility, astatine-211 (211At) has been reported as a nearly ideal emitter for alpha radionuclide therapy rendering 211At-based radiopharmaceuticals promising for the clinical management of mCRPC. Studies recently published by Pomper et al. have demonstrated the feasibility of 211At-labelled low molecular weight peptidomimetics targeting PSMA. [3] [4] [5]  in this work, we synthesised a library of compounds based on the clinically established PSMA-617, for their future application in 211At-based therapy of mCRPC. Methods: A series of iodinebearing PSMA-targeting inhibitors based on PSMA-617 were synthesised. Iodine was employed as a surrogate for astatine, since no stable isotope of astatine exists. PSMA-binding properties such as binding affinities and internalisation ratios of the newly synthesised series were evaluated in human PSMA(+) LNCaP cells. The most promising inhibitors were radiolabelled with gallium-68 (68Ga) for preliminary µPET/MRI imaging studies in LNCaP tumour-bearing mice (BALB/c nu/nu). Furthermore, astatine-211 and iodine-125 (125I) radiolabelling was performed via electrophilic aromatic substitution of trimethylstannate precursors. Results: The synthesised compounds showed high binding affinities and internalisation ratios, comparable to the current standard PSMA-617. Radiolabelling with 68Ga (RCC ≥ 99%), and 211At/125I via trimethylstannate precursors (RCC ≥ 95%) were effective. Moreover, similar properties were observed for the 211At and 125I compounds, with almost identical retention times in chromatographic studies. In vivo preclinical µPET/MRI studies with the 68Ga-labelled variants showed fast kidney-mediated clearance and high tumour enrichment (SUVmean values ranging from 0.22 to 0.61 g/mL 2 h p.i.) comparable to tumour uptakes shown by PSMA-617.6 Conclusions: The herein synthesised library of compounds based on the clinically established PSMA-617 has been shown to perform in a comparable manner to its parent structure. The chemical modifications done in this work had only slight impact on the binding properties, tumour uptakes and pharmacokinetic profiles of the inhibitors as shown by preliminary µPET data. It was also demonstrated that 211At-labelled structures could be obtained along with proven comparability between the 211At and its 125I counterpart. These preliminary results highlight the feasibility of 211At-based PSMA targeted radiotherapy and warrant future developments based on the presented strategy.

Anjul Khadria, California Institute of Technology, anjul.nitrkl@gmail.com Category: Systemic Diseases (Kidney, Liver and Pancreas) Abstract Body : People living with type 1 diabetes use exogenously administered rapid-acting insulin to control postprandial hyperglycemia. Most therapeutic insulins are stabilized as hexamers, which upon subcutaneous injection shall first dissociate into dimers and monomers in a time-dependent fashion thus delaying microvascular absorption.1 Research on increasing the hexamer-to-monomer dissociation rate yielded rapid-acting insulins such as insulin lispro and insulin aspart, which improved postprandial glucose control; however, rapid-acting insulins are still not fast enough to match carbohydrate absorption profiles from meals.1,2 Current literature casts doubt on whether the hexamer dissociation rate of rapid-acting insulin formulations is the absorption rate-limiting step, which has been a question of debate for more than 20 years.3,4 Ultra-rapid insulin formulation designs have shifted from a molecule-focus to formulation-focus to temporarily alter the characteristics of the injection site to enhance the rate of microvascular absorption.5 Despite significant research on rapid-acting and ultra-rapid insulin formulations, limited work has focused on understanding the dynamics of insulin at the injection site, thus limiting future advancements in rapid-acting insulins. Three-dimensional visualization and quantification of rapid-acting insulins in their respective formulations at the injection site can contribute to explaining several unknown processes. Previous injection site studies based on isotope imaging and computed tomography (CT) scan lacked live 3D structural and functional details covering the complete volume of injection at cellular level resolution.6,7 Photoacoustic microscopy (PAM) can be used to perform label-free imaging of blood and the measurement of local blood sO2 at cellular level resolution.8 PAM has never been used to quantify the absorption kinetics of biotherapeutics at the injection site as three-dimensional quantitative imaging of an external contrast agent in live animals remains one of the major challenges in the field of photoacoustic tomography.9 Here, we report the 3D quantitative study of near-infrared dyelabeled insulin lispro in the FDA-approved Humalog®10 and Lyumjev®11 formulations using optical-resolution photoacoustic microscopy (OR-PAM) in a mouse ear covering the complete 3D volume of injection at cellular level resolution. Both the Humalog and Lyumjev insulin formulations employ the same hexameric insulin lispro; however, the Lyumjev formulation is laced with treprostinil and sodium citrate to accelerate subcutaneous absorption.1,11 Through photoacoustic imaging, we found that the excipients in the Lyumjev formulation are responsible for temporary local tissue expansion. To determine the absorption kinetics of the insulin, we devised a novel 3D photoacoustic quantification approach based on noise suppression. We observed that the differences between the absorption kinetics of the Humalog and Lyumjev formulations determined through OR-PAM are similar to the pre-clinical data and the published clinical trials data. By modeling the imaging-based absorption kinetics and performing a separate pharmacokinetic study in pigs, we conclude that the hexamer dissociation rate of insulin lispro is not the rate-limiting step and that interstitial diffusion and vascular crossing rate determine the initial and overall absorption rate. We studied the diffusion of insulin lispro in both the formulations through photoacoustic imaging and then modeled it to calculate the diffusion coefficients to confirm that the diffusion in the Lyumjev formulation is faster than in the Humalog formulation. In the 100 years of history of therapeutic insulin, this is the first time that its diffusion in a live animal has been experimentally characterized. These results will pave the way towards the development of next-generation of insulins with better user control. The techniques and the models developed here will also be useful to study other injectable drugs such as antibodies and RNA therapeutics. Therefore, apart from solving some of the longstanding conundrums in the insulin field, we believe that our contribution will make a significant impact on how the injection-site dynamics of parenteral drugs are studied. Abstract Body : Although FDG has been used clinically to image tuberculosis (TB) granulomas over the past 20 years and has provided key insights in disease pathology [1] , as a glucose analog, its ability to demarcate specific cell populations has not yet been validated. As cellular composition appears to play a role in differential bacterial killing and treatment response [2] , FDG alone may be insufficient. LLP2A is a peptidomimetic that binds with high affinity to VLA-4 (integrin α4β1) [3] , a surface protein highly expressed by immune cells that mediates their trafficking to areas of inflammation. Accumulating evidence suggests that VLA-4 is involved in the anti-mycobacterial response in both murine TB and in patients, given its high expression on immune cells in latent infection [4] and the ability of these cells to confer protective immunity in early infection [5] . Previous studies have demonstrated different temporal patterns of 64Cu-LLP2A and FDG signal in macaque models of progressive TB [6] . In granulomas, FDG predominates in early disease, with 64Cu-LLP2A signal approaching that of FDG in later stages. LLP2A uptake was found to be facilitated mainly by macrophages and T cells. To better understand how immune cell dynamics change with treatment, macaques infected with Mycobacterium tuberculosis (mTb) were imaged with FDG and 64Cu-LLP2A PET/CT prior to and during linezolid treatment. We hypothesize that insights from FDG and 64Cu-LLP2A PET/CT, along with flow cytometry on granulomas post-treatment, may provide immune cell compositional signatures that indicate response to treatment at the individual granuloma level. To our knowledge, we are the first to perform dual-tracer PET such that both pergranuloma immune cell metabolic activity and immune cell composition can be tracked. Cynomolgus macaques (Macaca fascicularis) received 30 colony-forming units (CFU) of mTb Erdman bilaterally to the lungs and were monitored with FDG and 64Cu-LLP2A during TB progression and subsequent treatment with the antibiotic linezolid. Histopathology and granuloma CFU plating were undertaken at necropsy. Granulomas showed reduced FDG and 64Cu-LLP2A uptake after linezolid treatment, suggesting that treatment reduced local metabolic activity and resulted in fewer VLA-4+ cells at the granuloma level. Using the composite metric total PET Hot, 3 of 4 treated monkeys showed decreasing FDG and LLP2A signal, with resolving disease confirmed by histopathology. Similarly, untreated controls (n=2) showed increasing PET Hot and histological signs of progressive disease. Interestingly, a treated mixed responder, where the granulomas contained viable bacteria and a substantial proportion of foamy macrophages, displayed increasing 64Cu-LLP2A whereas FDG uptake remained stable, suggesting FDG and 64Cu-LLP2A may monitor different processes. For both PET tracers, individual granuloma uptake was variable, but aligned to treatment response. Future work will involve correlation of individual granuloma analysis to cellular composition via flow cytometry, with additional data from 6 subjects remaining to be analyzed. 

Jessica Wang, MGH/Martinos Center for Biomedical Imaging, jwang122@mgh.harvard.edu

Abstract Body : Introduction: Cyclooxygenase-2 (COX-2) is a prostaglandin-generating enzyme that exhibits low basal expression levels and is specifically upregulated in the brain in response to inflammatory challenges. COX-2 has been implicated in neurodegenerative and neuroinflammatory disease pathogenesis and is the major target of non-steroidal antiinflammatory drugs (NSAIDs) (1). We previously reported that BRD1158 is a selective COX-2 inhibitor with improved COX-2 affinity, plasma free fraction (fu,p) and faster on-rate (kon) compared to existing COX-2 ligands including rofecoxib, celecoxib, and MC1.

[11C]BRD1158 demonstrated saturable and COX-2-specific binding in vivo with PET in a localized overexpression rat model (intrastriatal AAV-COX-2). To further validate the performance of this radiotracer in vivo, we imaged Thy-1-COX-2 transgenic mice that constitutively overexpress human-COX-2 in neurons of the amygdala, striatum, cerebral cortex, and hippocampus (2) . We hypothesize that [11C]BRD1158 uptake correlates positively with COX-2 expression. Methods & Results: BRD1158 was radiolabeled at the methylsulfone by treating the corresponding thioester precursor with [11C]CH3I. Brain uptake of this radiotracer was evaluated by measuring whole brain SUV in mice with PET-MR. Regional brain time activity curves were generated with PMOD using M. Mirrione mouse atlas (3) . In vivo PET studies showed [11C]BRD1158 has high brain uptake and favorable wash out kinetics in both transgenic (whole brain SUV Cmax = 1.9; t1/2 = 43.2 min) and wild type mice (whole brain SUV Cmax = 1.5; t1/2 = 3.08 min). Our data show significantly higher radiotracer uptake in Thy-1-COX-2 transgenic mice (SUV30-50 min = 0.869) compared to wild type control (SUV30-50 min = 0.140). We report a 515% increase in [11C]BRD1158 wholebrain binding in Thy-1-COX-2 mice compared to WT. Conclusion: In vivo PET-MR imaging studies with [11C]BRD1158 show significantly higher brain uptake in Thy-1-COX-2 transgenic mice in specific brain regions that overexpress human-COX-2 compared to wild type mice. We demonstrate that [11C]BRD1158 is a COX-2-specific radiotracer with favorable pharmacokinetic properties that enable in vivo evaluation of COX-2 activity. Future work will prepare for first in-human [11C]BRD1158 PET neuroimaging of COX-2. Yttrium-90 (Y90) for HCC are first evaluated for lung shunt fraction (LSF) by Tc99m MAA imaging1. However, Tc99mMAA imaging may soon be omitted. For patients undergoing repeat SIRT, LSF will be measured on serial Y90 planar images to ensure safe lifetime lung dosimetry2. These images are affected by scatter that is difficult to model with energy window techniques3. Deep learning has been successfully applied for image-based classification tasks with large training sets4. However, training sets of Y90 planar images are limited. The aim of this project was to synthesize phantom Y90 training data and evaluate a deep learning shunt classification model. Methods and Materials: Y90 Therasphere 2D phantom (256 x 256 pixels) was generated to contain lungs (120 x 120 pixels) and liver (60 x 60 pixels) with random activity using Matlab (Mathworks, Natick, MA). Counts from anterior and posterior Y90 images from 3 patients were used to normalize phantom images. Y90 scatter was approximated with a 2D Gaussian smoothing kernel with standard deviation of 30. Poisson noise was added to phantom images. Images with calculated LSF from 0 to 30% were included -LSF less than 15% was classified as low shunt (LS [mean 8.3+/-3.8%]) and between 15% and 30% was labeled as high shunt (HS [mean 22.1+/-3.8%]). Dataset (DS#1) was separated into training (700 HS and 700 LS images) and validation (178 HS and 178 LS images) datasets. A convolutional neural network (CNN) was created for shunt classification. A smaller dataset (DS#2) Abstract Body : Introduction: Magnetic particle imaging (MPI) is an emerging trace-based imaging technique to directly visualize the spatial distribution of magnetic nanoparticles. The imaging tool offers high image contrast with zero background signal from tissue, ideal for applications such as in cell tracking, vascular imaging, and tumor imaging. Up until now, spherical superparamagnetic iron oxide nanoparticles (NPs) ( < 2 0 nm) and commercially available Vivotrax (VT; large-sized nanoclusters of iron oxide), have been used as suitable MPI contrast agents. However, an ideal tracer with tailored magnetic relaxation and enhanced cellular interactions could provide higher resolution images and a lower signal detection threshold. Here, we develop novel, self-assembled iron oxide nanochains (NCs) with better MPI contrast and tumor-targeting effect. Methods: Iron oxide NCs were synthesized via thermal decomposition of iron oleate complexes under vacuum conditions. The NCs and 15 nm spherical iron oxide NPs (900083, Sigma Aldrich) were then coated with DSPE-PEG to make them water-soluble. The particle product was evaluated for iron content via ICP-OES measurement. A cell uptake study was performed by incubating 4T1 cells with RITC labeled NCs and NPs at 25 µgFe/mL overnight and imaged using a fluorescence microscope (Keyence). MPI of nanoparticle phantoms was performed with 10 µgFe/mL NCs, NPs, and VT using an MPI scanner (MOMENTUM, Magnetic Insight). Cell imaging by MPI was performed by suspending different numbers of 4T1 cells incubated with 100 µgFe/mL NCs or VT. Finally, NCs (320 µgFe/kg) and NPs (780 µgFe/kg) were administered via tail vein injection in orthotopic 4T1 breast tumor mice and imaged after 24 hrs to validate systemic targeting and in vivo imaging capability. Results: Self-assembled iron oxide NCs were successfully synthesized via thermal decomposition method (Fig. 1A) and coated in DSPE-PEG without losing their characteristic chain structure (Fig. 1B) . After PEGylation, the NCs have a hydrodynamic diameter of 136±5 nm and a zeta potential of -4±1 mV as evaluated by DLS. Cytotoxicity in 4T1 cells was evaluated by MTT assay, and in concentrations up to 100 µgFe/mL, no significant toxicity was observed. The NCs were taken up significantly better than NPs, as shown in fluorescence microscopy images (Fig. 1C) . The NCs were also shown to have 1.9 and 2.1 times higher MPI intensity (a.u.) than VT and NPs respectively in equal Fe mass amounts (Fig. 1D ). Linear quantification of MPI signal intensity versus the number of labeled cells was detected in both NCs (R2=0.94) and VT (R2=0.96) (Fig.  1E ). Due to increased MPI intensity (Fig. 1D) and higher cell uptake of NCs than VT (Fig. 1C) , the NCs showed a lower limit of detection (40k cells) as compared with the VT (85k cells) (Fig.  1E) . Though the dosing for NCs and NPs was inconsistent, the preliminary in vivo imaging indicates that NCs and NPs both accumulated largely in the liver, but NCs produce a higher resolution image and appear to better target the tumor tissues (Fig 1F) . These experiments will be repeated with consistent dosing and more mice to validate these results. Conclusions: The enhanced image sensitivity, resolution, and systemic targeting ability would make these iron oxide nanochains an excellent new class of MPI contrast agent for cancer imaging studies. Follow-up studies are in progress to use the particles as noninvasive MPI imaging markers for therapeutic cell tracking (stem or immune cells). 

Haruka Yamaguchi Takezawa, Nippon Dental University, harukay@ngt.ndu.ac.jp

Abstract Body : Near-infrared photoimmunotherapy (NIR-PIT) is a new and promising cancer therapy based on a monoclonal antibody conjugated to a photosensitizer (IR700Dye) which is activated by near-infrared light irradiation, causing cell death. We previously reported a new NIR-PIT using a small protein mimetic, Affibody molecules (6-7 kDa) instead of monoclonal antibody. Due to its small size, Affibody has rapid clearance, high imaging contrast, and good tumor penetration. In this study, we investigated a combination NIR-PIT for HER2 overexpressing breast cancer (SK-BR3, MDA-MB361, JIMT1) using HER2 Affibody-IR700Dye conjugate and Trastuzumab-IR700Dye conjugate. HER2 Affibody and Trastuzumab target different epitopes of HER2 protein and do not compete each other. In vitro, NIR-PIT using both HER2 Affibody-IR700Dye conjugate and Trastuzumab-IR700 conjugate induced necrotic cell death of HER2-overexpressing breast cancer cells without damage to HER2 non-expressing cells (MCF7). Additionally, this combination NIR-PIT showed stronger cytotoxic effect against HER2 overexpressing cells including Trastuzumab resistant cells (JIMT1) than the NIR-PIT using HER2 Affibody-IR700Dye conjugate alone or Trastuzumab-IR700Dye alone. Furthermore, in vivo imaging exhibited strong fluorescence intensity of both Affibody-IR700 conjugate and Trastuzumab-Alexa488 conjugate in HER2 overexpressing tumor. In conclusion, the combination NIR-PIT using both Affibody and Trastuzumab has the potential to extend the target cancer of NIR-PIT. Affibody and IR700Dye are currently used clinically, and therefore, we would expect the current formulation to be safely and quickly transitioned into clinical trials. (Figure 1b-c) . The NPs showed 2-fold higher uptake in PSMA(+) PC3-Pip tumors to that of PSMA(-) PC3-Flu tumors with a tumor/blood ratio of 20; however, no significant influence of the ACUPA ligands were observed (Figure 1d-g) . Additionally, the NPs demonstrated fast release of carborane with low delivery of boron to tumors in vivo (Figure 1h ). Conclusions: These data demonstrate for the first time the feasibility of targeting PSMA with carborane NPs, and establish the foundation for future medicinal chemistry to enable their best use in vivo. Abstract Body : Contrast agents for magnetic resonance imaging (MRI) can improve anatomical visualizations. However, owing to poor image resolution in whole-body MRI, resolving fine structures is challenging. To address this problem, diverse contrast agents have been developed, with a structure of inorganic core and protecting shell, yet potential toxicity induced by organ accumulation hampers their application.1,2 Here, Fe-based novel nanoparticle is developed with inverted structure, polysaccharide supramolecular core and a shell of ferric oxide shell. The nanoparticle results in strong T1 MRI contrast effect (with a relaxivity coefficient ratio of ~1.2), with image resolutions of the order of a few hundred micrometres, of cerebral, coronary and peripheral microvessels in rodents and of lower-extremity vessels in rabbits. The nanoparticle is synthesized at room temperature in aqueous solution without surfactants, which contrasts with the conventional way for inorganic-based contrast agents. The way of synthesis results in unique characteristics of contrast agent, including long blood circulation for high resolution angiography and perfect renal celarance profiles without any accumulation in organs such as liver. The nanoparticle's biocompatibility and imaging performance may prove advantageous in a broad range of preclinical and clinical applications of MRI. 

Valerie Rouffiac, Gustave Roussy, Université Paris-Saclay, UMS AMMICa INSERM US23-CNRS 3655., valerie.rouffiac@gustaveroussy.fr

Abstract Body : Introduction Cardiovascular disorders are a major public health problem. Some of these disorders originate from endothelial dysfunction such as artherosclerosis or thrombosis. Developments of vascular endothelium repair therapies are thus challenging to restore physiological hemorheology and tissue properties. We propose in this study to evaluate by intravital microscopy, hPSC-ECs therapeutic potential to promote angiogenesis after vascular ischemia in mice. Materials & Methods Multiscale intravital imaging of the vascular network was performed through dorsal skinfold chamber. Surgical implantation was done at Day 0 (D0) onto nude mice divided into 3 groups: (G1)-4 control mice injected with 20 µL PBS with ischemia ; (G2)-7 treated mice injected with 3.105 hPSC-ECs suspended in 20µL of PBS with ischemia ; (G3)-7 treated mice injected 3.105 hPSC-ECs suspended in 20µL of PBS without ischemia. All mCherry-hPSC-ECs were injected close to ischemia induced by thermal cauterization of a macrovessel 15 minutes before cells injection to allow sufficient heat dissipation for preventing cell injuries. Surgical procedure was ended by closing the dorsal chamber with glass coverslips. Mice recovered until D5 and were imaged at D5, D19, D26 and D29 onto a macroscope (AZ100M, Nikon) and a confocal microscope (SP8, Leica) in wildfield and fluorescence mode after 100 µL Dextran-FITC intravenous injection (25µg/µL). Different Dextran-FITC molecular weights from 2000 to 70kDa were used. Acquisition settings were fixed identical as far as possible from D5 to D29. For each day and mouse, fluorescent images were post-processed with Fiji and vascular density was quantified using the skeleton plugin after background subtraction. Results & Discussion An unexpected mortality was observed for all mice after the 2nd Dextran injection for molecular weight ranging from 2000 to 150kDa. In a previous and similar study (Proust et al. 2020) , multiple Dextran 2000kDa-FITC injections resulted in a 100% survey in C57Bl6 mice. Dextran-FITC molecular weight was thus decreased until 70 kDa in order to reach 0% mice mortality. The number of mice/group was thus reduced to 1, 2 and 2 for G1, G2 and G3 respectively. Despite a reduced number of mice/group, qualitative observations of fluorescent images revealed a migration of hPSC-ECs towards the proximities of blood vessels in the presence of ischemia but also without vessel injury which was confirmed in post-mortem by immunofluorescence. Quantitatively, the number of new vessels did not differ between G1 and G3 with a slight increase of vascular density for G2. Further investigations need to be now conducted in order to: 1-elucidate the "intolerance" of Dextran-FITC ranging from 150 to 2000kDa after 2nd intravenous injection in nude mice, 2-the underlying processes for vessel density increase in presence of hPSC-ECs without ischemia and 3-to confirm the angiogenic potential of hPSC-ECs on a larger cohort of animals. Abstract Body : Metabolic MRI using hyperpolarized 13C nuclei has been becoming a popular tool for the study of metabolic process and has been used for a variety of applications ranging all the way from tumour treatment response [1] to the study of heart disease [2] . In this modality, the metabolic conversion of biologically relevant tracer molecules is studied by means of MRI imaging and spectroscopy. In order to make this modality technically feasible the signal of these marker molecules needs to be enhanced by several orders of magnitude prior to injection, commonly referred to as hyperpolarization. So far, the most prominent method and gold standard in this field is Dynamic Nuclear Polarization (DNP). However, for many applications, DNP is prohibitively expensive, complex and slow. In recent years ParaHydrogen Induced Polarization (PHIP) has been explored as a fast, cost-efficient alternative by several research groups [3, 4] although so far lacking a demonstration that it can compete with DNP in a clinical and preclinical environment. Here we present for the first time a study using parahydrogen based hyperpolarized fumarate and pyruvate at clinically relevant concentrations (> 100mM) and Hyperpolarization values up to 20 % at the time of injection. These benchmarks are reached by using specially tailored starting molecules and reaction conditions. The solutions are cleaned from the hydrogenation catalyst, impurities, reaction side products and organic solvents prior to injection by either precipitating the reaction product or employing a novel extraction of the hyperpolarized tracers from organic solvents (liquid-liquid separation). In a comparative study we show for the first time that PHIP based methods can compete and even surpass both polarization and concentrations levels of metabolic tracers prepared by DNP but at a fraction of the cost, complexity, preparation time and footprint of the polarizer. Figure 1 shows an example of this study of pyruvate converted to lactate in a tumour mouse model.

References: [1] Day, Sam E., et al. "Detecting tumor response to treatment using hyperpolarized 13 C magnetic resonance imaging and spectroscopy." Nature medicine 13.11 (2007): 1382-1387. [2] Rider, Oliver J., et al. " Noninvasive in vivo assessment of cardiac metabolism in the healthy and diabetic human heart using hyperpolarized 13C MRI." Circulation research 126.6 (2020): 725-736. [3] Knecht, Stephan, et al. "Rapid hyperpolarization and purification of the metabolite fumarate in aqueous solution." Proceedings of the National Academy of Sciences 118.13 (2021) . [4] Reineri, Francesca, Tommaso Boi, and Silvio Aime. "Parahydrogen induced polarization of 13 C carboxylate resonance in acetate and pyruvate." Nature communications 6.1 (2015): 1-6. Abstract Body : Many brain disorders are caused by genetic mutations in every cell in the body1, while many others are caused by the dysfunction of large brain regions. Any gene therapy attempting to treat these disorders will have to be safely delivered to large brain areas. Invasive intracerebral injections cannot be feasibly used for gene delivery to large brain regions as they would result in a significant tissue disruption2. Engineered viral vectors that cross through intact BBB are a promising alternative, but their BBB-permeation properties can be species-specific, and these vectors lack spatial targeting. A potential solution is to use focused ultrasound (FUS) induced BBB opening (FUS-BBBO) for AAV-mediated gene delivery to specific brain regions3.4. To date applications of FUS were focused on local/regional targeting, with at most several percent of the brain being targeted for gene delivery5. For large animal or human applications, however, even small brain regions would need to be targeted with dozens of insonations. Consequently, there is a need to evaluate safety and feasibility of targeting large numbers of brain regions for FUS-BBBO gene delivery. In this work, the safety and feasibility of gene delivery to large brain regions in a single FUS-BBBO session in mice were confirmed. Incrementally larger volumes of forebrains in mice were targeted, starting from 11 sites (~10% brain volume) up to 35 sites (~30% brain volume, covering an entire hemisphere). To validate our protocol BBB was first opened in 11 sites during a single insonation session and immediately afterward, EBD was injected into the tail veins of the mice. After 20 minutes, the mice were perfused, and their brains were sectioned for histology. An acoustic pressure of 0.27 MPa , 30 pulse trains of ultrasound ,10 ms burst duration and 1000 ms burst period was determined to be appropriate for FUS-BBBO, due to successful EBD delivery in each targeted site and lack of observed RBC extravasation (height > 50 µm and width > 50µm) in the majority (86.36 %) of the opened sites. Using the parameters established for EBD delivery, it was decided to test gene delivery to large brain regions with FUS-BBBO. AAV9 carrying a GFPs under CaG promoter was delivered intravenously and performed FUS-BBBO in 11 -22 sites in the forebrain. In the first group, 11 sites were targeted without overlap in the BBB opening. In the second group, 11 sites were targeted as well, but the beams were placed more densely and partially overlapping. Finally, in the third group 22 sites were targeted with partial overlap to determine safety of a large-region BBB opening. No significant weight loss in any of the tested mice at any point after the FUS-BBBO, suggesting no significant neurological impairment (n=3-4 per group; two-way ANOVA). After 3 weeks the mouse brains were extracted and sectioned. No signs of RBC extravasation or other damage were visible on histology, suggesting resolution of any acute RBC extravasation that may have been present. It was observed an 18-fold improvement in transduction as compared to untargeted sites (33% vs 1.8% positive cells, p=0.0019, unpaired, two-tailed, heteroscedastic t-test).To assess the preliminary safety of opening the BBB in larger brain areas, 35 sites (~30% of the brain volume) were targeted in a single FUS-BBBO session followed by EBD delivery. Successful EBD delivery in all sites and only 10% of the sites showed RBC extravasation >50 microns were observed. This study shows that gene delivery to large brain regions above 20% is feasible and safe in a single FUS-BBBO session, suggesting the potential use of FUS-BBBO in the treatment of brain disorders affecting large areas of the Brain.

References: 1.Turner, T. J., Zourray, C., Schorge, S., & Lignani, G. (2021) . Recent advances in gene therapy for neurodevelopmental disorders with epilepsy. Journal of Neurochemistry, 157 (2), 229-262. 2.Benger, M., Kinali, M., & Mazarakis, N. D. (2018) . Autism spectrum disorder: prospects for treatment using gene therapy. Molecular autism, 9(1), 1-10. 3.Hynynen, K., McDannold, N., Vykhodtseva, N., & Jolesz, F. A. (2001) . Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. Radiology, 220 (3) Focused ultrasound blood-brain barrier opening (FUS-BBBO) for gene delivery to large brain regions. The safety and efficacy of targeting between 10 and 30% of the brain volume in a single FUS-BBBO session in mice were tested. it was found that the procedures so far were well tolerated and resulted in successful gene delivery.

Last Name: Nouraein Email: sn54@rice.edu

Dangshe Ma, Regeneron Pharmaceuticals, dangshe.ma@regeneron.com

Abstract Body : Introduction: REGN5054 is a fully human monoclonal antibody that binds specifically to human and cynomolgus CD8 expressed on T cells. REGN5054 was radiolabeled with 89Zr, a positron emitting radionuclide, and has been developed and evaluated in preclinical studies for non-invasive immuno-PET for detection of increased tumor-infiltrating T cells in cancer immunotherapy.1,2 Here, we explore its application in detection of CD8 T cell infiltration in a non-human primate kidney transplant model. Assessment of CD8 T cell infiltration into solid organ allografts is a powerful approach to better understand and monitor early graft rejection.3 Biopsies are the gold standard to monitor graft immune cell microenvironment, detect early graft rejection and guide immunosuppressive (IS) therapy. However, biopsies suffer from sampling error and harbor the risks of an invasive procedure. Imaging T cell infiltration in a cynomolgus model would allow validation of the technology in a clinically relevant model. Methods: REGN5054 was conjugated to the bifunctional chelator p-SCN-Bn-deferoxamine (DFO) for 89Zr radiolabeling to generate 89Zr-DFO-REGN5054. A single dose of 1 mCi 89Zr-DFO-REGN5054 was intravenously injected into naïve cynomolgus monkeys at either 0.5 mg or 2.5 mg total REGN5054 dose (n = 2/group) in order to determine optimal dose for imaging. PET/CT imaging data was acquired at 2 hours and 1, 4, and 6 days post-injection in a Siemens Biograph mCT PET/CT scanner. For the kidney transplant study, four monkeys underwent induction regimen including splenectomy, rituximab, mycophenolatemofetil, tacrolimus and steroids, followed by allogeneic, orthotopic kidney transplantation. The contralateral, native kidney was left to serve as an internal control. Post kidney transplant, animals underwent an initial phase of immunosuppression (IS), a phase of simulated graft rejection by tapering down IS, and a phase of rescue by tapering up IS. At the end of each phase, a single dose of 1 mCi, 0.5 mg 89Zr-DFO-REGN5054 was injected and immuno-PET/CT images were acquired Day 1 and Day 4 thereafter. Needle core biopsies from transplanted kidneys were stained with PAS for routine histology and underwent immunohistochemistry (IHC) for CD8 followed by digital quantification using Halo (Indica Labs) for correlation analysis with PET Standard Uptake Value (SUV). Results: 89Zr-DFO-REGN5054 was well tolerated in all cynomolgus monkeys. 89Zr-DFO-REGN5054 immuno-PET revealed dosedependent uptake in T cell-rich organs; spleen, lymph nodes, and bone marrow with the 0.5 mg dose having a higher uptake in spleen, lymph nodes and bone marrow. The protein dose of 0.5 mg was selected for the transplant study. 89Zr-DFO-REGN5054 showed similar, low uptake in both the grafted and native kidneys during the pre-rejection phase. During the rejection phase, increased uptake was detected in the grafted kidneys by immuno-PET, correlating with increased interstitial infiltrates by histology. During the rescue phase, uptake of 89Zr-DFO-REGN5054 in the grafted kidneys was incompletely reduced compared to the rejection phase, in spite of histologic resolution, while the uptake in the native kidney remained similar across all phases of the study. Comparison of both Banff score and CD8 IHC from needle biopsy samples to PET SUV uptake demonstrated a good correlation among percent CD8+ cells, SUV and Banff score. Conclusion: This work demonstrates that 89Zr-DFO-REGN5054 can specifically detect CD8 T cells in lymphoid tissues of CD8 in naïve monkeys. Importantly, 89Zr-DFO-REGN5054 can detect CD8 T cell infiltration in early graft rejection after solid organ transplantation, and imaging data showed good correlation with gold standard biopsy analyses. The use of iPET to track CD8 T cells has applications in cancer treatment, inflammation and transplantation. Abstract Body : Background: Atherothrombosis, an atherosclerotic plaque disruption condition with superimposed thrombosis, is the underlining cause of cardiovascular episodes. Understanding the pathophysiology of the disease progression is the prerequisite for the early detection and successful treatment of this deadly condition. Current 2D in vitro atherosclerosis models and animal models have several limitations because of the lack of physiological microand macro-environment parameters and inter-species differences, respectively. Moreover, the failure rate of the new investigated drugs during clinical transition still remains approximately 95% due to these limitations. Hence, microfluidic lab-on-a-chip technologies are developed to fill the gap between in vitro and in vivo models with high precision. Aim: Our study aims to develop a physiological relevance in vitro microfluidic model for real-time observation of the site-specific atherothrombosis formation on-chip and drug discovery. Methods: The PDMS devices were fabricated by the standard photolithography and soft lithography techniques. The device consisted of two interconnected microchannels, viz main and supporting channels, where the former mimics the vessel geometry with different stenosis and the latter introduces plaque components to the circulation simultaneously. The interconnecting region is 400 μm length long with a pore size of 2 μm. Devices with different stenosis were fabricated by reducing the width of the main channel at the site of the porous region by increasing the blockage to mimic the plaque geometry. The gelatin-collagen composite hydrogel was infused as plaque components into the supporting channel and exposed to the main channel in a site-specific manner via the interconnected region. Human fresh whole blood was run through the main channel of the chips with different stenosis at a physiological arterial shear rate of 1,000 s-1 by a syringe pump for the real-time observation of the site-specific thrombus formation under the fluorescence microscope. Antiplatelet efficacy of the known drug aspirin was detected by adding the drugs at different concentrations (50 µM, 100 µM) in the blood before perfusion. Finally, we employed the device to test the targeted binding of the RGD (arginyl-glycyl-aspartic acid) labelled polymeric nanoparticles (PNPs) on the thrombus and compared the binding affinity with the non-targeted (RAD (Arg-Ala-Asp) labelled) particles. Results: A strong correlation was observed between vessel geometry and the thrombus formation phenomenon. Meanwhile, the complete occlusion time for the main channel of 64% stenosed and 45% stenosed chip was approximately 20 min and 30 min, respectively, but no occlusion was observed in the chip with 15% stenosis, which demonstrated the in vivo relevance of our design. Moreover, the chip exhibited profound sensitivity to detect the antiplatelet efficacy of the aspirin. In therapeutic doses (50 µM, 100 µM), aspirin prolonged the platelet adhesion time and reduced the thrombus area over the stenosis region in a dose-dependent manner. Finally, the targeted RGD-PNPs exhibited a strong affinity to bind to the thrombus immediately after perfusion and completely covered the surface of the thrombus after 10 min, while non-targeted particles showed minimum binding. Conclusion: We successfully developed and tested a site-specific atherothrombosis model on a microfluidic device for bridging the gap between in vitro and in vivo studies. This low-cost reusable device provides a versatile platform for fundamental vascular research and expands the use for discovering drug candidates, and testing target-specific drug carriers to improve the therapeutic profile. Abstract Body : Thrombosis is a condition where the formation of blood clot or thrombus occur inside the blood vessel, with related diseases estimated to be the cause of 1 in 4 deaths, making it one of the main causes of mortality worldwide1. Along with the COVID-19 outbreak in 2019, thrombosis is even more prominently relevant as one-third of COVID-19 related deaths were due to thromboembolism2. Establishing a clot-targeting theranostic particle for simultaneous diagnosis and treatment of thrombosis related diseases is crucial to provide rapid life-saving intervention. In this study, we developed a robust, activated platelet targeted gold-iron oxide nanoparticle (scFv-AuIONP) tagged with Cy5 for multi-modality imaging including magnetic resonance imaging (MRI), fluorescence imaging (FI), and photoacoustic imaging (PA). Additionally, due to the presence of gold layer on scFv-AuIONP, this theranostic particle was utilised to facilitate photothermal thrombolysis, stimulated by the exposure to near-infrared (NIR) laser at 808 nm. AuIONP generated was specifically designed to be asymmetrical through the seeding method to produce maximum absorption in the NIR wavelength of >750 nm and enhance significant thermal increase after laser exposure. The functionalised AuIONP demonstrated great potential as a multi-modal diagnostic contrast agent. In-vitro imaging results obtained on an in-vitro thrombus model, produced strong signal in all imaging modality of up to 3-fold increase compared to the non-targeted particle (MutscFv-AuIONP). In-vivo observation with AlCl3 carotid arterial injury model further corroborates the positive results from in vitro, exhibiting a significant change in T2* contrast with the MRI, with T2* signal enhancement doubled post injection of scFv-AuIONPs. Observation of photoacoustic imaging on an MSOT system produced more prominent photoacoustic signals with MSOT value increase of up to 3fold, indicating targeted particle was able to enhance clarity of signal on thrombus area. Furthermore, rapid increase of fluorescence intensity in the thrombus area zwas also observed with fluorescence imaging in an IVIS system after 5 minutes post injection of scFv-AuIONP. Additionally, upon exposure to NIR laser, blood flow comparison between before and after NIR laser treatment detected higher blood flow after laser in the targeted AuIONP group compared to the non-targeted group. These results indicate that the scFv-AuIONP construct was able to perform as a theranostic nanoparticle for thrombosis, by facilitating triple modality imaging which will enhance the precision of site-specific hyperthermia mediated thrombolysis. 

Yuao Wu, Griffith University -Queensland Micro Nanotechnology Centre, yuao.wu@griffith.edu.au

Abstract Body : Metal oxide-chitosan compounds as theranostic modular nano-cocktails for ROS and inflammatory related diseases Yuao Wu1,2, Gary Cowin4, Shehzahdi S. Moonshi1, Run Zhang2, Andrew Whittaker2,5, Huong D.N. Tran1,2, Najma Fithri1, Hang T. Ta1,2,3 1Queensland Micro-and Nanotechnology Centre, Griffith University, Brisbane, 4111, Australia 2Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane, 4072, Australia 3School of Environment and Science, Griffith University, Brisbane, 4111, Australia 4Centre of Advanced Imaging, University of Queensland, Brisbane, 4072, Australia 5ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, The University of Queensland, Brisbane, QLD 4072, Australia Presenting author: Yuao Wu, yuao.wu@griffith.edu.au Corresponding author: Hang Ta, h.ta@griffith.edu.au Inflammation plays an essential role in the progression of many chronic diseases like hepatopathy, atherosclerosis and rheumatoid arthritis. Cytokines such as tumour necrosis factorα (TNF-α), interleukin-6 (IL-6), cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) play important roles in the regulation of the inflammation. In this study, modular two-inone nano-cocktails were synthesised to provide treatment of inflammatory diseases and also enable tracking of their delivery to the disease sites. Chit-IOCO loaded with treatment module (cerium oxide nanoparticles) and imaging module (iron oxide nanoparticles) were synthesised by electrostatic self-assembly. Its MRI capability, anti-inflammatory and anti-fibrosis ability were investigated. Results demonstrated that Chit-IOCO significantly reduced the expression of ROS, TNF-α and COX-2 in the LPS-stimulated macrophages. Cytotoxicity studies showed that the nano-cocktails inhibited the proliferation of macrophages. Additionally, Chit-IOCO is a great MRI contrast agent in macrophages. It is possible to track the delivery of Chit-IOCO to the inflamed livers of CCl4-treated C57BL/6 mice, demonstrated by a shortened T2* relaxation time of the livers after injecting Chit-IOCO into mice. In vivo anti-inflammatory and blood tests demonstrated that Chit-IOCO reduced inflammation-related proteins (TNF-a, iNOS and Cox-2) and bilirubin in CCl4 treated C57BL/6. Histology images indicated that the nano-cocktails reduced fibrosis of CCl4-treated mouse liver and did not affect other organs of the mice. This is the first reported data on the anti-inflammation and anti-fibrosis efficacy of Chit-IOCO in C57BL/6 mouse liver inflammation model. Overall, Chit-IOCO nano-cocktails have shown great potential in MR imaging/detecting and treating/therapeutic capabilities for inflammatory diseases. Potentially, these nano-cocktails can be modified with antibodies or binding peptides, allowing these nanoparticles to target the inflammatory biomarkers for the diagnosis of diseases. I forgot to include persuasive data in my first submission. So I submit again for assessment and if possible wish to withdraw the first one. 1 ImmunoPET provides the opportunity to noninvasively decode immune cell motility, distribution, and homing. Engineered single-chain variable-fragment (scFv)-heavy-chain 3 (CH3) antibody fragments (minibodies) possess optimal distribution and clearance properties particularly for PET imaging, capable of both patient stratification and guiding immunotherapies. Currently, the radiolabeled human CD8 targeting minibody 89Zr-Df-IAB22M2C (Crefmirlimab) is being evaluated in a phase II clinical study.2 In this project, we investigated whether its mouse CD8 directed counterpart is applicable to longitudinally monitor the CTL migration and homing dynamics during immune checkpoint blockade (ICB) in a syngeneic tumor mouse model. Methods: The desferrioxamine conjugated murine CD8 targeting minibody IAB42 (DFO-mCD8-Mb) was radiolabeled with 89Zr. Labeling efficiency was assessed via HPLC and TLC. The immunoreactive fraction of 89Zr-DFO-mCD8-Mb and its cellular internalization were tested on freshly isolated murine CTLs. MC38 murine colon adenocarcinoma cells were injected subcutaneously in C57BL/6 mice. When the tumors reached a diameter of ~6-8 mm, mice were treated either with 500 µg of αPD-L1/αLAG-3 mAbs, or 100 µg of αPD-1 mAbs. To block lymphocyte migration from the lymphoid organs, 20 µg of Fingolimod (FTY720) was repetitively administered intraperitoneally. 2 MBq/10 µg of 89Zr-DFO-mCD8-Mb was injected intravenously one day before therapy initiation. Simultaneous PET/MR scans were performed 24 h post-injection (baseline, day 0) and 1-7 days post-treatment to follow T cell migration into the tumor and lymphatic organs. Mice were sacrificed after the last imaging time point for ex vivo organ biodistribution analysis and immunohistochemistry. Tumor growth ratios (calculated as the volume of the imaging endpoint divided by the volume of the baseline scan) Results: The radiolabeling efficiency of 89Zr-DFO-mCD8-Mb was constantly >90.0%. The immunoreactive fraction, tested on CTLs, yielded 95.4±0.7%. Rapid tracer incorporation into CTLs was achieved with 32.3±0.3% of the 89Zr-DFO-mCD8-Mb being internalized within 4 h of incubation. Based on the in vivo MC38 tumor growth rates, we identified seven treatment responders out of 15 experimental mice treated with αPD-L1/αLAG-3 mAbs. 89Zr-DFO-mCD8-Mb uptake in the tumor of responding mice (2.58±0.34 %ID/ml) was two-fold higher compared to the uptake in the non-responding group (1.31±0.23 %ID/ml) seven days after ICB onset, which was confirmed by ex vivo biodistribution analysis. Interestingly, the longitudinal in vivo tumor uptake graphs of both groups separated already at a very early time point of 2 days of ICB, suggesting that repetitive imaging of CTLs allows for early response evaluation. A second cohort of experimental tumor-bearing mice was treated with a suboptimal ICB dose of αPD-1 mAbs to mimic the clinical situation of a huge variety of treatment responses. To elucidate whether the differences in 89Zr-DFO-mCD8-Mb tumor uptake were due to the immigrating CTLs from the lymphatic organs, another experimental group was additionally treated with FTY720. In line with the first experiment, we were able to differentiate responding and non-responding MC38 tumors as early as 2 days after treatment initiation by PET. Importantly, FTY720 treatment resulted in significantly lower 89Zr-DFO-mCD8-Mb tumor accumulation compared to the responding mice and similar uptake as mice refractory to ICB. We further identified the spleen with increased tracer uptake by ex vivo biodistribution analysis as a potential source for anti-tumoral CTLs that migrate to the tumor during effective ICB. Conclusion: The internalized 89Zr-DFO-mCD8-Mb and the long half-life of 89Zr enable the longitudinal and non-invasive monitoring of the migration of endogenous CTLs in response to ICT. Furthermore, our data emphasize the possibility to non-invasively predict the patientspecific outcome to immunotherapy at early time points.

Vera Jörke, Werner Siemens Imaging Center, Eberhard Karls University Tübingen, vera.joerke@med.uni-tuebingen.de

Abstract Body : Diet-induced liver steatosis promotes lipid-mediated toxicity and mitochondrial dysfunction resulting in nonalcoholic steatohepatitis (NASH) which is a major cause of hepatocellular carcinoma (HCC). The progression to NASH and HCC is driven by hepatocyte death, endoplasmic reticulum-stress, fibrosis and the inflammatory infiltrate including CD8+ T cells but the exact mechanisms are unknown. Our aim was to characterize the alterations in the liver tissue in vivo during the progression of NASH using noninvasive proton magnetic resonance spectroscopy (MRS) to address the lipid profile along with positron emission tomography (PET) using the 89Zr radiolabeled anti murine CD8 minibody (Mb) IAB42 (89Zrdf-CD8 Mb) to investigate the CD8+ T cell infiltrate. C57BL/6J mice were fed with a cholinedeficient high fat diet (CD-HFD) or standard chow over a time course of 12 months1. We performed MRS with a water-suppressed STEAM sequence using a 7T MRI after 3, 6, 9 and 12 months of diet. The CD8+ T-cell infiltrate was investigated by PET 24h after intravenous 89Zrdf-CD8 Mb injection at 3, 6, 9 and 12 months of CD-HFD. For anatomical reference, magnetic resonance imaging was performed. We harvested liver tissue and performed histopathology (hematoxylin & eosin, H&E), immunohistochemistry (IHC) and flow cytometry (FC) focusing on CD8+ T cells. All data is presented as mean ± SEM. On CD-HFD, the body weight and liver volume of the mice increased significantly compared to the control group with standard diet. Already at 3 months, MRS revealed drastic changes in the fractional lipid mass, saturated lipids and the lipid mean chain lengths in the livers of CD-HFD animals, whereas the histopathological analysis showed only a minimal steatosis with focal necrosis and inflammation. Interestingly, 89Zr-df-CD8 Mb-PET revealed no differences in the CD8+ T cell infiltrate at 3 months in line with FC or IHC. The changes of the metabolic profile detected by MRS further increased at 6 months of CD-HFD. Typical histological features of NASH were still scarce in some animals at 6 months of CD-HFD, though three animals out of five fed with the CD-HFD were categorized as potential NASH or NASH according to the scoring system. The CD8+ T cell infiltrate was only marginally increased at 6 months of CD-HFD detected by 89Zr-df-CD8 Mb-PET and FC. At 9 months of CD-HFD, typical histopathological signs of NASH were observed in 5 of 7 animals, whereas MRS did not reveal any further changes compared to 6 months of CD-HFD. 89Zr-df-CD8 Mb-PET yielded a slight increase in CD8+ T cells in CD-HFD animals. Finally, after 12 months of CD-HFD the metabolic profile detected by MRS remained stable compared to 6 and 9 months of CD-HFD. Typical histological features of NASH were present in all CD-HFD animals. 89Zr-df-CD8 Mb-PET revealed a high intragroup variability of the tracer uptake with an overall slightly increased uptake in the livers of CD-HFD mice compared to control mice. IHC confirmed an increase in CD8+ T cells in the livers of CD-HFD mice, while FC showed a tendency to an enhanced CD8+ T cell infiltrate at 12 months. Our results indicated that noninvasive in vivo MRS is a promising tool in the early detection of changes in the hepatic lipid profile during NASH development. We further demonstrated the feasibility of noninvasive in vivo monitoring of the CD8+ T cell infiltrate in NASH representing a novel tool to study the role of CD8+ T cells during disease progression from steatosis to NASH and HCC. Whether the potential clinical translation of these noninvasive imaging techniques allows an early diagnosis of NASH or even a prediction of HCC needs to be studied further in preclinical experiments as well as in clinical trials. 

Shadi Esfahani, Massachusetts General Hospital, esfahani.shadi@mgh.harvard.edu

Abstract Body : Purpose: Neuroendocrine tumors (NET) are known as immune deserts, due to paucity of immune cells in the tumor, which results in very low response rate to immune check point inhibitors (ICI). We hypothesize that combination of peptide receptor radiotherapy (PRRT) with somatostatin analogs (SSA) results in increased tumor inflammation and release of tumor antigens and thus increase the response rate to ICIs. Here we discuss the results of combining ICI and PRRT in a humanized mouse model of NET using human granzyme B specific peptide PET/MR imaging. Methods and Materials: In this IACUC-approval study, humanized immunocompromised NSG-PBMC mice (n= 48) were implanted with QGP-1 NET cells in the subcutaneous space of the right flank. After the tumor volume reached 150 mm3, mice were treated with saline (control), pembrolizumab (anti-PD-1), high-dose (HD) PRRT only (using 177Lu-DOTATATE), or a combination of pembrolizumab with low (LD), medium (MD) or high (HD) dose of PRRT. Mice undergone 68Ga-NOTA-hGZP PET/MR imaging at baseline and 6 days after treatment (n=8/group). Tumor tissues were extracted and stained for H&E and GZB and analyzed for immune cell populations using flowcytometry (n=4/group). Tumor volumes were measured twice a week until 21 days after initiation of the treatment and growth curves were drawn for each treatment group. Statistical analyses was performed using PRISM 9. Paired and unpaired t-test and repeated measures ANOVA were used for comparison. Linear regression analysis was performed for evaluation of the correlation of GZB expression level in tissues and GZP PET uptake. Results: 68Ga-NOTA-hGZP PET/MRI demonstrated a significant increase in the SUVmax of tumors treated with HD PRRT + Pembro (3.7±0.3) and MD PRRT + Pembro (3.4±0.3) compared to LD PRRT + Pembro (1.2±0.2), Pembro only (1.4±0.2), HD PRRT only (2.2±0.3) , and Saline (1.3±0.2) (p 0.05). Tumor growth curves showed a significant reduction in the tumor volumes in the MD PRRT + Pembro and HD PRRT + Pembro compared to other groups (p Conclusions: The results of this study showed that combination of PRRT and ICI therapy can markedly increase granzyme B expression in the neuroendocrine tumors and reduce the tumor growth compared to solo ICI or PRRT. Quantitative changes in GZB specific PET uptake could be used to predict response to these therapies within few days after initiation of treatment and can help with personalizing the treatment of NET in advanced stages.

Image/Figure Caption: Combination of PRRT and immunotherapy improves treatment response in neuroendocrine tumors. A)Representative 68Ga-NOAT-hGZP PET/MR Images of NSG-PMBC humanized mice with human neuroendocrine QGP tumors at baseline and 6 days after treatment with saline (as control), pembrolizumab only, high-dose (HD) PRRT only, or combination of pembrolizumab with low dose (LD), medium dose (MD) or HD PRRT. B) PET SUVmax in the tumors treated with combination MD PRRT + Pembro and HD PRRT + Pembro is significantly higher than tumors treated with saline, pembrolizumab only, and HD PRRT only. Significantly higher tumor uptake is seen in medium and high dose PRRT groups compared to the low dose PRRT. However, no significant difference is seen between the high dose and medium dose groups. Uptake in the MD and HD PRRT + Pembro groups, and to lesser degree in HD PRRT only group increased post-therapy compared to the baseline whereas uptake in all groups was similar. C&D) Immunohistochemistry analysis of the tumor tissues confirms increased GZB in the treated tumors with high and medium dose of PRRT combined with pembrolizumab compared to other treatment group and control, while the percentage of increase in GZB in the tumors was not significantly different between the MD and HD PRRT groups. E) The level of GZB expression in the extracted tumor tissues is significantly correlated to the degree of PET uptake. F) Representative growth curve analysis of all groups shows that medium and high dose PRRT + Pembro significantly reduced tumor growth compared to all other groups. PRRT only also decreased the average tumor size but to much lower extent. The low dose PRRT + pembro and pembro only somewhat slowed the tumor growth compared to the saline but did not stop the tumor from growing. The tumors in the control group consistently grew. Abstract Body : Abstract Introduction The colorful fluorescent carbon dots (CDs) excited at one wavelength is very promising nanoprobes for multi-color bioimaging. Because they prossess the advantages of label-free, simple synthesis, multi-color visualization and prevention of background interference. [1] [2] [3] [4] [5] Nowtodays, with the rapid development of the world economy, cancer has become a major cause of death worldwide, causing nearly 10 million deaths in 2020. One of the most effective treatments for cancer is surgical resection. [6] Compared with preoperative imaging examination, intraoperative visual examination or palpation, fluorescent imaging-guided nanosurgery is better. However, there is almost no report on the use of fluorescent CDs for imaging-guided surgical resection. Here, we prepared the green source CDs through green synthesis method for accurately resect tumor. We utilized the multi-channel fluorescent imaging property of CDs to track the real-time imaging that CDs are internalized by different cancer cells lines，and multi-color imaging of the tumor is carried out in the situ pancreatic cancer model mice through fluorescent intraoperative navigation equipment to accurately achieve the pancreatic tumor resection. This work is the first time that CDs are employed for fluorescent intraoperative navigation to accurately resect tumor, which broadens the horizon for the application of CDs in biology. Methods

The prepared of CDs, we selected glucose and amino acids that are essential nutrients for the human body, and prepared the green source CDs through a one-pot green synthesis method. With the help of confocal laser imaging microscope (CLSM), we utilized the multi-channel fluorescent imaging property of CCs to track the real-time imaging that CCs are internalized by different cancer cells lines. Then, multi-color imaging of the tumor is carried out in the situ pancreatic cancer model mice through fluorescent intraoperative navigation equipment to accurately achieve the pancreatic tumor resection. The situ pancreatic tumor mice were intravenously injected with CDs. Meanwhile, we also proved that CDs have excellent biocompatibility. Thus, the CDs can be employed as a promising nanoprobes for fluorescent intraoperative navigation to accurately resect tumor.

Through the analysis of laser confocal experiments, we proved that the prepared colorful CDs can be effectively Endocytosis by tumor cells. In testing different tissue samples of different thicknesses, we analyzed that the signal-to-noise ratio of carbon dots to tumors is the highest. Therefore, in subsequent experiments, we constructed an orthotopic pancreatic tumor model and navigated through the carbon dots with the help of fluorescent surgery. The function of multi-color fluorescence can accurately remove pancreatic tumors. Conclusions In short, CDs with multi-color fluorescent imaging function were successfully prepared by hydrothermal reaction by glucose and amino acid as starting materials. CDs have excellent water solubility, biocompatibility, good stability and multi-color imaging characteristics. With the help of highresolution animal real-time imager and Cellvizio system, it is proved that CDs can effectively accumulate in the tumor site. At the same time, the situ pancreatic tumor can be accurately resected with the help of the fluorescent intraoperative navigation and multi-color imaging function of CDs. It's worth mentioning that this is the first report on CDs for intra-fluoroscopy navigation.

References: [1] and labelled with a fluorescent P-selectin aptamer (5'-azide-P-Ap-3'-Cy3) using a copper-free click chemistry approach. B) Fluorescent visualization of MBs successfully labelled with Cy3-labelled P-selectin aptamer (5'-azide-P-Ap-3'-Cy3) (red). C) Bar graph summarized mean ± standard deviations of the targeted US signal (a.u.) using non-targeted MBs (blue) and P-selectin targeted MBs (green) in control (left) and treated, acute IBD induced (right) mice. D) Bar graph summarized mean ± standard deviations of the targeted US signal using non-targeted MBs (blue) and P-selectin targeted MBs (green) in IL-10 KO mice (that were chemically induced with TNBS; where * p < 0.05, ** p < 0.01).

Last Name: Goncin Email: ung039@usask.ca

Han Deng, The southern medical university,zhujiang hospital, d_hann@163.com

Abstract Body : Introduction Continuously updated diagnostic methods and advanced imaging methods have led to an increase in the early detection rate of small liver cancer，however, liver cancer still increase almost 3% per year (1) . The main reason for this phenomenon is that, many liver cancer nodules are accompanied by cirrhotic nodules, accurate judging a hepatocellular carcinoma (HCC) nodule with diameter less than 2 cm under Liver cirrhosis background is still a huge challenge by current diagnosis methods (2) . Hence, failure to exactly diagnose liver cancer at an early stage have lost the best time for treatment. Noninvasive Imaging methods nowadays have limitations in the diagnosis of small HCC under complex liver environment for its lack of specificity (3) . Therefore, to solve this issue, a new technology is needed to detect HCC nodules under cirrhosis which a targeted probe Fe3O4-GOD-GPC3 to combined with the photoacoustic imaging (PAI)/ Magnetic Particle Imaging System (MPI). PAI is used to provide noninvasive images at depths of several centimeters with a resolution of 30 µm (4) and MPI is used to effectively reduce background noise from the tissue specimen while assuring high sensitivity and in-depth penetration (5) , which makes it possible to detect small HCC with diameter less than 2cm. For the improvement of specificity, Fe3O4-GOD-GPC3 was designed that specifically targets hepatocellular carcinoma, which could recognize biomarker GPC3 on HCC cell membrane. Besides, Fe3O4-GOD-GPC3 not only have strong PAI/MPI signal, but also play a therapeutic role continuedly. it can effectively and accurately kills tumor cells by a sequential catalytic reactions. In this study, we focus on a new technology for imaging of targeted small HCC biological processes under liver cirrhosis background with high spatial resolution by PAI/MPI. Methods After the synthesis of Fe3O4-GOD, we modify the nanoparticles with peptide, which can recognition GPC3 specifically anchored to the cell membrane. Fe3O4-GOD-GPC3 appeared to be a useful contrast agent for PAI/MPI. The carcinogen-induced HCC mice (n=6) model was imaged by PAI/MPI after intratumorally injected with Fe3O4-GOD-GPC3 every 2 weeks. Then, treatment effect is monitored, in which survival rate significantly increase in xenograft HCC mice model (n=6). During process, we also demonstrated the nontoxicity of the probe at the cellular level, and the excellent efficacy of therapy with probes at the animal level. Results In our experiments, the PAI signals of Fe3O4-GOD-GPC3 gradually reduced with the increase of their respective concentrations. During the imaging process, we successfully captured the tumor signal under cirrhosis background. And in contrast to liver cirrhosis, the unique imaging character of the tumor are extracted by its dynamic contrast enhanced imaging. Clearly, targeted probe was capable of recognition of hepatocellular carcinoma. At last, we can remove the tumor successfully by its sequential catalytic reactions properties. Conclusions The target of this study was to detection small hepatocellular carcinoma under cirrhosis background using novel nanoparticles Fe3O4-GOD-GPC3 in vivo by

Seok-Yong Lee, Seoul National University Hospital, iamlsy25451@snu.ac.kr

Abstract Body : Introduction: Uncoupling protein 1 (UCP1) is abundantly expressed in interscapular Brown Adipose Tissue (iBAT) and is used as a biomarker of iBAT. Recently, UCP1-Luc2-tdTomato transgenic mice have been established and used in various iBAT studies. [18F] FDG-positron emission tomography (PET) can be used to image iBAT by monitoring glucose uptake in the iBAT, but higher glucose uptake in the brain interferes with iBAT imaging. The translocator protein (TSPO) targeting probe such as [18F] fluoromethyl-PBR28-d2 ( [18F] fm-PBR28-d2) has also been proposed to visualize the iBAT. Currently, there are no studies on the UCP1 expression by comparing PET imaging and Cerenkov luminescence imaging (CLI) using [18F] FDG or [18F] fm-PBR28-d2. Thus, we aim to observe the difference between [18F] FDG uptake and [18F] fm-PBR28-d2 binding in iBAT on PET imaging and CLI in UCP1 Thermomice. Methods: UCP1 Thermomice were established by insertion of a Luc2-T2A-tdTomato cassette into the initiation codon of the Ucp1-coding sequence in exon 1. Immunohistochemistry and western blot were performed to observe expression of UCP1 and TSPO in iBAT. Bioluminescence imaging (BLI) and CLI was monitored using an IVIS 100 imaging system (Xenogen, Alameda, CA, USA). PET scans were acquired by a simultaneous small animal PET insert (SimPET, Brightonics imaging, Seoul, Korea). Each group was anesthetized with 1.5% isoflurane combined with oxygen during imaging time and intravenously injected with MBq of [18F] FDG or [18F] fm-PBR28-d2. (11.1 to 14.8 MBq / mouse). Results: First, bioluminescence or fluorescence signals were clearly showed in iBAT. We found that immunohistochemical images of iBAT that both UCP1 and luciferase expression were significantly higher at same region. In UCP1 Thermomice, we determined that the expression of UCP1 and TSPO in iBAT was significantly higher than epididymal White Adipose Tissues (eWAT) or inguinal White Adipose Tissues (iWAT). [18F] fm-PBR28-d2 binding was clearly observed in the iBAT region where Cerenkov luminescence was emitted compared to [18F] FDG uptake. In [18F] FDG-PET was 5.08-fold higher than iBAT in brain, but TSPO-PET was 12.92fold higher than brain in iBAT. [18F] FDG-CLI was 1.5-fold higher than iBAT in brain, and we found that the TSPO-CLI was 1.92-fold higher than brain in iBAT. The group of high UCP1 endogenous expression was 1.67-fold higher versus group of low UCP1 endogenous expression. We showed [18F] FDG-CLI and [18F] FDG-PET imaging that there was no difference in the PET imaging by UCP1 endogenous expression. Interestingly, the TSPO-CLI was 1.33-fold and TSPO-PET was 2.59-fold significantly higher in the group with high UCP1 endogenous expression than in the group with low UCP1 endogenous expression. Conclusions:

In conclusion, our current study provides that the UCP1 thermomice make it possible to study iBAT target imaging. These results show that iBAT imaging can be replaced PET images by using optical imaging such as CLI with [18F] fm-PBR28-d2, TSPO targeting probe. (SWIR, 900-1700nm) , is an emerging technology with great potential for biomedical applications. Compared with the visible and near-infrared-I (NIR-I) spectra, the SWIR provides advantages such as higher signal to noise ratio and lower light absorption and scattering. These optical improvements result in higher transparency of the biological sample and a significant gain in depth penetration and image resolution1. However, despite recent progress in SWIR detection technology, there are a very limited number of biocompatible SWIR fluorescent probes with sufficient quantum yield (QY) to be used for biomedical applications. Quantum dots (QDs) are semiconductor nanoparticles with excellent characteristics for imaging due to their high fluorescence QY (~20-80%), great photostability and tunable emission wavelengths (from the visible to the SWIR). METHODS: In this study, we synthesized two populations of PbS/CdS core/shell QDs (A and B) with different PbS core sizes and CdS shell thicknesses to produce fluorescence probes with bright, narrow and distinctive emission in the SWIR spectrum, suitable for multiplexing. The PbS/CdS QDs were micelle encapsulated in lipid -polyethylene glycol (lipid-PEG) through thin film rehydration, providing the QDs with water solubility and terminal azide functional groups available to 'click react' with any moiety (antibody, peptide, small molecule) engineered with alkyne reactive functional groups2. Their spectral emission profile (from 900-1700 nm, 5 nm/step) was analyzed using an IMA™ hyperspectral microscope (Photon etc). Their photostability/photobleaching was evaluated in aqueous solution under continues exposure to a 785 nm laser illumination at 1.5 W for 5 min. Whole body biodistribution was investigated in mice intravenously (IV) injected with the QDs, using an IR VIVO (Photon etc) multispectral preclinical imager equipped with an InGaAs (ZephIR™ 1.7) detector. RESULTS: The spectral profile of the two populations of PbS/CdS QDs indicate peak emissions at 1280 nm (PbS/CdS QDs-A) and 1525 nm (PbS/CdS QDs-B), coinciding with the two SWIR optical sub-windows, the NIR-IIa (1.3-1.4 mm) and NIR-IIb (1.5-1.7 mm) , previously demonstrated to exhibit improved imaging metrics3. Both PbS/CdS QDs-A and -B showed resistance to photobleaching, with no significant loss of fluorescence intensity during 5 min of constant exposure to laser illumination. Biodistribution studies of the QDs IV injected via tail vein in mice showed a very strong signal in the vasculature and clearance organs such as liver, and spleen. The signal in the vascular network was significantly higher in animals injected at the same dose with PbS/CdS QDs-B compared to PbS/CdS QDs-A. This could be due to both the higher overall emission of PbS/CdS QDs-B and the improved signal to noise ratio and lower scattering in the NIRIIb sub-window. CONCLUSIONS: We have produced very bright, photostable, water soluble and biocompatible PbS/Cd QDs tuned to emit in the two most favorable optical sub-windows within the SWIR region (~1300 and 1500 nm). Their strong emission allows excellent visualization in vivo of the mouse vascular network when injected intravenously. Their selective accumulation in clearance organs (liver, spleen) indicates low potential toxicity in non-target tissues. The incorporation of terminal azide handles to the micelle encapsulated QDs will allow controlled conjugation of any moiety of interest (antibodies, proteins, peptides, etc) by ' copper-free click chemistry'. This functionality can be exploited to investigate in vivo the biodistribution and pharmacokinetics of therapeutic candidates in preclinical studies using SWIR imaging.

Sera Oh, Seoul National University, ohseraaaa@snu.ac.kr

Abstract Body : Introduction: Claudin-3 (CLDN3), a tight junction protein, regulates cell-to-cell interactions in epithelial or endothelial cell sheets. During tumorigenesis, epithelial cells are transformed and tumor cells proliferate through out-of-plane division, resulting in external exposure of CLDN3. This alteration of CLDN3 expression is associated with cancer progression, correlating with malignancy in various carcinomas. Since CLDN3 is particularly overexpressed in most ovarian cancers and used as an effective diagnostic marker, we tested the possibility of using a CLDN3-specific antibody as a novel imaging probe. Materials and Methods: After reducing the CLDN3 specific antibody to expose the -SH group, click chemistry was used to conjugate radioactive isotope 111In or fluorescent protein FNR648. Human ovarian cancer OVCAR-3 cells and human glioblastoma (U87MG) cells were used as CLDN3 positive and negative cells, respectively. Flow cytometry was used to measure the binding of CLDN3 IgG1 monoclonal antibody to theses cell lines. To establish xenograft model, OVCAR-3 cells were injected subcutaneously into the mice. 111In-labeled CLDN3 antibody (370 kBq/50 μl) was administered intravenously to mice with. After 24 hours, organs including tumor were excised and measured with a γ-counter. Images were acquired with IVIS and SPECT/CT. Results: The labeling efficiency of NOTA-111In or antibody-NOTA-111In was 98.52% or 100%, respectively. FNR648 labeled CLDN3 antibody was bound to the cell surface of OVCAR-3 at 83.4% and to U87MG at 5.7%, respectively. In OVCAR-3 tumor xenografted mice, mice injected with CLDN3 antibody showed 2.5-fold higher tumor uptake (20.4 ± 7.4% ID/g) than mice injected with human IgG (8.8 ± 2.6% ID/g) at 24 hour p.i. The fluorescence signal of CLDN3 antibody peaked at 24 hour p.i. Conclusion: We successfully conjugated radioisotope and fluorescent protein using the CLDN3 specific antibody. Since the specific binding of CLDN3 antibodies to OVCAR-3 tumors has been validated in a mouse model and diagnostic radionuclides can be replaced with therapeutic radionuclides, this human monoclonal antibody could be used as a useful theranostic probe.

First Name: Sera Last Name: Oh Email: ohseraaaa@snu.ac.kr Organization: Seoul National University muscle ) was better than that of monomer peptides. Immunohistochemistry confirmed that SMMC-7721 tumor expressed GPC3 and PSMA. CONCLUSION: The heterodimer 68Ga/18F-TJ12P2-PSMA targeting both GPC3 and PSMA was successfully synthesized and used for HCC imaging. The molecular probe has ideal labeling rate, radiochemical purity and stability. It showed good tumor targeting ability, which is better than the corresponding monomeric counterpart in vivo and in vitro experiments. Its promising in vivo performance makes it an ideal candidate for future clinical translation. KEYWORDS: Glypican-3; prostatespecific membrane antigen; gallium-68; fluorine -18; hepatocellular carcinoma; positron emission computed tomography References: Reference: [1] Filmus J, Capurro M, Rast J. Glypicans. Genome Biol. 2008; 9(5):224. doi: 10.1186 /gb-2008 Abstract Body : Introduction: An understanding of the importance of the gut microbiome in many diseases has been rapidly increasing, with connections to many autoimmune diseases (e.g. rheumatoid arthritis, type 1 diabetes); metabolic syndromes (e.g. type 2 diabetes, coronary artery disease); and neuropsychiatric disorders (e.g. depression, psychosis). However, attempts to modulate the microbiome in order to impact these diseases have been hampered by difficulties in assessing the success of microbial delivery, colonization, persistence and clearance using current clinical and research tools. To address these challenges, we are developing the methods needed for in vivo imaging of microbial therapies. Hypothesis: Transplantation of the probiotic Escherichia coli Nissle 1917 labeled with 89Zr (half-life, 3.3 days) will demonstrate the utility of longitudinally tracking microbial cells in the mammalian gut and beyond, using positron emission tomography/magnetic resonance imaging (PET/MRI).

The pig provides an ideal large animal model of bacterial transplantation, displaying gastrointestinal anatomy and physiology relevant to humans and permitting imaging on clinical scanners for expedient translation to medical practice. The following research aims to provide needed information about imaging logistics and animal/patient monitoring, required for future clinical studies. Materials and Methods: The cell surface of cultured probiotic E. coli was labeled with 89Zr chelated to pisothiocyanato-benzyldesferrioxamine (DBN) by adapting a published procedure [1] . Colony forming units (CFUs) were determined at sequential time points to assess viability of 89Zr-DBN labeled bacteria [2] . Stability of the radiotracer was evaluated in co-culture [3] . Radiolabeled bacteria were encapsulated in gelatin pills and introduced to the stomach of an approximately 25 kg pig using a feeding tube. Hybrid PET/MR (Siemens Biograph mMR) was performed at 4 bed positions for whole body coverage between 0-6 hours post-ingestion (day 0) and again on days 4 and 7. Both T1-weighted in-phase Dixon and T2-weighted HASTE sequences were collected at 3 Tesla, simultaneously with PET, and fused for segmentation and to generate maximum intensity projections (MIP). Biodistribution of 89Zr was determined by segmenting coronal images at each time point. Results: Live bacteria were radiolabeled with 75% efficiency (0.001 Bq/CFU) and displayed viability comparable to unlabeled cells throughout the time course. Encapsulated 89Zr-DBN labeled Nissle 1917 was appropriately delivered to the stomach (Figure 1 ). Most of the ingested bacteria (99%) exited the GI tract of a healthy recipient via feces, theoretically leaving only the actively growing bacterial strains to persist in the gut. At day 4 post-ingestion, 89Zr was evident in the intestinal compartment; however, by day 7 the signal was diffuse and near background. Little if any radiolabel appeared in urine and blood while uptake in the liver, kidneys, joints and lungs was recorded. Discussion: Pilot data demonstrates the feasibility of our methods and shows for the first time that E. coli (probiotic strain) can be monitored in vivo over days. Ingestion of 89Zr-DBN labeled bacteria has potential for monitoring gut persistence and permeability of microorganisms, with little non-specific background even at early time points.

Further improvement to PET/MR image contrast may be obtained with additional sequences and by reducing bowel activity.

References: 1. Bansal, A., et al., Novel (89) Zr cell labeling approach for PET-based cell trafficking studies. Eur J Nucl Med Mol Imaging Res, 2015. 5: 19. 2 In this sample data (n = 1), some reflux was noted in the tracheal tube and snout. At 4 days post-ingestion, remaining radiotracer was largely contained within the intestinal compartment. Reuse of the tracheal tube showed residual 89Zr on PET/MRI and was excluded from further analysis. By 7 days postingestion, remaining radiotracer was diffuse and close to background. Abstract Body : Pancreatic cancer remains exceedingly difficult to treat effectively. As the fourth most common cause of cancer-related deaths, pancreatic cancer presents patients with a five year overall survival rate of just ten percent. Treatments for pancreatic cancer still rely heavily on chemotherapeutic regimes, often receiving drugs such as gemcitabine for first line chemotherapy and second line treatment combinations such as FOLFIRINOX. Notably, both of these chemotherapeutic agents, as well as recently the combination of trametinib, a MEK1/2 inhibitor and palbociclib, a CDK4/6 inhibitor, have been known to induce cellular senescence in pancreatic cancer, yielding a state of permanent cell cycle arrest. Senescence activity is associated with activation of beta galactosidase (βgal) functioning as a surrogate marker where the conversion of X-gal in the presence of βgal yields a bright blue product which has become the gold standard in senescence imaging. More specific markers based upon the secretory profile of senescence are needed and immunoPET agents can specifically target both shed and membrane bound antigens that make up the senescence associated secretory phenotype (SASP) including VEGF, p-selectin, and interleukin-6. We measured the degree of senescence in the pancreatic cancer line MIAPaCa2 treated with several chemotherapy agents using the gold standard X-gal as an output. Senescence staining was tested in 6-well, 24-well, and 96-well plate formats, varying the number of cells plated from 10,000-100,000 per 9.5 cm2 well to find an optimal cell density for senescence measurement as well as treatment conditions. We found that 60,000-100,0000 cells per 6-well when treated with the combination of trametinib and palbociclib (TP) provided the best ratio between 3.9-4.8 fold over untreated ( Figure 1A) . Of the four drugs tested, the strongest induction of senescence was found with gemcitabine, especially at lower concentrations where a six-fold increase in activity was observed, with four-fold increases also seen with the combination therapy trametinib and palbociclib (TP) as well as FOLFIRINOX ( Figure 1B ). Concurrent viability assessment revealed less than two-fold reductions or expansions in cell population, indicating that the cells were not rapidly dividing nor being killed by the range of administered chemotherapy agents (not shown). We found miniaturization to a 24-well format to yield the best combination of well uniformity and absorbance intensity. We then administered 89Zr-deferoxamine-aflibercept targeting VEGF-A and found increased binding with administration of TP that was blocked by adding chlorpromazine, a clatherin mediated endocytosis inhibitor ( Figure 1C ). Orthogonal tests with FDA approved antibodies targeting P-selectin, VEGF, and IL-6 are planned using both Cy5.5 and 89Zr-DFO labeling methods to quantify SASP in-vitro. Conclusion: we have found that administration of chemotherapeutics induces senescence in the pancreatic cancer line MiaPaCa2 and that gemcitabine delivered the most robust induction by βgal activity. We found that radiolabeled aflibercept for VEGF-A in vitro was elevated around two-fold under combination TP treatment. Further experiments with immunoPET agents against SASP targets are warranted and urgently needed to best characterize senescence in-vivo with and immunofluorescence as well as immunoPET imaging agents. Abstract Body : Introduction. Ataxia telangiectasia and Rad3-related (ATR) threonine/serine kinase is one of the three key members of the PIKK family orchestrating in the DNA damage response responsible for preserving genome integrity via checkpoint 1 activation. Triggered by ssDNA breaks via e.g., UV light and drugs like cisplatin ATR in concert with ATM (Ataxia telangiectasia mutated) engages in the repair of DNA breaks. An estimated 50% of the human cancer cell lines have a mutation in ATM which sensitizes the cells to ATR inhibition. [1] Loss or mutation of the ATM function renders cancer cells sensitive to ATR inhibitors (ATRi's). Our aim was to rationally design, synthesize and evaluate a PET radiolabeled ATRi and evaluate its in vivo biodistribution in mouse models. We previously demonstrated the potential of a fluorine-18 based ATRi PET tracer in a glioblastoma mice model. [2] However, the half-life of iodine-124 will allow longer monitoring of the uptake and distribution of the PET probe. Here, we present the radiolabeling and the results of its in vitro and in vivo evaluation in murine models of prostate cancer (PC). Methods. Our [124I]-ATRi is based on the design of the well-studied ATRi VE-821. We synthesized the corresponding boronic acid precursor and performed radiolabeling with iodine-124 using copper (ii) catalyzed radioiodination. We also performed in vitro assays in LNCaP PC cell lines. Subcutaneous LNCaP xenografts were established in immunocompromised mice by administering 2-5 X 106 LNCaP cancer cells. Mice bearing tumor xenografts (~300 mm3) were administered i.v. with [124I]-ATRi (150 µCi) and PET imaging was performed on an Inveon microPET/CT instrument at different time points. Biodistribution studies were conducted sacrificing mice after the scan to correlated subsequent organ uptake. Results. Boronic acid precursor was ideal for [124I]-ATRi as it resulted in high radiochemical yield of 80% (isolated) at specific activity of 0.65Ci/µmol. In vivo imaging experiments show that [124I]-ATRi clears rapidly from blood pool and clears primarily via the hepatobiliary pathway. The tumor to background ratios were low but the uptake could be blocked specifically with VE-821. Conclusion. Our findings establish the pharmacokinetic profile of the VE-821 analog [124I]-ATRi and demonstrated sub-optimal tumor targeting. Molecules with a suitable pharmacokinetic profile will be explored to image ATR dependent tumors. Abstract Body : We re-engineered an anti-PSCA A2scFv-Fc2DM fusion proteins with optimized pharmacokinetics and biodistribution for radioimmunotherapy of prostate and pancreatic cancer. The scFv-Fc (110 kDa) clears primarily through the liver, sparing the more radiosensitive kidneys. Point mutations in the FcRn binding site (double mutant, DM) accelerate blood clearance with the intention to reduce hematological toxicity. Here, we radiolabel the A2scFv-Fc2DM and the wild type control A2scFv-Fc2 with zirconium-89 for surrogate immunoPET to profile pharmacokinetics in a human PSCA knock in (hPSCA KI) mouse model implanted with syngeneic hPSCA-expressing prostate cancer cells (RM9-hPSCA). The humanPSCA knock in mouse model represents a physiologically more relevant disease model because it enables the evaluation of anti-PSCA antibodies in immunocompetent mice and in the context of normal tissue expression of PSCA. hPSCA KI mice express PSCA at low level in the normal prostate, bladder and stomach, reproducing the expression pattern observed in humans. Methods: A2scFv-Fc2 and A2scFv-Fc2DM were conjugated with the chelator p-SCN-Bn-Deferoxamine (SCN-DFO) and successful conjugation was confirmed by SDS-PAGE and size exclusion chromatography (SEC) analysis. The DFO-conjugated proteins were radiolabeled with zirconium-89 (89Zr). 89Zr-A2scFv-Fc2 and 89Zr-A2scFv-Fc2DM (10 µg/2.6 MBq) were injected intravenously into hPSCA KI mice bearing subcutaneous RM9-hPSCA or RM9 tumors. ImmunoPET/CT scans were acquired at 4, 24 and 96 h post injection. Following the last scan, ex vivo biodistributions were conducted. To determine the plasma half-live, blood samples were taken between 3 min -96 h p.i., gamma counted and fitted using a two phase decay nonlinear fit (GraphPad prism). Results: The anti-PSCA A2scFv-Fc2/DM antibody fragments were successfully radiolabeled with similar results for labeling efficiency (around 80%), resulting in specific activities of 4.1 ± 2.5 µCi/µg and yielding radiochemical purities of >95%. ImmunoPET studies in hPSCA KI mice bearing bilateral RM9 and RM9-PSCA tumors confirmed the in vivo specificity of both anti-PSCA scFv-Fc antibody fragments, showing higher uptake in RM9-PSCA tumors compared to antigen negative RM9 tumors. The accumulation of activity in the liver of mice injected with 89Zr-A2scFv-Fc2DM confirmed the rapid hepatic clearance of the double mutant. High retained activity in the heart on mice injected with 89Zr-A2scFv-Fc reflects the longer blood retention time of this tracer. Ex vivo biodistribution confirmed that 89Zr-A2scFv-Fc2DM cleared significantly faster from blood compared with 89Zr-A2scFv-Fc (2.9±0.1 vs 7.7± 0.1 %ID/g at 24 h p.i. and 0.2±0.01 vs 5.6±0.9 %ID/g at 96 h p.i.). 89Zr-A2scFv-Fc2 reached higher uptake in the PSCA positive tumor, but the long circulation time results in lower tumor:blood ratios (2.1 ± 0.5 at 96 h) while the tumor:blood ratio for 89Zr-A2scFv-Fc2DM reaches 25.8 ± 2.5 by 96 h p.i. The biodistribution and clearance of 89Zr-A2scFv-Fc2 and 89Zr-A2scFv-Fc2DM was not altered by the normal tissue expression of PSCA and no increased uptake was observed in bladder or stomach. Half-life of 89Zr-A2scFv-Fc2 and 89Zr-A2scFv-Fc2DM was determined after a single dose i.v. injection and antibody concentration determined by gamma counting. 89Zr-A2scFv-Fc2 showed a terminal half-life (t1/2ß) of 74.7 h, while the double mutant 89Zr-A2scFv-Fc2DM was eliminated from the blood more rapidly, resulting in a terminal half-life (t1/2ß) of 12.2 h (n=5 ). Conclusion: 89Zr-A2scFv-Fc2 and 89Zr-A2scFv-Fc2DM surrogate immunoPET studies confirmed target specificity and hepatic clearance for both proteins. While 89Zr-A2scFv-Fc2 showed slow clearance from the blood, the double mutant 89Zr-A2scFv-Fc2DM clears rapidly and could provide an improved therapeutic window for radioimmunotherapy using beta-emitting 177Lu. Abstract Body : Introduction: Inflammatory bowel disease (IBD) is a costly and complex group of diseases which, in Canada, disproportionately affects people in rural northern First Nations communities1. The low water quality present in these communities, including pathogens and high levels of various metals2, is likely a contributing factor. However, the combinations of chemical and biological water contaminants most likely to contribute to IBD development are unknown. In this project the use of rainbow trout (Oncorhynchus mykiss) as an animal model for the development of IBD is presented. The immune and gastrointestinal systems of fish are similar to those of humans in both structure and function3. Their aquatic habitat makes fish inherently sensitive to water quality, giving them potential as an environmental sentinel4. If contrast-enhanced ultrasound (CEUS) can be performed using fish as a model species, wild fish from contaminated waters can be non-lethally used to collect epidemiological data for use in identifying bodies of water which may be contributing to IBD development. Contrast enhanced ultrasound, using gas-filled microbubbles (MBs) as a contrast agent, has been used extensively for mammalian studies, and has clinical applications for cardiology, liver and kidney perfusion imaging5. However, the use of CEUS in fish is relatively new, and typical perfusion patterns in these animals have not been studied except for in perfusion of the liver6. The goal of this study is to investigate CEUS perfusion imaging in the bowels of rainbow trout, with the intention of developing a molecular imaging model to assess bowel inflammation in trout to evaluate the roles of environmental factors in IBD. Methods: After two days of fasting, rainbow trout (n=8, 60-150g) were anaesthetized with Tricaine methane sulfonate (MS-222, 0.08 g/L water). Acute bowel inflammation was induced in half the trout through rectal administration of the haptentizing agent Trinitrobenzene sulfonic acid (TNBS), while the other half received a placebo rectal administration of deionized water. Twenty-four hours later, the fish were again anaesthetized. This time they were placed in a device which held them inverted with a flow of cooled anaesthetic water running through their mouths and over their gills to maintain oxygenation throughout the imaging process. Scales were carefully removed from the area posterior to the pelvis fin and anterior to the anus, over the region through which imaging was performed. The bowel was cleared of fecal matter through rectal administration of ultrasound gel. A bolus of MBs (polydisperse, 1-5um, 1.5x106 MBs/g, 115ml total) was injected intravenously through the caudal tail vein and visualized using the non-linear contrast mode on a small animal ultrasound system (VEVO3100 preclinical ultrasound system, 20 MHz transducer). For analysis, a region of interest (ROI) was drawn around the bowel, and time-intensity curve was generated, and was used to determine peak enhancement. Fish were euthanized after imaging and bowels were harvested for ex vivo histology. Results: Preliminary data show the gut of rainbow trout is acoustically visible and highly vascularized. Administration of microbubbles to rainbow trout with inflamed bowels resulted in an average peak enhancement value of 0.85 a.u., which was significantly lower than in uninflamed bowels, where the average was 0.94 a.u. (F1,8 = 6.552, p = 0.43) suggesting that blood flow decreases with high levels of inflammation, possibly due to edema, similar to other pre-clinical studies7. Histology confirms damage to the epithelial layer and increased thickness of villi, indicating edema in the TNBS-treated bowels. Conclusion: The bowel of rainbow trout are acoustically visible, respond to TNBS with acute inflammation, and show a decrease in bowel perfusion 24 hours post TNBS administration. This approach may provide a non-invasive means of evaluating the impacts of water quality on gut inflammation. Abstract Body : Introduction Site-specific approaches to antibody bioconjugation based on ligations between maleimides and free cysteine residues have long stood as attractive alternatives to strategies predicated on the random modification of lysines. Yet the inherent instability of the thiol-maleimide linkage has fueled the search for new, more stable thiol-reactive prosthetic groups. Our laboratory has recently developed a novel bioconjugation reagent based on a phenyloxadiazolyl methyl sulfone (PODS) scaffold that selectively reacts with free cysteines to form highly stable and well-defined radioimmunoconjugates. In this investigation, we report a second-generation, PODS-based bifunctional chelator ¾ DiPODS-NOTA ¾ that is capable of reacting with two cysteine residues and thus rebridging reduced disulfide linkages. Furthermore, we describe the optimization and validation of this approach to bioconjugation with a HER2targeting Fab fragment (FabHER2) as well as the radiolabeling and in vitro characterization of a pair of radioimmunoconjugates: [68Ga]Ga-NOTA-DiPODS-FabHER2 and [64Cu]Cu-NOTA-DiPODS-FabHER2. Methods DiPODS-NOTA was synthesized via the reaction of DiPODS-NH2 with p-SCN-Bn-NOTA and purified and characterized via standard organic chemistry techniques. Subsequently, the modification of a HER2-targeting Fab fragment ¾ FabHER2 ¾ with DiPODS-NOTA was optimized, and NOTA-DiPODS-FabHER2 was characterized using MALDI-ToF mass spectrometry, size exclusion HPLC, SDS-PAGE, and circular dichroism spectroscopy. Finally, the radiolabeling of NOTA-DiPODS-FabHER2 with both [68Ga]GaCl3 and [64Cu]CuCl2 was optimized, and the binding of the resultant pair of radioimmunoconjugates ¾ [68Ga]Ga-NOTA-DiPODS-FabHER2 and [64Cu]Cu-NOTA-DiPODS-FabHER2 ¾ was assayed using a bead-based immunoreactivity assay. Results DiPODS-NOTA was synthesized and purified in high yield and purity. FabHER2 was first incubated with 20 equivalents of TCEP to reduce its disulfide linkage, and then 15.0 equiv. of DiPODS-NOTA were added. This approach ultimately producing a homogeneous and well-defined immunoconjugate ¾ NOTA-DiPODS-FabHER2 ¾ with a degree of labeling of 1.0 NOTA/Fab. Subsequently, 300 mg NOTA-DiPODS-FabHER2 was incubated with 4.0-4.5 mCi of [68Ga]GaCl3 in 0.5 M sodium acetate buffer at pH 5.5 for 30 min at 37 °C to produce [68Ga]Ga-NOTA-DiPODS-FabHER2 with >99% radiochemical yield, >99% radiochemical purity, and a specific activity of 9.6 mCi/mg. In addition, 100 mg NOTA-DiPODS-FabHER2 was incubated with 1.0-1.1 mCi of [64Cu]CuCl2 in 0.5 M ammonium acetate buffer at pH 5.5 for 30 min at 37 °C to produce [64Cu]Cu-NOTA-DiPODS-FabHER2 with >99% radiochemical yield, >99% radiochemical purity, and a specific activity of 9.7 mCi/mg. The immunoreactivities of these two radioimmunoconjugates with HER2-coated Ni-NTA beads were 94% and 95%, respectively, far higher than those exhibited by analogous radioimmunoconjugates ¾ [68Ga]Ga-NOTA-Lys-FabHER2 and [64Cu]Cu-NOTA-Lys-al lysine-directed stochastic approach to bioconjugation (with immunoreactivities of 47% and 45%, respectively). Conclusion The data suggest that DiPODS-NOTA is a highly effective reagent for the synthesis of homogeneous, highly stable, and highly immunoreactive radioimmunoconjugates with intact interchain linkages. We are currently in the process of validating the in vivo performance of [68Ga]Ga-NOTA-DiPODS-FabHER2 and [64Cu]Cu-NOTA-DiPODS-FabHER2 in murine models of HER2-expressing breast cancer. Abstract Body : Advances in in vivo imaging have enabled monitoring of cells in the living body, and the next generation of tools should include minimally invasive means of manipulating cells to treat disease with image guidance. Precedence exists for using bacteria to impact mammalian cell physiology as treatment, bacteriotherapy, and many of these are used clinically. Therefore, the field of bacteriotherapy provides motivation for the development of a set of tools that can be paired with imaging and improve control of those therapies in vivo. There are many bacteriotherapy approaches under investigation, and FDA review, for a variety of human cancers1-6. Synthetic biology has allowed us to utilize temperature-sensitive repressors (TSRs) that we have engineered into the model organism, Bacillus subtilis, towards the development of a minimally invasive system for genetic control. Directed delivery and targeted activation can improve the therapeutic effect and reduce toxicity of bacteriotherapies and imaging can be used to assess delivery, retention and activation within the target tissue to guide development of novel bacteriotherapies. B. subtilis has multiple inducible systems including several sugar-regulated inducible systems. However, these inducible systems have limited control for in vivo applications due to lack of localized delivery. TSRs are a class of repressors that bind an operator-promoter region with temperature dependence, and show promise for in vivo control with local heating7. With the addition of thermal energy to the system, a structural change occurs that releases the repressor from DNA resulting in transcription. Thus, TSRs are different from heat shock promoters (HSP) and rely on housekeeping sigma factors such as σA in B. subtilis. TSRs offer a greater dynamic range than HSP and do not necessitate stress conditions for induction. We have shown that TSRs from Gram-negative bacteria function in the Grampositive bacterium, B. subtilis, to control either individual genes or operons. TSRs have the potential to be paired with a method of localized thermal energy generation to cause transcriptional control of bacteriotherapies in vivo. Iron oxide nanoparticles (IONPs) are a useful imaging contrast agent in magnetic resonance imaging (MRI) and magnetic particle imaging (MPI). MPI detects the IONP directly, providing a readout of iron content and location with high specificity and sensitivity. Further, this technology can be coupled with electromagnetic energy generated by alternating magnetic fields (AMF) to cause local temperature increase known as magnetic hyperthermia8-10 to precisely heat the iron-containing area identified using imaging. Therefore, IONPs could be used to generate thermal energy to regulate TSRs in B. subtilis and for imaging in vivo for bacteriotherapy approaches. Asporogenic B. subtilis ZB307 (derivative of B. subtilis strain 168) was coated with Synomag-D superparamagnetic IONPs containing carboxyl groups to facilitate interactions with B. subtilis. Transmission electron microscopy coupled with energy dispersive X-ray spectroscopy (TEM-EDS) was performed and displayed association and retention between the nanoparticles and B. subtilis. After this interaction was confirmed, MPI (Momentum, Magnetic Insight CA) was performed to demonstrate in vivo tracking capabilities for future studies. To illustrate control of potential bacteriotherapies, magnetic hyperthermia technology (HYPER, Magnetic Insight, CA) will be combined with reporter protein output assays to show thermal regulation of bacterial transcription. Results show that 30 min of thermal stimulus at 39° C induced expression of luxA-E with significant luminescence at 1 h post-induction. Initial findings indicate that HYPER parameters will need to be tuned to optimize sustained thermal energy generation above the threshold required to impact B. subtilis transcription. Pairing TSRs with magnetothermal energy using IONP for localized heating with AMF can lead to regional transcriptional control in the bacteriotherapy as guided by MPI or MRI for new approaches to bacteriotherapy.

Daniel Gebrezgiabhier, University of California, San Francisco, Daniel.gebrezgiabhier@ucsf.edu Category: Systemic Diseases (Kidney, Liver and Pancreas) Abstract Body : Motivation & Goals: Transrectal ultrasonography (TRUS)-guided biopsy is considered the standard approach for histopathologic diagnosis and grading of prostate cancer.1,2,3 However, TRUS is limited for directly visualizing and targeting prostate lesions and therefore the fusion of magnetic resonance (MR) images with US overcomes many of these limitations1,2. Since conventional anatomic and diffusion MRI does not provide metabolic information on cancer aggressiveness or extent,4,5,6 this project was designed to develop specialized hardware and software to enable multiparametric MR incorporating hyperpolarized (HP) 13C-pyruvate MR molecular imaging for improved MR-US fusion biopsy guidance. Recent studies have shown that HP 13C-pyruvate MRI in a rapid 2-minute addition to MRI exams can detect metabolic reprogramming in prostate cancer improving the detection of aggressive cancers and response to therapy. In this project, new methods to acquire and display 13C-pyruvate to 13C-lactate conversion rate constants (kPL) images were developed and applied for guiding MR-US fusion biopsies in prostate cancer patients for the first time. Materials & Methods: In order to obtain the highest sensitivity HP C-13 and H-1 MRI data, a new dual-element endo coil was developed to better detect aggressive prostate cancers within the prostate7, 8,9. Computer design software (SolidWorks) and commercial 3D printing was utilized to develop the new ER probe contoured to anatomy with tolerability and size similar to the transrectal ultrasound (TRUS) probe used for biopsy guidance in these patients. With this approach, all mechanical details were 3D modeled and 3D-printed faster and at lower cost compared to the extensive machine shop milling in making the original endo 13C/1H coil10. So far three patients have been studied with this coil, one of which had also been scanned using the original endo coil 1 year before. As shown in the figure, this subject was previously diagnosed with biopsyconfirmed localized intermediate risk prostate cancer with Gleason 3+4 disease and PSA of 7.5. The 13C scan was acquired with 8mm isotropic (0.5cc volumetric) EPI imaging with 2s temporal resolution. The images were reconstructed using Orchestra toolbox (GE) and kPL was calculated using a two site exchange model6. The kPL was then transmitted onto PACS and an experienced radiologist outlined 13C-kPL targets on Dynacad. Results & Discussion: The new 13C/1H endocoil (ERC) ( Figure 1A ,B,C) provided improved patient comfort/tolerance and compared to prior design demonstrated substantially improved 13C and 1H MRI sensitivity and with negligible rf coupling in bench electronic testing. Phantom performance testing of new ERC showed a 1.8fold improvement in SNR compared to the original ERC10. As shown in Figure 1D&E , images from a patient study demonstrated not only feasibility for guiding HP 13C mpMR-TRUS fusion biopsies, but also improvements in quantitative measures including signal-to-noise ratios (SNR) and coverage. This patient was scanned using the older endo coil, external coils and the new endo coil in a time span of over a year. Qualitative and quantitative comparison of the data acquired showed an improvement in SNR using the new ERC. The results from the new coil on the same patient ( Figure 1 D & E) showed substantial improvement with SNR greater than the phantom improvement of 1.8-fold. Three kPL targets were identified in this case ( Figure 1D ), one of which aligned with the standard PIRADs and PSMA-PET lesion. The other two high kPLtargets did not have PIRADS correlation, suggesting that kPL provides unique metabolic information not depicted by conventional proton imaging for guiding biopsies. Conclusion: This novel approach with the new 13C/1H ERC provided a substantial increase in SNR and demonstrated the feasibility for guiding HP 13C mpMR-TRUS fusion biopsies using kPL maps for identifying aggressive cancers acquired as a 2minute addition to proton MRI. Bubbles were diluted 1,000x in Isoton® II solution with the number of bubbles at each measured time point normalized to their initial total number concentration respectively. (B) In vitro normalized cellular viability for DTX-NBs at 1-MHz focused ultrasound (FUS) pressures (0-1.36 MPa) with NBs and Taxotere® groups assessed using an MTT assay on murine breast cancer EMT-6 cells with DTX concentrations normalized to 20 nM (n ≥ 6). Statistical analysis was conducted using a one-way ANOVA and Tukey's honesty significance difference (HSD) posthoc test on GraphPad Prism 8.0; ns means non-significant, **p Figure 2 . Representative in vivo contrast-enhanced ultrasound (CEUS) imaging of docetaxel-loaded nanobubbles (DTX-NBs) on the subcutaneously injected murine mammary breast cancer EMT-6 tumour of the right flank on a female BALB/c mice following tail vein administration at a normalized DTX dosage of 3 mg/kg (~1010 bubbles/mL) (n = 3). Panel (a) represents the brightness mode (B-mode) image of the tumour where panels (b) to (k) represent CEUS images acquired at minute intervals following administration. CEUS images were acquired using the EPIQ 7G clinical ultrasound scanner and the L12-5 linear array transducer (MI = 0.07). Figure 3 . Preliminary work demonstrating the in vivo CEUS images of docetaxel-loaded nanobubbles (DTX-NBs) using the EPIQ 7G clinical ultrasound scanner and the L12-5 linear array transducer (MI = 0.07) and their ability as vascular disruption agents to achieve acute perfusion loss in the subcutaneously injected CT26 tumour (yellow dotted lines) on the right flank of a BALB/c mice after exposure Abstract Body : Introduction: Glioblastoma (GBM) is an aggressive disease, which is highly recurrent and leads to a median survival of 16 months [1] . Thus, it is imperative that physicians can quickly diagnose and monitor the treatment of these tumors. The hypothesis of this project is that a novel metabolic imaging technique, known as hyperpolarized magnetic resonance (MR), can predict recurrence of these tumors prior to anatomic re-presentation [2] , [3] . This follows research previously presented at WMIC which demonstrated hyperpolarized MR could detect the metabolic changes in tumor growth before aggressive volumetric expansion as well as tumor regression following radiotherapy prior to significant volume reduction. Methods: Athymic mice were intracranially implanted with patient-derived glioma sphere-forming cells . Twenty-five days after implantation, a cohort of ten of these mice received 2 fractions of wholebrain irradiation to a dose of 10 Gy. Tumor volume was measured in vivo every 3-4 days with T2-weighted MRI. Every 7 days, hyperpolarized MR experiments were conducted to measure the amount of pyruvate-to-lactate conversion (quantified by nLac) in vivo. The endpoint of these measurements Day 72, and any surviving mice were euthanized on Day 94. Survival analysis was conducted between treated and untreated mice, and changes in tumor volume and pyruvateto-lactate conversion was statistically analyzed with ordinary one-way ANOVA and follow-up Fisher's Least Significant Difference tests. Tests that produced p Results: The median survival of untreated mice was significantly lower than treated mice (34 vs. 88 days, p 0.4 died from tumor burden before reaching the Day 94 endpoint. Discussion: Radiotherapy was successful at extending the survival of GSC-811 implanted mice, but they eventually succumbed to recurrent disease. These results demonstrate that hyperpolarized MR can detect significant changes in metabolism of recurrent disease prior to significant increases in tumor volume. Thus, hyperpolarized MR would be an excellent screening tool for GBM patients in remission following treatment. Furthermore, nLac values below 0.4 that were measured immediately following treatment were predictive of mice surviving long-term with 100% sensitivity and 60% specificity. While this sample size of 10 is too small to draw definitive conclusions, these results are promising for the utility of hyperpolarized MR as a measure of early response to therapy, and further studies are encouraged. The results of this and the previously presented project demonstrates that hyperpolarized MR has clinical value of interrogating tumor viability throughout each stage of progression (development, regression, and recurrence). We believe that clinical implementation of hyperpolarized MR will lead to improved patient care. Abstract Body : Melanoma is an aggressive type of skin cancer that can metastasize to draining lymph nodes and distant organs. Early detection of melanoma holds the promise of improved patient outcomes by enabling earlier surgical intervention. Photoacoustic imaging of melanoma can be used to detect chemical entities that can absorb light of distinct wavelengths, such as dark-pigmented melanin produced by melanoma cells. Multi-Spectral Optoacoustic Tomographic (MSOT) imaging is whole-body photoacoustic imaging used to gain structural and functional information in mice or other animals. Here, we compared two routes of administration of the melanoma cells to determine the detectability of melanoma by MSOT either directly in the skin or deeper within mice. MSOT imaging was done at 5-day intervals to monitor melanoma growth and metastasis. MSOT signal for melanin was readily detectable in both models, but we failed to observe metastasis from the skin in our intradermal model. Pseudo-metastasis was observed following intravenous administration, with tumors primarily observed in the lung, liver, and adrenal glands. We used standard histological analysis to characterize the melanoma tumors and the extent of immune infiltrates. To further characterize the tumor microenvironment, we administer a molecular probe directed at neutrophil elastase and observed by four-channel MSOT signal unmixing neutrophil activity in intradermal tumors and surrounding tissues. Our results suggest that the rapid development of melanoma tumors ( < 2 1 days) may lead to the accumulation of neutrophils in the tumor areas. Further studies will determine the impact of these tumor-associated neutrophils and their role in preventing metastatic spread in mice with fully competent immune systems. Figure Caption: Figure legends . A) Schematic outline of the investigations using NSC mimetics. B) Transmission electron microscopy and NTA image show the NSC-EV-PLGA NPs size and core-shell morphology. C) Celigo® all-in-one fluorescence microscopy, and D) Confocal image-based analysis show the uptake efficiency of NSC mimetics using patientderived GBM cell line-based 3D tumor spheroids. E) 3D co-culture study was performed by coculturing NSCs and U87-GBM cell lines and then treating with different NSC mimetic formulations loaded with antimiR-21. After treatments, we performed LC/MS based proteomics to determine treatment-mediated changes at a proteomic level, and specifically the effects on apoptosis and autophagy. F) Fluorescence image analysis shows the indocyanine green-labeled NSC-EV-PLGA-antimiR-21 injected GBM mice have a robust accumulation of NSC mimetics within GBMs. G) qRT-PCR analysis on isolated organs from NSC mimetic-mediated antimiR-21 treated mice shows a higher accumulation of delivered miRNAs in the brains of mice harboring GBMs. H) Representative figure shows the multimodal molecular images of NSC mimeticmediated nanotheranostics delivery of GIONs. I) Translational feasibility of NSC mimetics and their preclinical investigation. We prepared NSC-derived vesicles loaded with antimiR-21 and antimiR-10b using GMP scale microfluidics, and then investigated their efficacy in different GBM mouse models. Abstract Body : Introduction: Magnetic particle imaging (MPI) is a tracer-based molecular imaging technique that directly detects and quantifies magnetic nanoparticles (MNPs) tracers by exploiting their magnetization [1, 2] . The point spread function (PSF) and its corresponding full width at half maximum (FWHM) are key parameters for characterizing tracer performance in MPI because they describe the image spatial resolution of the MNPs. Today, a big effort is being undertaken to design and develop new MPI-specific MNPs with high resolution. In this work we carried out a comparative study of PrecisionMRX®, Synomag®, Nanomag® and Perimag® commercial MNPs using an arbitrary-waveform relaxometer (AWR) and we imaged the MNPs with highest resolution using a phantom in an MPI scanner. Materials and Methods: Five MNPs types are employed in this work: PrecisionMRX® (Imagion Biosystems, Inc., USA), Synomag®, Nanomag®, Perimag® and Iron oxide particles (45-00-252)( micromod Partikeltechnologie GmbH, Germany) with core diameters between 22 and 250 nm and different coatings (see Table 1 ). Imagion Biosystem particles are single core whereas Micromod particles are cluster-type. The PSF was obtained using an AWR and the FWHM was extracted from the obtained data [3] . For these measurements, a sinusoidal AC magnetic field at 20 kHz with field strengths up to 12 mT was applied. Finally, we used a field-free line (FFL) MPI scanner with a 6.3T/m gradient and 40 mTpp, 20 kHz excitation magnetic field with a field-of-view (FOV) of 10.2 cm x 6.3 cm to image samples with the smallest FWHM values [4] . Results: As shown in Figure 1 (a), the FWHM of the samples as measured by the AWR decrease with size between 22 and 70 nm. The FWHM does not change significantly between 70 and 130 nm and finally increases again, reaching values of 30 mT at particle sizes close to 250 nm. This behavior can also be seen in the PSF vs magnetic field curve in samples A1, D2 and E1 (see Figure 1 (b)). The FWHM values of all the tested particles are listed in Table 1 . Of these, B3, C1, D1 and D2 show the smallest FWHM with values around 4.4 mT. Figure 1(c) shows the MPI projection image of a linear phantom containing samples B3, C1 and D2. As indicated on the figure, sample C1 (Nanomag®-100 nm) displays the highest resolution. Discussion and Conclusion: Langevin function predicts a reduction in FWHM with cubic increase in the diameter of the magnetic particles, however our previous work demonstrated a deviation from this Langevin theory due to relaxation wall effect [5] . In the current abstract, large sized nanoparticles with clustered core showed better FWHM in the sizes of 50-130 nm, than the non-interacting single core nanoparticles of sizes ~25 nm. Interacting magnetic particles can improve MPI resolution and sensitivity.

References: [1] Gleich B and Weizenecker J, Nat 2005; 435 (7046) Table 1 . Samples characteristics and their corresponding FWHM obtained from the PSF curve. Figure 1 (a) FWHM vs sample size abstained from the PSF data (b) PSF functions of samples A1, D2 and E1 measured in the AWR. (c) Magnetic particle image scan of sample B3, C1 and D2. 

A02A-References: 1. Paull TT. Mechanisms of ATM Activation

Imaging multidrug resistance P-glycoprotein transport function using microPET with technetium-94m-sestamibi

Chimeric antigen receptor T-cell therapy in glioblastoma: charging the T cells to fight

CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease

CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products

CAR T cells for brain tumors: Lessons learned and road ahead

CXCR1-or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors

Intravital imaging reveals synergistic effect of CAR T-cells and radiation therapy in a preclinical immunocompetent glioblastoma model

In vivo "MRI phenotyping" reveals changes in extracellular matrix transport and vascularization that mediate VEGF-driven increase in breast cancer metastasis

Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells

Applications of nuclear-based imaging in gene and cell therapy: probe considerations

Inhibition of cell adhesion by anti-P-selectin aptamer: a new potential therapeutic agent for sickle cell disease

Molecular Contrast-Enhanced Ultrasound Imaging of Radiation-Induced P-Selectin Expression in Healthy Mice Colon

Chemically induced mouse models of intestinal inflammation

Quantification and Monitoring of Inflammation in Murine Inflammatory Bowel Disease with Targeted Contrast enhanced US

Ultrasound molecular imaging with targeted microbubble contrast agents

Image/Figure Caption: Fig. 1. Copper-free click conjugation of aP-selectin to microbubbles

Azide) and labelled with aP-selectin-DBCO using a copper-free click chemistry approach. B) Fluorescent visualization of MBs successfully labeled with aP-selectin (green). C) Bar graph summarized mean ± standard deviations of the targeted US signal (a.u.) using non-targeted MBs (blue) and Pselectin targeted MBs (green) using a biotin-streptavidin labelling approach (left panel) and azide-DBCO labelling approach

First Name: Maria Last Name: Moreno Email: maria.moreno@nrc-cnrc.gc.ca Organization: National Research Council Country: Canada References: 1

Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications

Macrophages orchestrate breast cancer early dissemination and metastasis

Increasing Prevalence and Stable Incidence Rates of Inflammatory Bowel Disease Among First Nations: Population-Based Evidence From a Western Canadian Province

The use of animals as a surveillance tool for monitoring environmental health hazards, human health hazards and bioterrorism

Contrast-enhanced ultrasound imaging for assessing organ perfusion in rainbow trout (Oncorhynchus mykiss)

Assessment of Inflammation in an Acute on Chronic Model of Inflammatory Bowel Disease with

Image/Figure Caption: Figure 1. Maximum intensity projection PET images of representative mice from both site-specific pretargeting strategy (A) and non-site-specific pretargeting strategy

Therapeutic bacteria to combat cancer; current advances, challenges, and opportunities

Efficacy and safety of Bacillus Calmette-Guerin for bladder cancer: A protocol of systematic review

Tunable thermal bioswitches for in vivo control of microbial therapeutics

Use of bacterial magnetosomes in the magnetic hyperthermia treatment of tumours: a review

Magnetic particle hyperthermia-biophysical limitations of a visionary tumour therapy

An entirely humanized CD3 zeta-chain signaling receptor that directs peripheral blood t cells to specific lysis of carcinoembryonic antigen-positive tumor cells

Norberg M. Transrectal ultrasound and core biopsies for the diagnosis of prostate cancer. A study of pretreatment investigation strategy for patients with suspected prostate cancer

Investigation of analysis methods for hyperpolarized 13C-pyruvate metabolic MRI in prostate cancer patients

Endorectal coil MRI and MR-spectroscopic imaging in patients with elevated serum prostate specific antigen with negative trus transrectal ultrasound guided biopsy

MRI of the Prostate With and Without Endorectal Coil at 3 T: Correlation With Whole-Mount Histopathologic Gleason Score

High-resolution optoacoustic imaging of tissue responses to vascular-targeted therapies

Fully automated identification of skin morphology in raster-scan optoacoustic mesoscopy using artificial intelligence

Noninvasive imaging in dermatology and the unique potential of raster-scan optoacoustic mesoscopy

A copolymer-in-oil tissue-mimicking material with tuneable acoustic and optical characteristics for photoacoustic imaging phantoms

A Phase I Study of a PARP1-targeted Topical Fluorophore for the Detection of Oral Cancer

Drug Design

Development of a PET radioligand for potassium channels to image CNS demyelination

Detecting Demyelination by PET: The Lesion as Imaging Target

Evaluation of the potassium channel tracer

3F4AP in rhesus macaques

Annual Meeting Abstract #1441

Radiation dosimetry of 18F-FDG PET/CT: incorporating exam-specific parameters in dose estimates

Observer study-based evaluation of a stochastic and physics-based method to generate oncological PET images

Full-count PET recovery from low-count image using a dilated convolutional neural network

Image denoising by sparse 3-D transform-domain collaborative filtering

Image/Figure Caption: Figure 1. (a) Results from representative slices for comparison of the LC-PET images and denoised PET images from Total Variation (TV)

Emerging PET radiotracers and targets for imaging of neuroinflammation in neurodegenerative diseases: Outlook beyond TSPO

Imaging of hepatocellular carcinoma: diagnosis, staging and treatment monitoring

Image/Figure Caption: Figure 1. a)-c) Concentrations of [3,3'-2H2] lactate

6'-2H2] fructose, and [6,6'-2H2] glucose in cell culture media after incubating HepG2 cell suspensions with 10 mM

Name: Guannan Last Name: Zhang Email: ZhangG1@mskcc.org Organization: Memorial Sloan Kettering Cancer Center Country: United States References: inducer of graft-versus-host disease

An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin

bone marrow control (BM) or GvHD mice. Key organs, namely spleen, mesenteric LN (MLN) and intestine showed high ICOS-PET signal specifically in GvHD mice, not observed in the control groups. B. Quantitative PET ROI analysis and C. ex vivo biodistribution analysis (lower panels) analysis of spleen, MLN, intestine, liver and heart

%ID/g, p=0.00046) and BM (spleen 10.91 %ID/g, p=6

Quantitative "Hot Spot" Imaging of Transplanted Stem Cells using Superparamagnetic Tracers and Magnetic Particle Imaging (MPI)

Current state of melanoma diagnosis and treatment

Deep tissue volumetric optoacoustic tracking of individual circulating tumor cells in an intracardially perfused mouse model

High-frequency sonography and color Doppler in the management of pigmented skin lesions

Performance of a Multispectral Optoacoustic Tomography (MSOT) System equipped with 2D vs. 3D Handheld Probes for Potential Clinical Translation

Fast multispectral optoacoustic tomography (MSOT) for dynamic imaging of pharmacokinetics and biodistribution in multiple organs

Cancer cells induce metastasis-supporting neutrophil extracellular DNA traps

Engineered antibodies: new possibilities for brain PET? EJNMMI

Image/Figure Caption: Figure 1. a,c. Autoradiography (ARG)

Intranasal delivery of targeted polyfunctional gold-iron oxide nanoparticles loaded with therapeutic microRNAs for combined theranostic multimodality imaging and presensitization of glioblastoma to temozolomide

Multiple sclerosis: Current and emerging disease-modifying therapies and treatment strategies

3. Phelps ME. Positron emission tomography provides molecular imaging of biological processes

18 F-FAC PET visualizes brain-infiltrating leukocytes in a mouse model of multiple sclerosis

Build your own 3D scanner: 3D photography for beginners

which shows a detection limit of 66,000 cells. (D) SPIO labeled and irradiated CAR-T cells, stained with annexin V-FITC, a marker for early apoptosis, analyzed by FACS after 24 hours of incubation. (i-iii) display the histograms of SPIO labeled, 5 Gy, and 10 Gy (G) is the 10 Gy irradiated cells. The lower left quadrants (Q4) represent the proportion of non-apoptotic cells

Prospective motion correction in brain imaging: a review

Datadriven motion detection and event-by-event correction for brain PET

Self-encoded marker for optical prospective head motion correction in MRI

Motion Correction for Simultaneous PET/MR Brain Imaging Using a RF-Penetrable PET Insert

Motion Correction for Simultaneous PET/MR Brain Imaging Using a Radiofrequency-Penetrable PET Insert

Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge. EClinicalMedicine, 31, 100683. 2. Awojoyogbe

The brain atlas concordance problem: quantitative comparison of anatomical parcellations

Acknowledgements We thank Alexandra de Francisco, Yolanda Sierra and María de la Jara Felipe, from the Biomedical Imaging and Instrumentation Group of Hospital Gregorio Marañón de Madrid, for their excellent work with animal preparation and imaging protocols. This work has been supported by "Diagnosis and treatment follow-up of severe Staphylococcal Infections with Anti-Staphylococcal antibodies and Immune-PET -Grant Fundación BBVA a Equipos de Investigación Científica 2018". This work has been also supported by Ministerio de Ciencia e Innovación, Instituto de Salud Carlos III, project "PI20/01632", co-funded by European Union, European Regional Development Fund (ERDF), "A way of making Europe". Lastly, authors thank Fundación Ramón Areces for its support. This study has been funded by Instituto de Salud Acknowledgements This study was partially supported by the following grants: R01NS114066, P41EB022544, S10OD018035 and an Innovation Award from The Polsky Center at The University of Chicago.

Travis Shaffer, Regeneron Pharmaceuticals, Inc, travis.shaffer@regeneron.com Category: New Chemistry, Materials and Probes Abstract Body : Background. Adeno-associated virus (AAV), composed of a single-stranded DNA genome encapsulated within capsid protein, has emerged as key delivery vehicle for genetic therapies with clinical applicability. Taking advantage of tropism, different AAV serotypes can target specific organs in vivo. Imaging AAVs in vitro and in vivo can elucidate AAV cellular distribution, whole-body distribution in vivo, and delivery of genetic therapies. There are recent reports on in vivo PET imaging of AAV delivery1 and AAV transduction2. Interestingly, in the few reports that synthesize fluorescently labeled AAVs, critical details related to reaction conditions and characterization quality control are absent. Since typical starting AAV concentrations are log orders lower than those used in analogous protein chemistry reactions, unique challenges are presented in terms of conjugation, purification, and product yields that need addressed. Investigating the dependence of AAV quality characteristics such as monomerity and infectivity on lysine-conjugated molecules would allow the preparation of AAVs with the highest imaging sensitivity without adversely affecting AAV biology. While AAVs may have 300-500 accessible lysines, previous studies often fail to report imaging molecules per AAV with reasonable precision (if at all). Therefore, this work aims to establish a conjugation protocol that yields 1) predictive dye:AAV ratios (DARs), 2) AAVs with a broad range of DARs, and 3) high AAV recovery. Methods. The serotypes AAV1 and AAV8 had the fluorescent dye AF647 NHS ester conjugated at six dye-to-AAV reaction ratios, ranging from 100-10,000 dyes per AAV. After a 2-hour incubation, the reaction was quenched using tris-HCl and AAV-AF647 conjugates were purified on a Big Tuna automated dialysis instrument. Purification was followed by characterization using dynamic light scattering (DLS), sizeexclusion chromatography (SEC), SYPRO Ruby, and Coomassie Stains. In vitro infectivity assays were conducted on HEK293T cells to determine the DAR effect on AAV infectivity, with GFP as a readout of transduction and AF647 signal as a readout of AAV capsid binding and internalization. This complete conjugation workflow was completed twice for both serotypes. Results. A linear relationship was established for predicting DARs from starting AAV:AF647 reaction ratios. DARs from 0. 2-22 and 0.2-4 were achieved with AAV1 and AAV8 respectively, with monomerity >98%. AAV recovery using the Big Tuna instrument averaged 91%, compared to 50% with previous spin filtration methods. Infectivity was shown to be minimally affected by DARs 8 demonstrates a steady decrease in transduction as measured by GFP. Conclusion. This work establishes a workflow for controllable AAV conjugation with high AAV recovery post purification. Conditions were established for reliable conjugation of AF647 to AAV1 and AAV8 with controllable DARs and establishes a desired maximum on lysine conjugation. The methodology for conjugating imaging molecules and other agents to AAVs for in vitro and in vivo applications will be aided by this work.References: 1. Positron emission tomography imaging of novel AAV capsids maps rapid brain accumulation, Nature communications, 2020. 2. Positron emission tomography reporter gene strategy for use in the central nervous system, PNAS, 2019. Abstract Body : Background Metabolic rewiring is an essential hallmark of cancer. Pancreatic cancer is a prime example of genetically defined metabolic abnormalities.1 Genetic mutations trigger specific signaling pathways that are associated with metabolic transformations. The Warburg effect is a metabolic feature of cancers that causes them to preferentially metabolize pyruvate to lactate via the glycolytic pathway.2 Another pathway of interest in pancreatic cancer is glutaminolysis.3 Being one of the most abundant free amino acids, glutamine supports bioenergetics, biosynthesis, and tumor growth through glutaminolysis in cancers. In glutaminedependent cancer cells, more than half of the tricarboxylic/critic acid (TCA) metabolites are derived from glutamine. Glutaminolysis controls the process of converting glutamine into TCA cycle metabolites through the regulation of multiple enzymes, among which glutaminase shows importance as the very first step in this process. Targeting glutaminolysis via glutaminase inhibition is emerging as a promising strategy to disrupt cancer metabolism and tumor progression.4 Therefore, metabolomics can be employed to view the metabolites which play a role in determining whether or not someone has pancreatic cancer or if glutaminase inhibitionbased treatment is working. Methods The main goal of this project is to study the metabolites of pancreatic tumors from mouse models treated with a glutaminase inhibitor, V9301, to understand the metabolic changes and profiles of pancreatic cancer and how this is changing with treatment. This ultimately will determine whether specific treatments are working to slow down the progression of cancer. Four groups of pancreatic cancer mice with KRAS, P53, and SMAD mutations were employed. The first group was treated with 12.5 mg/kg of V9301 (low dosage treatment), twice per day for four weeks; the second group was treated with 75 mg/kg single bolus dose for four hours before they are sacrificed (high dosage treatment); the third and fourth groups are control mice with pancreatic cancer that received a sham vehicle treatment in low and high dosage respectively. The identity of the groups is unknown as this is a blinded study. After the mice were sacrificed, frozen tumor samples are collected and are lysed to extract all the water-soluble metabolites. High-resolution Nuclear Magnetic Resonance (NMR spectroscopy) is then used to analyze the specific metabolites and determine the metabolic profiles in the tumor samples. Results Lactate, alanine, and glutamine are the primary metabolites that were analyzed. Lactate is high in cancer due to the Warburg effect. If the treatment is working, the amount of lactate decreases. Alanine levels are low in cancer, so a successful treatment would increase alanine levels. Glutamine results in tumor growth, so a glutaminase inhibitor reduces levels of glutamine and tumor progression. Our results show changes in the level of these three metabolites. The level of lactate was higher in Group 2 compared to Group 3. The level of alanine is higher in Group 4 compared to Group 3. The level of glutamine is higher in Group 2 compared to the other groups. The results strongly indicate Group 2 and 3 are possibly controls, while Group 4 received one of the glutaminase inhibitor treatments. Conclusion Comparing metabolites and outlining metabolic pathways can be an effective method in determining the efficacy of cancer therapies. This method could serve as an alternative to expensive imagingbased methodologies that utilize in vivo hyperpolarization-based Magnetic Resonance Imaging (MRI) or Positron Emission Tomography (PET) to determine metabolic changes in real-time. Acknowledgments This work was supported by NIH/NCI R25CA056452 (Trinity Brigham) Trinity Brigham was supported by a training grant from the National Cancer Institute Abstract Body : Introduction In clinical high-field MRI, superparamagnetic iron oxide nanoparticles (SPIONs), which affect T2/T2* as well as T1 relaxation processes of nearby spins, have been widely used for molecular imaging.1,2 In particular, the combined use of SPIONs and hyperpolarized (HP) gases, has been shown to be of particular advantage for the detection of submillimeter cancer metastases in the lungs, where traditional 18F-FDG-PET lacks both resolution and specificity. 3 Here, we investigate the combined use of SPIONs and HP gas at ultralow magnetic fields. MRI at ultralow field strengths recently gained renewed interested because of its lower cost and potentially higher clinical accessibility. For hyperpolarized nuclei, low field strengths appear even more advantageous as the intrinsically lower bulk magnetization experienced at low field is bypassed by the hyperpolarization process. To this end, the scope of this work was to quantify the relaxivity of SPIONs in the ultralow field regime as a first step toward molecular MRI in the lungs at ultralow magnetic field strengths. Methods The longitudinal relaxivity of SPIONs was measured at ultrahigh and ultralow field for 1H and HP 129Xe nuclei. For the latter, relaxivity was investigated for both the gas phase and dissolved phase. Ultrahigh field studies were performed on a high resolution 500 MHz NMR spectrometer, while ultralow field studies were performed on a home-built, variable-field NMR spectrometer at 25 kHz. For 1H relaxivity measurements at high field, inversion recovery sequences were performed on a 99% D2O 1% H2O solution. At low field, a pre-polarization scheme was employed to overcome low thermal 1H polarization levels followed by a variable delay before excitation pulse transmission and signal acquisition. For 129Xe relaxivity measurements, a HP compatible ventilator was used to deliver gas to either a suspension of SPION in water (dissolved phase relaxivity), or an empty NMR tube with SPIONs attached to the inside surface to simulate the environment of the gas phase in vivo. A small flip angle sequence was used to probe the magnetization as a function of time and the data was fit appropriately to account for the perturbation caused by the excitation pulses.4 Results The results show a significant increase in T1 relaxation at low magnetic field strengths for both nuclei. A 200-fold increase in the r1 value was found for 1H at 0.6 mT, which agrees with previous studies on 1H SPION relaxivity at ultralow field strengths.5 In comparison to measurements made at 11.7 T, a 23-fold and 10-fold increase in the r1 value for gas and dissolved phase HP 129Xe was found at 2.1 mT, respectively. For the HP 129Xe gas phase, the measured reduction in T1 is an underestimation of the true reduction as most spins were far from the SPIONs during measurement, which may explain the relatively weak effect given the concentrations used. Ongoing imaging experiments are expected to give more accurate quantification of the actual SPION relaxivity on the spins of nearby gaseous 129Xe atoms. Conclusions While at high magnetic field strengths SPIONs predominately affect the transverse relaxation time of nearby spins, in ultralow magnetic fields the effect is predominantly on the longitudinal relaxation time of the gas, which could increase detection sensitivity particularly for the detection of cancer metastases in the lungs. For both 1H and 129Xe, the enhanced T1 relaxivity is due to a better match between the frequency of the SPIONs magnetic fluctuations and the Larmor frequency.References: 1. Strobel, K. et al. Early detection of lung inflammation: Exploiting T1-effects of iron oxide particles using UTE MRI. Magn. Reson. Med. 68, 1924 -1931 Magnetic susceptibility matching at the air-tissue interface in rat lung by using a superparamagnetic intravascular contrast agent: Influence on transverse relaxation time of hyperpolarized helium-3. Magn. Reson. Med. 54, 28-33 (2005 J. Magn. Reson. 222, 68-73 (2012) . 5. Yin, X. et al. Large T1 contrast enhancement using superparamagnetic nanoparticles in ultra-low field MRI. Sci. Rep. 8, 1-10 (2018) .

Image/Figure Caption: Illustration of samples used for measurements (top left). For 129Xe gas measurements, a cluster of SPIONs were attached on the inside surface of an NMR tube to which gas was delivered by using a HP-gas compatible ventilator. For water-dissolved 129Xe measurements, gas was bubbled directly into SPION dilutions in water. Plots showing reduction in T1 as a function of SPION molar concentration for HP 129Xe gas (top right), water-dissolved HP 129Xe (bottom left), and 1H (bottom right). For the gas phase, the decrease in T1 was found to be 6 times greater at 2.1 mT (circles, red) when compared to measurements made at 11.7 T (diamonds, blue). A 3-times and 14-times greater reduction was measured for dissolved 129Xe and 1H, respectively. Abstract Body : Small cell lung cancer (SCLC) is a particularly lethal form of lung cancer, accounting for roughly 15% of new lung cancer cases.1 Delta-like ligand 3 (DLL3) has recently emerged as a therapeutic target in SCLC, in part because DLL3 cell surface expression is restricted almost exclusively to malignant tissue. Multiple DLL3-targeted therapies have been tested clinically, including the antibody-drug conjugate rovalpituzumab teserine (Rova-T); the bispecific T-cell engager AMG 757; and the CAR-T cell AMG 119.2 As a companion diagnostic to evaluate DLL3 expression, we recently developed an immunoPET strategy by directly radiolabeling the DLL3-targeting SC16 antibody component of Rova-T with Zr-89.3 While our immunoPET tracer was able to clearly delineate subcutaneous, orthotopic, and metastatic SCLC xenografts in mice, optimal imaging was not achieved until 120 post-injection of the [89Zr]Zr-DFO-SC16 because of the antibody's slow pharmacokinetics. Pretargeting strategies that combine antibodies with small molecule radioligands have recently gained popularity for both in vivo imaging and radioimmunotherapy of cancer.4 Pretargeting takes advantage of the excellent affinity and specificity of antibodies while simultaneously evading the limitations associated with their slow pharmacokinetics. This approach not only allows for faster imaging postadministration of the radiotracer, but also lowers systemic radiation dose to the patient. Using pretargeting to lower radiation dose becomes especially relevant in radioimmunotherapy, as the decrease in systemic dose widens the therapeutic index and reduces the risk of toxicity.5 Because pretargeting cannot be performed with the SC16 antibody (SC16 is rapidly internalized by SCLC cells upon its binding to DLL3) we partnered with the Tri-Institutional Therapeutics Discovery Institute to generate a panel of anti-DLL3 antibodies in the pursuit of finding a non-internalizing antibody for pretargeted immunoPET imaging and radioimmunotherapy. Herein we report the preclinical imaging of anti-DLL3 monoclonal antibodies to find the antibody clone best suited for pretargeted immunoPET imaging and radioimmunotherapy. After in vitro screening of 27 antibodies for low internalization rates, three monoclonal IgG4 antibodies were evaluated in vivo: A18, E9, and J8. To ensure adequate binding to DLL3 in vivo, the three antibodies were first bioconjugated to p-SCN-Bn-DFO chelators and then radiolabeled with Zr-89 for injection via tail vein into athymic female mice bearing right flank subcutaneous H82 xenografts (250-300 μCi, 30 μg). ImmunoPET imaging was performed every 24h until 120h, when a terminal ex vivo biodistribution study was performed. The immunoPET images and ex vivo biodistribution profiles indicated strong tumor uptake of the antibodies in the xenografts, ranging from 20-50 %ID/g, confirming that these antibodies have sufficient binding to DLL3 in vivo. Pilot pretargeting experiments were then performed using the bioorthogonal IEDDA chemistry between trans-cyclooctene (TCO) and tetrazine (Tz). TCO-NHS ester was bioconjugated to the antibodies and purified antibody-TCO conjugates were injected via tail vein into the same xenograft model as previously described (100 μg, 0.67 nmol). After allowing the antibody-TCO conjugates to accumulate at the tumor site and clear from non-target tissue for 72h, [64Cu]Cu-SarAr-Tz was injected (490-540 μCi, 0.67 nmol) and immunoPET images were taken 4h, 12h, 24h, and 48h post-administration before a terminal ex vivo biodistribution was performed. While absolute tumor uptake was significantly lower in the pretargeting experiments than the directly labeled Zr-89 experiments (5-8 %ID/g compared to 20-50 %ID/g), the tumors were still able to be clearly delineated in the PET images, and the ex vivo tumor-to-tissue ratios were quite high. All three antibodies performed very similarly, and there was no antibody that was clearly superior to the others. Optimization experiments with varying antibody mass and accumulation intervals are currently ongoing to determine the most preferable antibody, and ultimately one will be selected to move forward with pretargeted radioimmunotherapy using Ac-225. Abstract Body : Pro-tumoral and immunosuppressive M2-like tumor-associated macrophages (TAMs) contribute to tumor progression and distal metastasis. However, current TAMsmodulating therapeutic strategies often encounter challenges including insufficient immune activation, weak antigen presentation ability and unsatisfactory antitumor immune performance. Herein, cyclic RGD peptide functionalized and manganese doped eumelanin-like nanocomposites (RMnMels) were designed for combined hyperthermia-immunotherapy against BX-PC3 prostate cancer. The RMnMels could promote M2-to-M1 macrophage repolarization via scavenging reactive oxygen species and remodel the tumor immunosuppressive microenvironment (TIME). Following near-infrared light irradiation, RMnMels-mediated local hyperthermia not only could destroy tumor cells directly through thermal ablation, but also elicit the release of damage associated molecular patterns and tumor-associated antigens, which could act as effective immunological stimulators to provoke increased tumor immunogenicity, robust tumor immunogenicity and strong antitumor immune responses. The results showed that RMnMels could effectively scavenge reactive oxygen species and promote M2-to-M1 macrophage repolarization both in vitro and in vivo. Synergistically enhanced anti-tumor therapeutic efficacy was achieved following single administration of RMnMels plus single round of laser irradiation, evidenced by decreased primary tumor sizes and decreased number of distant liver metastatic nodules. The as-developed RMnMels may represent a simple and highperformance therapeutic nanoplatform for immunomodulation and enhanced antitumor immune responses. This is accomplished by modifying the biomolecule in a manner that allows it to react or bind to a separately administered radioligand in a biorthogonal reaction that occurs in vivo. We have recently reported the first use of host-guest chemistry as the biorthogonal in vivo interaction between biomolecule and radioligand3. In those studies, an anti-carcinoembryonic antigen (CEA) monoclonal antibody (mAb) was modified to incorporate a cucurbit [7] uril (CB7) to act as the host and the radioligand is functionalized with a ferrocene (Fc) which acts as the guest. The 68Ga-labeled radioligands showed excellent tumor delineation in pretargeting experiments, but the uptake in tumors peaked at about 4%ID/g. In that case, the CB7 modification was done in a non-site specific manner, which limited the degree of labeling (DoL) that could be achieved without compromising immunoreactivity of the mAb. We hypothesized that using recently developed phenyloxadiazole (PODS)-based site-specific labeling strategy would allow us to improve the degree of CB7 conjugation, thereby increasing the number of "host" sites and increasing the tumor specific uptake of Fc-based radioligands for nuclear imaging in cancer models relative to the non-specific conjugation methods4. PODS was selected because it offers an improvement over maleimide based site specific labeling due to its greater in vivo stability and is significantly more cost effective than commercially available kits. Herein we present the first studies of site-specifically labeled host-guest pretargeting based on the PODS site-specific labeling technique. For these studies, a novel PODS derivative was prepared by functionalizing a previously reported precursor4 with dibenzylcyclooctyne (DBCO) to form PODS-DBCO. Then, site specifically conjugated to the same anti-CEA mAb (M5A) (M5A-PODS-DBCO) by reducing the disulfide bridges with TCEP and then reacting the free thiols with the phenyloxadiazole moiety of PODS-DBCO. Then, M5A-PODS-DBCO was reacted with CB7-N3 to form the final antibody-host compound M5A-PODS-CB7. We then used a previously reported fluorescence-based assay to determine the DoL for M5A-PODS-CB7. The results indicated a DoL of 1.16 CB7s per antibody, which was 50% higher than the previously reported DoL of 0.773. The site specifically labeled M5A-PODS-CB7 with improved DoL was then used for pretargeting studies. We compared the site-specifically modified M5A-PODS-CB7 directly to non-specifically modified CB7-M5A with a DoL of 0.77. As the guest radioligand we used [64Cu]Cu-NOTA-PEG3-NMe2-Fc, which was prepared in >95% radiochemical yield and >96% radiochemical purity with a specific activity of ~600 mCi/nmol. As the tumor model we used nude mice bearing subcutaneous BxPC3 xenografts (n=4/group). The antibody conjugates (100mg per mouse) were injected and a 6-day lag time was allowed between administration of the mAb and radioligand components before injecting with radioligand (~400mCi/mouse, 0.66nmol). Biodistribution and PET imaging were performed at 8 and 24 hours after administration of the guest radioligand. PET images acquired at 8h showed tumor specific uptake as well as radioligand retention in the GI tract indicating the expected hepatobiliary clearance of the radioligands. At 24h PI, tumor uptake remained high and GI retention was significantly reduced, increasing the tumor contrast. Surprisingly, total uptake was similar to that seen with the non-specific conjugation method. Future studies will aim to further increase the DoL to two CB7 moieties per mAb and to determine the effects of ligand stoichiometry on total tumor uptake. Figure 1 : Impact of time, positioning, tissue and operator-dependent variation sources on the signal stability of the photoacoustic system in vitro and in vivo. Signal stability in a phantom over time is shown along four strings embedded at four different depths without replacement of the phantoms (A) and with replacement of the phantom between each image acquisition step (B) . C) Representative x/y MIPs are shown for an agar-based phantom with strings embedded at different angles towards the illumination direction (marked with white arrows; Scale bar 1 mm) D) Quantified mean signal intensity for strings at different angles (n=16). Representative x/y maximum intensity projections (MIP) for healthy (ear, E) and pathological (tumour, F) tissue are shown (Scale bar = 1mm). G) Normalised blood volume is shown over time in healthy (black, n=5) and tumour tissue (green, n=5) without replacement of the mouse. H) Normalised blood volume is shown in tumour tissue with replacement of the mouse by two different operators (each n=5, operator 1=black, operator 2=green). I) The "belly" (left) and "leg" (right) positioning of the mouse in the system are indicated (created with Biorender). J) Correlation of calculated blood volume between belly and leg positioning of the mouse is shown (n=134). All data is shown as mean ± SD. Abstract Body : Objectives: Chimeric antigen receptor (CAR) T cells have become an integral therapeutic tool for the treatment of B-cell neoplasms. However, development of CAR T cell therapy outside of hematologic malignancies has stalled due to lack of solid tumor efficacy, antigen escape mechanisms, and toxic side effects. As such, there is a large demand for combination of orthogonal methods of tumor cell killing within CAR T cell therapy. In addition to the demand for more efficacious CAR T therapy, there is also a demand for tracking CAR T cells within patients, as traditional pharmacokinetic (PK) methods are not suitable for these living drugs. Previously, the scFV C825 with picomolar affinity for benzyl-DOTA radiohaptens ([86Y]Y-/[177Lu]Lu-DOTA-Bn) and a second generation "Proteus" DOTA-platform, such as [111In]InPr/[225Ac]AcPr, has been developed for pretargeted imaging and radioimmunotherapy. Recently, our group showed that the humanized scFv huC825 can be expressed in CD19 CAR T cells (named THOR CAR cells) enabling in vivo PET tracking with [68Ga]Ga-NODAGA-Pr. The aim of this study was to assess the impact of the reporter gene design on (radio-)hapten capture in order to select the most promising candidate for optimized CAR T-based radiotheranostic applications. Methods: We engineered human 19bbz (anti-CD19) CAR T cells to express different versions of the huC825 reporter, one with no spacer between the scFv and the CD4 transmembrane domain (huC825s), and another with a hinge spacer derived from IgG4 between the scFv and the CD4 transmembrane domain (huC825). Additionally, control T cells only harboring huC825-GFP were generated. Successful transduction was confirmed with flow cytometry. THOR CAR T cells harboring huC825s or huC825 were assessed for CAR functionally based on cytolytic ability (using the Matador assay with CD19+ RAJI tumor cells) and cytokine secretion (using Luminex). CAR, non-transduced (NT) and T cells modified with huC825-GFP served as controls. In addition, CD4/CD8 T cell ratios were determined (using flow cytometry). We quantitively assessed (radio-)hapten capture of huC825s and huC825 employing a biotinylated DOTA-probe (Biotin-Pr) in combination with streptavidin−fluorophore anti-biotin to determine the number of binding sites per T cell using flow cytometry and in in vitro binding assays using [111In]InPr. Ex vivo cell selection was performed using Biotin-Pr in combination with immunomagnetic microbeads. Results: We generated THOR CAR T cells, as well as CAR T cells and huC825-GFP T cells, and confirmed successful transduction. We observed no difference in CAR T cytolytic ability whether the cells harbored huC825s, huC825 or no DOTAspecific scFv. Additionally, there was no significant difference in cytokine secretion or the CD4/CD8 composition of these T cells. Quantitative flow cytometry using (non-radioactive) Biotin-Pr and in vitro radiotracer binding assays using [111In]InPr revealed that huC825 bound DOTA-haptens at a significantly higher level (approximately 3X in both assays) compared with huC825s, which suggested that the spacer increased the efficiency of the reporter to capture (radio-)haptens. Conclusions: We engineered human CAR T cells to express different compositions of the huC825 reporter. We observed no differences in CAR performance or CD4/CD8 ratios. However, inclusion of an Ig hinge domain significantly increased the performance of reporter gene/probe binding in in vitro assays, which may predict superior radiotheranostic targeting in vivo. Continued in vitro characterization and in vivo assessments are underway. Abstract Body : Background and Rationale: In the field of optical imaging, the ability to image tumors at depth with high selectivity and specificity remains a significant challenge. Surface enhanced resonant Raman scattering (SERRS) nanoparticles (NPs) can be employed as image contrast agents to specifically target cells in vivo,1-5 however this technique typically requires time-intensive point-by-point acquisition of Raman spectra, hindering the real-time image acquisition desired for clinical applications. In addition, traditional approaches involving Raman spectroscopy are limited in their inability to probe through tissue depths of more than a few millimeters6, 7. Thus, there is an unmet need to develop Raman imaging systems that can probe deeper into tissue to detect bulk regions of interest and delineate tumor margins at depth in a more clinically relevant time-period. Here, we combine the use of "spatially offset Raman spectroscopy" (SORS) with SERS in a technique known as "surface enhanced spatially offset resonance Raman spectroscopy" (SESORRS) to image deep-seated tumors in vivo7, 8. Additionally, by accounting for the laser spot size, we report an experimental SESORRS approach for detecting both the bulk tumor, and subsequent delineation of tumor margins at high speed, with fewer measurements than are typically applied. Methods: To optimize light collection efficiency, we applied four modifications to a previously reported custom built SORS system by increasing the: (i) numerical aperture (NA) of the lens (0.2 to 0.34) (ii) working distance of the probe (9 mm to 40 mm), (iii) NA of the fiber (0.2 to 0.34) and (iv) fiber diameter (100 µm to 400 µm). Sampling frequency calculations, i.e. the number of point spectra obtained for each image, were performed by taking into account the laser spot size of the elliptical beam (6 x 4 mm). For example, par sampling represents a step size of 6 mm in the x direction and 4 mm in the y direction, whereas x10 sampling frequency represents a 0.6 mm step size in x and a 0.4 mm step size in y. A PTFE-skull-tissue "brain tumor" phantom was used to optimize the system and carry out proof of concept SORS imaging at varying spatial offsets. Using SERRS contrast agents, in vivo SESORRS imaging was performed using a GL261 glioma model at four different sampling frequencies: par-sampling frequency and over-frequency sampling by 2, 5 and 10. Results: In comparison to the previously reported SORS system, the 2nd generation showed 60% improved depth of imaging, as well as improvements in spectral resolution and up to a 3fold increase in signal-to-noise ratios (SNR) using calibration standards and the brain tumor phantom. Gliomas were imaged in vivo using SESORRS in mice (n = 5) and confirmed using MRI, histopathology and BLI. The results demonstrate the ability to acquire distinct Raman spectra from deep-seated gliomas in mice through the skull using a low power density (6.5 mW/mm2) and 6-times shorter integration times than a previous report (500 ms versus 3000 ms). More importantly, the ability to map the whole head of the mouse and determine a specific region of interest using as few as 16 spectra (total acquisition time 8 seconds) is achieved. Subsequent use of a higher sampling frequency demonstrates it is possible to delineate the tumor margins in the region of interest with greater certainty. Conclusion: Our approach enables improvements in the detection of deep-seated tumors in vivo through depths of several millimeters due to improvements in SNR, spectral resolution, and depth acquisition. Through optimization of SORS instrumentation and sampling frequency approaches, the data indicates that high sampling frequencies typically used in SERRS and SESORRS imaging may not be necessary for tumor detection and subsequent delineation.

Initial curative therapy and its relationship to detection by a PSMA-targeting PET agent (18F-DCFPyL) and multiparametric MRI in men with biochemically recurrent prostate cancer Liza Lindenberg, Molecular Imaging Branch, CCR, NCI, NIH, liza.lindenberg@nih.gov

Abstract Body : Despite initial curative intent through prostatectomy or radiation therapy, prostate cancer recurrence occurs in approximately 40%. Detecting recurrence can be challenging with conventional imaging (technetium 99m-bone scan and CT.) 18F-DCFPyL is a novel PSMA targeting PET agent useful in identifying prostate tumors and recently approved by the FDA for patients with biochemical recurrence. This study examined patient characteristics and evaluated lesion detection by a PSMA-targeting PET agent, 18F-DCFPyL, with regards to therapy to determine if curative treatment choices impact recurrent tumor findings on imaging. Methods: This prospective analysis included men with rising prostate specific antigen (PSA) (median 2.04 ng/mL; range 0.2 -35.5 ng/mL) after prostatectomy and/or whole prostate radiation and no evidence for prostate cancer on conventional imaging (99mTc-bone scan or CT). Patients were injected with a mean dose of 298.96 MBq [8.08 mCi] 18F-DCFPyL and were imaged from head to feet two hours post-injection on PET/CT. This is a subgroup analysis of a larger, ongoing HIPAA compliant, single institution approved trial (ClinicalTrials.gov NCT03181867). Results: A total of 136 men were evaluated. Lesion analysis excluded 11 men with negative findings on 18F-DCFPyL. Prior prostatectomy occurred in 38% (52/136 of men; median time from surgery to imaging of 3.4 years (range 49 days -19.6 years) and median PSA 0.73 ng/mL, mean 1.5 ng/mL. Radiation therapy (external beam radiation therapy, intensitymodulated radiation therapy or brachytherapy) transpired in 29% (40/136) of men; median time from therapy to imaging of 6.1 years (range 1.9 years -15.3 years) and median PSA 4.0 ng/mL, mean 7.2 ng/mL. Men underwent both therapies in 32% (44/136) of the population; median time from last treatment to imaging of 4.3 years (range 6.8 months -16.1 years) and median PSA 2.4 ng/mL, mean 4.0 ng/mL. Total lesion counts by group were surgery = 99, radiation = 328 and both =147. In the surgery group, 16 lesions were located in the prostatectomy bed, 63 were pelvic lymph nodes and 20 were metastases ( 4 bone, 15 non-pelvic lymph nodes and 1 soft tissue.) In the radiation group, 46 lesions were in the prostate, 66 were pelvic lymph nodes and 216 were metastases ( 160 bone, 48 non-pelvic lymph nodes and 8 soft tissue.) In the combined group, 6 lesions were in the prostatectomy bed, 78 were pelvic lymph nodes and 63 were metastases (14 bone, 45 non-pelvic lymph nodes and 4 soft tissue.) Histologic samples were obtained from 53 men in 109 locations comprising 24 sites for the surgical group, 71 sites for the radiation group and 14 sites for the combined group. Sensitivity, specificity and positive predictive values were: surgery: 54% (7/13), 73% (8/11), 70% (7/10); radiation: 81% (25/31), 88% (34/40), 83% (25/30); and combined: 70% (7/10), 75% (3/4), 88% (7/8) . Conclusions: 18F-DCFPyL PET/CT identified more recurrent/metastatic prostate cancer lesions in men after radiation therapy with the most lesions detected in bone metastases. 18F-DCFPyL also had the highest sensitivity and specificity in the radiation treatment group. Curative therapy method (surgery, radiation or both) appears to influence lesion detection by 18F-DCFPyL in men with BCR. Further analysis will be undertaken to explore these implications in initial treatment choice. Abstract Body : Current lack of depth resolution and ability to quantify sub-surface fluorophore concentration negatively affects the utility and objectivity of fluorescence guidance. Utilizing a picosecond, single photon sensitive time-of-flight imager, the authors developed a novel widefield fluorescence LiDAR capable of localizing the depth and quantifying concentration of fluorescent objects in heavily scattering medium such as tissue with sub-millimeter depth accuracy. The fluorescence time-of-flight signal is indicative of both of the fluorescent object's topology (depth) as well as the optical properties. The authors hypothesized that a concurrent measurement of both the time-of-flight information together with diffuse reflectance parameters will allow recovery the location, shape, and concentration of fluorophore in the object. The experimental setup was realized with 0.262 megapixel SwissSPAD2 sensor, and two diffuse reflectance imaging modalities (reflectance time domain imaging using same sensor, and spatial frequency domain imaging using ReflectRS system). ToF easurements of NIR fluorescence dyes (IRDye 680RD) in Intralipid (IL) phantoms revealed 0.3 mm depth recovery accuracy at 5 mm depth for 10 μM, 4 mL IRDye 680RD inclusion. In signal-limiting scenario (50 nM, IRDye 680LT, 1% bovine blood + 3% IL), the system achieved 0.1 mm accuracy at 1 mm depth, and 0.7 mm accuracy at 4 mm depth. Perceived fluorescence intensity on surface was corrected from 15-30% to 60-80% of true (non-embedded) fluorescence intensity of the inclusion. Finally, the authors recorded first clinical ex vivo fluorescence LiDAR imaging of a resected head & neck (H&N) tumor tissue, selectively labeled with ABY-029, an IRDye 800CW-labeled anti-epithelial growth factor receptor Affibody molecules. This experiment demonstrated feasibility of fluorescence ToF imaging by detecting picomolar fluorophore concentration during a clinical, microdose fluorescence guided surgery, achieving inter-frame signal-to-noise ratio of ~15. Further ex-vivo tumor margin assessment experiments are ongoing. It is difficult to detect due to its asymptomatic presentation at early stages.1 Therefore, there is an unmet need for non-invasive imaging markers that help identify the aggressive sub-type(s) in a pancreatic lesion at an early time point in pancreatic cancer. One of the most commonly used imaging biomarkers is the conversion of hyperpolarized pyruvate to lactate and alanine by the Warburg effect.2 It has been previously demonstrated that at early timepoints of pancreatic cancer the Warburg effect kicks in and promotes the conversion to lactate.3 With metabolic Hyperpolarized Magnetic Resonance (HP-MR) imaging, the conversion will be monitored between different animal models at different timepoints. Afterwards, the addition of metabolic and anatomical MR imaging will be implemented for the early detection of pancreatic cancer, rather than simply monitoring tumor growth. Methods: Hyperpolarized 1-13C Pyruvate MRS was employed to study the metabolic processes in genetically engineered mouse (GEM) models (P48:Cre; LSL-KRASG12D (KC)) with pre-invasive pancreatic intraepithelial neoplasia (PanIN) precursor lesions, invasive pancreatic cancer model (P48;Cre; LSL-KRASG12D; LSL-p53R172H (KPC)) and control animals (P48:Cre or WT C57BL/6) without pancreatic lesions. The dissolution DNP (HyperSense, Oxford Instruments) operating at 3T was utilized to hyperpolarize 1-13C pyruvate. The 13C magnetic resonance spectra of hyperpolarized 1-13C pyruvate were acquired at 7T Bruker MRI scanner. These mice were imaged at different time points in their lifespan, at 14, 21 and 28 weeks. The biochemical changes of alanine transaminase (ALT) and lactate dehydrogenase (LDH) enzyme activity were also assessed by immunohistochemistry. Results/Discussion: The alanine-to-lactate signal intensity ratio was found to decrease as the disease progressed from low-grade PanINs to high-grade PanINs (Figure 1 ). At the same time, the lactate-to-pyruvate ratio increased in the KC models compared to the control model ( Figure 1 ). These results demonstrate that there are significant alterations of ALT and LDH activities during the transformation from early to advanced PanINs lesions. Furthermore, we demonstrated that real-time conversion kinetic rate constants (kPA and kPL) can be used as metabolic imaging biomarkers of pancreatic premalignant lesions. As for the KPC mouse model, only one of the animals survived for two time points but there was a significant increase of the lactate-to-pyruvate ratio (0.35) compared to the first time point (0.27). The second time point ratio compared to the KC and control mouse models was significantly higher, (0.34 compared to 0.26 and 0.15 respectively) indicating the invasive nature of the cancer. The aggressiveness of this models was also observed as all the other animals in the group died within 7 weeks of the first imaging timepoint. In the future, imaging at earlier timepoints or at smaller intervals would be helpful in the KPC model, to observe the exact moment the cancer became invasive. Also, in the future, we plan to implement some Artificial Intelligence (AI) component to our metabolic profiles to further predict pancreatic cancer at even earlier stages.4 Conclusion: Findings from this HP-MR technique can be potentially translated to the clinic for detection of pancreatic premalignant lesion in high-risk populations. With the future addition of AI we hope to facilitate the translation to the clinic sooner. (1). To expand its utility, we are also investigating its suitability in detecting esophageal adenocarcinoma (NCT03085147) (2) . Currently, image analysis is performed manually in several time-consuming post-processing steps, that include autofluorescence subtraction, brightness and contrast adjustments, and placement of regions of interest (ROIs). It requires up to 40 man-hours per sample. While useful in a pre-clinical trial setting, such laborious and time-consuming steps are not practical in a clinical setting where results are needed instantaneously with high precision. Additionally, manual methods can have potential user-to-user variability. To expedite the process and reduce the user-variability automation of the analysis tools is imperative for wide acceptance of this technology in routine clinical care. Here we present the preliminary results for the use of a computer-based segmentation tool that is being developed to cut down the analysis time and could potentially be incorporated into the imaging system allowing real-time PARPi-FL fluorescence analysis. METHODS: As per clinical trial protocol (NCT03085147), esophagectomy specimens were submerged in a 1 µM solution of PARPi-FL for 5 minutes followed by a washing step (30% PEG/PBS). Fluorescence measurements of the lesion and surrounding normal tissue were taken using a Quest Spectrum fluorescence camera optimized for PARPi-FL imaging (1) . For each specimen, five frames were selected containing both normal and tumor tissue. Manual quantification of tumor-to-normal tissue ratio (TNR) was performed by placing 5 regions of interest (ROIs) in the tumor area and dividing them by the average of 5 ROIs taken from the normal surrounding tissue of that frame. For automatic segmentation of tumor region, the intensity value >150 was excluded considering as artifacts (light reflection). The images were then normalized, and a median filter is applied to remove the impulse noise. Fuzzy c-means clustering (FCM) algorithm was applied to cluster the image into normal, tumor, and artifacts that were posteriorly excluded from analysis. After FCM the clustered regions were post-processed with morphological operators (dilation and erosion) to obtain the final segmented regions. The tumor-to-normal tissue ratio was then calculated from the automated segmentation. The Mann-Whitney test was used to compare the results obtained with manual and automatic quantifications. RESULTS: Esophageal biospecimens of three patients (four lesions in total -one patient harbored two tumors), were imaged. Tumor areas were confirmed by histology and PARP1 expression by immunohistochemistry. PARPi-FL signal could be identified in all lesions using both the manual and the automated algorithm for image segmentation. The performance of the automated segmentation method was evaluated qualitatively and demonstrated an adequate visual correlation with the fluorescent regions. The average TNRs obtained via manual quantification (1.80 ± 0.19 on patient 02, and 2.53 ± 0.57 on patient 03 -lesion 1, 2.02 ± 0.24 -lesion 2) were similar to TNRs obtained using the automated quantification (1.64 ± 0.12, 2.18 ± 0.08 and 2.02 ± 0.13, respectively; p > 0.05 ). The average TNRs for patient 01 obtained with the manual quantification (1.57 ± 0.01) was lower when compared to automated segmentation (1.83 ± 0.14; p=0.01). CONCLUSION: PARPi-FL staining is a diagnostic tool that can delineate esophageal adenocarcinoma. Our preliminary attempts at automating the semi-quantitative analysis of the samples demonstrates high fidelity to manual automation methods. Larger sample population analysis and refinement of automated protocol are underway to robustly test our segmentation results that can provide accurate analysis of the sample. Specimens of patients harboring adenocarcinoma were submerged in a 1 µM solution of PARPi-FL in 30% PEG 300 in 30% PEG/PBS) for 5 minutes followed by a washing step (30% PEG 300 in 30% PEG/PBS) of also 5 minutes. (A) Representative image of patient one (P01). Imaging was carried out on a tissue area containing both normal and tumor tissue (blue circle) using the Quest Spectrum fluoresce system, customized for PARPi-FL (excitation: 465/30 nm, emission: 520-580 nm). (B) Representative image of P01 histology and PARP1 immunohistochemistry (IHC). Tumor and normal tissue areas were confirmed by H&E and PARP1 expression. (C) White light and fluorescence image after PARPi-FL staining. Frame containing tumor (delineated with dotted line) and normal surrounding tissue. (D) Manual quantification of tumorto-normal tissue ratio was performed by placing 5 ROIs in the tumor area (green) and dividing them by the average of 5 ROIs taken from the normal surrounding tissue (red). For automatic segmentation of tumor region, the intensity value >150 was excluded considering as artifacts such as light reflection. The images were then normalized, and a median filter applied to remove the impulse noise. Fuzzy c-means clustering algorithm was applied to cluster the image into background, tumor, and stents. The performance of the automated segmentation method was evaluated qualitatively and demonstrated an adequate visual correlation with the fluorescent regions (Overlay image). (E) The quantifications between automation and manual method and there was no statistical significance (p>0.05). Abstract Body : Background: Physiological distribution of FDG has been well established in research; being high in the brain, liver, excreted in the urine, and accumulates to a variable degree in the intestines. However, researches on its uptake in the spinal cord is relatively recent and few. Aim: To evaluate physiological 18F-FDG uptake in the spinal cord of cancer patients and its correlation with patient's characteristics. Materials and methods: 150 18F-FDG PET/CT scans were retrospectively included in this study. Patients were referred to scanning for various oncological indications; none of them had cord metastasis. 51.3 % of patients had lymphoma and 34.7 % had breast carcinoma as the primary with the remaining patients had colorectal, sarcoma, thyroid, pancreatic and prostatic carcinoma. Patient's demographic data obtained from medical records included; age, sex, body mass index (BMI), outdoor temperature, blood glucose level at the time of 18F-FDG injection, 18F-FDG dose, and 18F-FDG uptake period. To measure maximum standardized uptake value (SUVmax) 6 volumes of interest (VOIs) were drawn over the cervical cord (opposite lower vertebrae; C4-C5 and C6) and dorsal cord (opposite DV11 and DV12) any pathological uptake had been excluded to avoid artifacts in SUVmax measurements. Results: 62 males and 88 females were retrospectively recruited with a mean age of about 48.37 ± 14.9 years (Range: 18-79 years), mean BMI of27.8 ± 7.6, mean uptake period was 71.9± 28.8 min. and mean temperature was 32.7± 7.9. The highest cord uptake was in the dorsal level followed by the cervical one (4.8 and 4.4 respectively). Mean cervical cord uptake was significantly higher in females than in males (2.1 vs. 1.8 with PConclusion: The highest spinal cord 18F-FDG uptake was in the lower dorsal level. Uptake at lower cervical and lower dorsal levels were significantly positively correlated additionally they were significantly positively correlated with BMI. Cord uptake insignificantly negatively correlated with the FDG uptake period. Females had significantly higher cervical uptake. Diabetics had insignificant lower cord uptake. [1, 2] . Alternatively, focused ultrasound (FUS) has been proposed for local drug release to tumours from drug-loaded phospholipid microbubble contrast agents (d~1-8μm) [3] . While these studies have demonstrated improved antitumour efficacies following microbubble administration, the injected gas volume is often neglected and constitutes a significant safety metric for cavitation-mediated applications [4, 5] . To improve the limited loading capacities of microbubbles normalized to safefor-injection gas volume dosages, nanobubbles (NBs) have emerged as alternative drug carriers owing to their higher surface area to volume ratios. Despite NBs demonstrating their utility for contrast-enhanced ultrasound (CEUS) imaging at off-resonant frequencies [6, 7] , few studies have examined DTX-loaded NBs for concurrent real-time imaging and FUS-triggered release. This study assesses: 1) DTX loading capacity and in vitro stability of phospholipid-stabilized DTXloaded NBs (DTX-NBs) compared to unloaded NBs; 2) the ability to visualize these DTX-NBs via CEUS in vitro and in vivo; and 3) FUS-stimulated cavitation of DTX-NBs for DTX release and in vitro cytotoxicity in comparison to Taxotere® (clinical DTX formulation). Methods. DTX was loaded on phospholipid (DPPA/DPPC/DPPE-PEG2000)-stabilized, decafluorobutane gasfilled NBs and suspended in saline to form an injectable suspension of DTX-NBs. In vitro size distribution and stability in comparison to unloaded NBs was assessed using the Multisizer 4e and a 10-μm aperture on 1,000x diluted aliquots of bubbles at 37°C. In vitro cytotoxicity of Taxotere®, NBs, and DTX-NBs with or without FUS exposure was examined on murine mammary breast cancer EMT-6 cells using an MTT assay. Samples were cavitated under peak negative pressures (0.25-1.36MPa) using a 1-MHz FUS transducer (d~1.5", focal length~6") to assess DTX cytotoxicity as a function of pressure. In vitro bubble echogenicity and destruction was confirmed via CEUS pre/post-FUS exposure using the L12-5 linear array transducer and EPIQ7G clinical ultrasound scanner (MI=0.07). In vivo circulation lifetimes of DTX-NBs were assessed by examining CEUS recordings utilizing the same imaging transducer/scanner following bolus injection into the subcutaneously injected EMT-6 tumours on the right flank of female BALB/c mice via tail vein catherization. DTX loading and DTX degradation was quantified using liquid chromatography tandem mass spectrometry. Results. 105±8 μg of DTX was loaded onto ~1010 bubbles with a mode diameter of ~230 nm per ~0.4 μL of gas (n>6) and with >99.5% bubbles measured 50% of the initial population remaining up to 60 min at 37°C. DTX-NBs and NBs demonstrated in vitro echogenicity at off-resonant frequencies (MI=0.07) using a clinical ultrasound scanner with bubble destruction confirmed following FUS exposure and possessed in vivo circulation lifetimes of ~6 min. DTX-NBs exerted more cytotoxic effects than Taxotere® in vitro without any FUS exposure and showed increasing FUS pressure-dependent cytotoxicity. Conclusions. At safe-for-injection gas dosages, DTX-NBs can load DTX comparable to the recommended FDA-approved dosages of Taxotere® (~2.5 mg/kg). FUS can cavitate these agents to exert elevated cytotoxic effects in comparison to non-FUS-stimulated DTX-NBs and Taxotere®. By monitoring these agents with in vivo circulation lifetimes >5 min via CEUS at off-resonant frequencies (with ultrasound equipment utilized in the clinic today) and controlling their release using FUS, these DTX-NBs show potential as theranostic agents for simultaneous imaging and localized DTX delivery. Future work aims to assess the in vivo biodistribution and pharmacokinetic profile of DTX-NBs with and without FUS and longitudinal survival studies examining DTX delivery in combination with vascular disruption capabilities for tumour regression in preclinical breast cancer mice models.

tumours following treatment with FUS at 1.65 MPa or at 0 MPa. A portion of the tumour region with perfusion following FUS treatment was observed (marked by the red arrow). [18F] 3F4AP, is a PET radiotracer for voltage gated potassium (K+) channels in the brain based on the FDA-approved drug 4aminopyridine (4AP, dalfampridine)1. Preclinical studies in rodents and nonhuman primates have shown that this tracer localizes to demyelinated lesions in the brain where the expression and accessibility of K+ channels increases2,3. As the first step towards the evaluation of this tracer in humans with various demyelinating diseases, we assessed the biodistribution, safety and dosimetry in four healthy human volunteers. Methods [18F] 3F4AP was produced in a cGMP laboratory under an IND as recently communicated4. The study was approved by the institutional review board (IRB) and registered at clinicaltrials.gov (NCT04710550) prior to commencement. Four healthy human volunteers (2 female) underwent a 4-hour dynamic PET scan from cranial vertex to mid-thigh using multiple bed positions after administration of 9.94 ± 0.48 mCi (368 ± 17.9 MBq) of [18F] 3F4AP. Volumes of interest for relevant organs were manually drawn guided by the CT and PET images and time-activity curves (TACs) were extracted. Radiation dosimetry was estimated using integrated TACs in OLINDA software. Safety assessments included measuring vital signs immediately before and after the scan, monitoring for adverse events, as well as a comprehensive metabolic panel (CMP) blood test and electrocardiogram (ECG) within 30 days before and after the scan. Results [18F] 3F4AP distributed throughout the body with the highest levels of activity in the kidneys, urinary bladder, stomach, liver, spleen and brain and with low accumulation in muscle and fat. The tracer cleared quickly from circulation and from most organs. The clearance of the tracer for all organs was noticeably faster than previously reported clearance in nonhuman primates3. The average effective dose (ED) across all subjects was 11.4 ± 1.6 μSv/MBq which is lower than the estimated ED from the nonhuman primate studies (21.6 ± 0.6 μSv/MBq) as well as the ED of other fluorine-18 radiotracers such as [18F] FDG (~20 μSv/MBq)5. No differences in ED between males and females were observed. No substantial changes in safety measures or adverse events were recorded. Conclusion Results from the first human study with [18F] 3F4AP are reported. The tracer and study procedures were well tolerated with no safety concerns. [18F] 3F4AP showed faster than expected clearance. The calculated dose of a standard PET/CT scan after a 10 mCi (370 MBq) tracer injection to both males and females is 4.2 ± 0.8 mSv plus 1 mSv from the CT. These results justify further investigation of the tracer in disease populations.

Kaushik Dutta, Washington University in St. Louis, kaushik.dutta@wustl.edu

Abstract Body : Objective: Low count imaging, either due to low dose or short acquisitions, in preclinical PET imaging can have numerous benefits in animal logistics, maintaining integrity in longitudinal studies and promoting higher throughput. This work aims to develop deep learning (DL) based approaches to generate high count preclinical PET images from low count PET images and assess the performance on basis of image quality and quantitative performance metrics. Method: This study was conducted in the context of simulated [18F] -Fluorodeoxyglucose (FDG)-PET images of mice with tumors implanted in the mammary fat pad. The MOBY [1] digital phantom was utilized for realization of mouse anatomy. FDG-PET images were generated for twelve mice using forward projection and reconstructed by 2D OSEM (subset no = 32, iteration = 4) using a physics-based PET simulation software [2] . Two separate FDG-PET scans were simulated: one high count (HC-PET) ( ̴ 1.2 ꓫ 109 counts) and one low count (LC-PET) ( ̴ 4.8ꓫ 107 counts) consisting of 1/25th (or 4%) of the standard HC photon count level. The Residual UNet (RUNet) [3] and a modified Dilated-UNet (D-Net) [4, 5] models were implemented to reconstruct HC-PET images from LC-PET images. The integration of residual learning in the U-Net architecture enhanced feature mapping and faster convergence. The dilated kernels allow the architecture to observe an enlarged field of view by increasing the receptive field size to incorporate multiscale context. The models were evaluated using a leaveone-out cross validation on 12 subjects. The quality of the DL-generated HC PET images were compared with several existing denoising methods, including Total Variation (TV) [6] , Non-Local Means (NLM) [7] and Block Matching and 3D Filtering (BM3D) [8] in terms of Structural Similarity Index Metrics (SSIM), Peak Signal-to-Noise Ratio (PSNR) and Normalized Root Mean Square Error (NRMSE) with respect to the HC-PET. Quantitative analysis using established metrics such as Standardized Uptake Value (SUV): SUVMax and SUVMean were performed for the lesions of interest. Bias in SUVmax and SUVmean were compared against the HC-PET (true) images. One-way ANOVA followed by a Holm-Bonferroni post-hoc analysis was performed to assess for statistical significances between methods for each performance metric with a P Results: Both DL models exhibited significantly better performance (P≤0.05, Fig  1a, b,c) in terms of SSIM, PSNR and NRMSE scores than other non-DL denoising approaches signifying enhanced image quality and tradeoff between noise and bias. Although D-Net exhibited marginally better mean performance than RUNet in all three metrics (SSIM: 0.856 ± 0.02 vs 0.839 ± 0.03; PSNR: 37.81 ± 1.50 vs 36.52 ± 0.92; NRMSE: 0.071 ± 0.006 vs 0.082 ± 0.007), its performance was not statistically better (P>0.05) than RUNet . The D-Net and RUNet exhibited less than 10 % with respect to HC-PET when subjected to quantitative analysis in terms of SUVMax and SUVMean. D-Net SUVMax bias (-1.94 ± 3.08) was significantly lower (P≤0.01) than RUNet SUVMax bias (7.694 ± 3.18) . RUNet SUVMean bias (-2.28 ± 2.044) was significantly lower (P≤0.01) than DUNet SUVmean bias (-4.54 ± 2.31). In our experience, RUNet generates HC-PET images 2.5-fold faster than DUNet. Conclusion: DL based methods synthesized preclinical HC-PET images from LC-PET images significantly better than non-DL algorithms. DL generated HC-PET images exhibited similar image metrics in terms of image quality, lesion detectability and quantitative analysis to that of actual HC-PET images; however, RUNet takes significantly less computing time to generate images.

Poorva Jain, University of Miami Miller School of Medicine, poorva.pj.jain@gmail.com

Abstract Body : Objectives: Chronic maladaptive innate immune responses drive disease and disability in multiple sclerosis (MS).1 However, innate immune cells are highly context dependent, and therefore cannot be sufficiently studied through in vitro cross-sectional sampling alone. Thus, methods to accurately characterize these dynamic immune processes over time in MS are critically needed. Positron emission tomography (PET) imaging provides a non-invasive means to investigate and track the spatiotemporal dynamics of immune cells in living subjects with high specificity and sensitivity. Several PET radiotracers have been developed for candidate biomarkers of neuroinflammation including translocator protein 18kDA (TSPO).1,2 However, most of these targets face challenges that limit their overall utility such as low signal-to-noise ratios (SNR) and/or suboptimal cellular specificity ( Figure 1A ). To overcome this, strategic biomarker selection and rigorous validation is necessary prior to resource intensive tracer development and preclinical assessment. Here, we propose a new systematic and unbiased approach for screening and identifying candidate imaging biomarkers of neuroinflammation in the context of MS. Methods: Experimental autoimmune encephalomyelitis (EAE) -a validated model of MS -was induced in female C57/BL6 mice. Spinal cord tissues were harvested from naive and EAE mice (at multiple stages of disease severity) and processed for high throughput gene expression analysis. Our multiplexed genetic barcoding assay afforded data on expression changes of 770 genes implicated in neuroinflammation in EAE (n=10) compared to naïve mice (n=5). Subsequently, the Human Protein Atlas, Barres Lab Brain RNAseq, Reactome, and Gene Ontology databases were used to further screen targets based on our apriori specified criteria. Criteria for a promising CNS imaging biomarker are as follows: (1) low basal expression in tissue(s) of interest to ensure optimal SNR, (2) sufficient change in expression (fold change > 2fold) during disease, (3) cell surface expression to enhance tracer binding accessibility, (4) high specificity for a cell type of interest (e.g., microglia, lymphocytes, or astrocytes), (5) minimal expression in peripheral tissues (e.g., blood, gastrointestinal system, lungs, muscle), and (6) a defined functional role in inflammation and MS. Results: Our data revealed 680 genes that had significant expression change between EAE and naïve mice (FDR adjusted P-value ( Figure 1B,  1C) . Cutoffs for basal expression and dynamic ranges were determined apriori using levels of known PET imaging targets (i.e., TSPO, Colony Stimulating Factor 1 Receptor, and Triggering Receptor Expressed on Myeloid Cells 1) as references. After further screening for cell surface expression, low expression in peripheral tissues, and specificity for a single cell type, 71 genes were identified ( Figure 1C ). These remaining genes were then triaged based on their functional characterization and implication in clinical MS. To do so, Pubmed searches were completed using target name and the following terms: "Neuroinflammation", "Inflammation"-AND-"CNS", "Inflammation"-AND-"Brain", "Inflammation"-AND-"Spinal Cord", "Innate Immune"-and-"CNS", "Microglia", "EAE", and "Multiple Sclerosis. After cross-referencing our list with available literature, we cultivated a shortlist of 14 genes that met all our criteria ( Figure 1C ). Conclusions: Our high-throughput screening methodology offers a means to rapidly generate a shortlist of promising biomarkers for innate immune processes in MS prior to time and resource intensive radiochemistry, preclinical and clinical studies. We propose standardizing this method and prioritizing biomarker validation prior to developing PET imaging probes. Investigation of the spatial distribution and specificity of our top 14 genes at the protein level using a multiplex proteomics technology is currently underway. Our long-term goal is to develop PET radiotracers for the top 3-5 biomarkers as specific and sensitive imaging tools for improved detection and treatment of neuroinflammatory diseases. Abstract Body : INTRODUCTION Hepatocellular carcinoma (HCC) has become one of the leading causes of cancer-related deaths due to its aggressive malignancy, which remains a major challenge for early detection and treatment. Much effort has been devoted to developing diagnostic techniques,1 such as CT, FDG-PET, 1H MRI, for targeting and imaging HCCs, however, none of the methods provide information on tumor metabolism, which is important for tumor detection and evaluation of treatment response. Recently, deuterium (2H or D) metabolic imaging (DMI) has been demonstrated as a simple and powerful method for clinical imaging of tumor metabolism in vivo.2 Fructose, which is mainly metabolized in liver, is a promising reporter of metabolism in liver tumors. Here, we show dynamics of [6,6'-2H2] fructose metabolism in mouse liver at 9.4 T, demonstrating the feasibility of developing deuterated fructose as a novel deuterium imaging probe for detecting liver tumors in vivo. RESULTS AND DISCUSSION To test the possibility of monitoring the metabolism of [6,6'-2H2] fructose in liver cancer cells, human-derived HepG2 liver cells were incubated for 24 hours with 10 mM [6,6'-2H2] fructose and 10 mM [6,6'-2H2] glucose as reference. Signals of 2H-labeled glucose or fructose, lactate, glutamate, and HDO were observed in the culture media for the samples by measuring 2H NMR spectroscopy (Figure 1a-c) , indicating HepG2 cells actively metabolize both glucose and fructose. The concentration of the metabolites was further determined from the NMR spectra. The lower concentration (lower production rate) of [3,3'-2H2] lactate as well as the higher concentration (lower consumption rate) of [6,6'-2H2] fructose for samples incubated with 2H-labeled fructose implies that the glycolytic pathway is more favorable for HepG2 cells. The ratio of the production rate of HDO over the consumption rates of glucose or fructose showed that 54.5% and 67.6% of the deuterium label on glucose or fructose was lost to water in the glycolysis or fructolysis pathway and TCA cycle. The feasibility of the visualization of fructose metabolism in vitro allows further study of its metabolism in vivo. Dynamics of [6,6'-2H2] fructose metabolism were monitored in a mouse liver in vivo by a 2D CSI sequence using a 2H surface coil (Figure 1d ,e). After intravenous injection of 1.95 g/kg [6,6'-2H2] fructose, dynamics of the 2H signal from [6,6'-2H2] fructose, [3,3'-2H2] lactate, and HDO were observed in the liver (Figure 1f,g) . By converting the signal of metabolites into concentrations, metabolite concentration maps were generated (Figure 1h ). From the map, it can be seen that 2H-labeled fructose was delivered to the liver, reaching the highest concentration at ~15 mins, followed by an increase in the 2H-labeled lactate concentration. Then the concentrations of fructose and lactate both decreased. The HDO concentration started to increase after fructose injection and kept increasing until the acquisition ended. Since the metabolism of fructose is mainly restricted to the liver, wash-in of HDO from other organs of the body, however, cannot explain the continuously increased HDO concentration in the liver. Such observation may be caused by the conversion from [3,3'-2H2] lactate to [3,3'-2H2] pyruvate which takes part in the TCA cycle and therefore generates the excess amount of HDO. CONCLUSION In summary, we have demonstrated the feasibility of developing [6,6'-2H2] fructose as a novel deuterium imaging probe to study liver metabolism in vivo. The dynamics of fructose metabolism were monitored by a 2D CSI sequence with 5 mins temporal resolution. The resulting quantitative metabolic maps showed fructolytic flux from fructose to lactate, demonstrating the feasibility of using deuterated fructose as an imaging probe to quantitatively detecting liver tumors and monitoring treatment response in future studies. Figure 1 : Longitudinal measurements of GSC 8-11 tumor volume and pyruvate-to-lactate conversion (nLac) following radiotherapy treatment. No significant changes in tumor volume were observed during regression or recurrence. nLac significantly decreased by Day 48 before significantly increasing by Day 68. * indicates p < 0 .05.

Last Name: Salzillo Email: tcsalzillo@mdanderson.org

Israt Alam, Stanford University, israt@stanford.edu

Abstract Body : Objectives: Acute graft versus host disease (aGvHD) remains a major complication of allogeneic hematopoietic cell transplantation (HCT), a well established therapeutic option for hematological malignancies and bone marrow failure states. GvHD is primarily mediated by activated donor T cells that attack key host tissues, namely the gastrointestinal (GI) tract. Current approaches for diagnosis rely on clinical and pathological criteria, which manifest at late stages and necessitate invasive evaluation. Early aGvHD diagnosis is critical for effective disease management, providing a strong rationale for noninvasive, whole-body imaging of T cell activation with positron emission tomography (PET). Inducible T cell COStimulator (ICOS) is a cell surface marker, highly specific for activated T cells and implicated in aGvHD pathogenesis.1 Here, we evaluate the diagnostic utility of a recently developed immunoPET tracer [89Zr]ICOSmAb, in a major histocompatibility complex (MHC)-mismatch mouse model of aGvHD. Methods: Female Balb/C mice underwent total-body irradiation (TBI, 8.8 Gy) and received an intravenous (i.v.) transplant of 5 x 106 T-cell depleted bone marrow cells from C57BL/6 mice (BM group) or additionally 1 x 106 T cells positively selected from C57BL/6 luciferase+ mice to induce GvHD. Desferoxamine (DFO) conjugated murine anti-ICOS monoclonal antibody (antagonist mAb) was radiolabeled with zirconium-89 (mean 1.4 DFOs/mAb, molar activity; 7μCi/μg, radiochemical purity; >99%). On day 4, mice had no overt clinical signs of disease and underwent bioluminescence imaging (BLI), followed by an injection of [89Zr]ICOSmAb (50 µCi, i.v., n=7-11/group). PET/CT images were acquired 48 hours post tracer injection. Post-scan, key tissues were harvested for ex vivo gamma counting to confirm tracer biodistribution. Flow cytometry was conducted on lymphoid organs from a separate cohort of mice at day 4 and day 7, to quantify ICOS expression on donor T cells (n=9-11/timepoint). The safety of ICOSmAb administered at an imaging dose (10µg) on day 4, was assessed in GvHD mice using disease severity and survival as outcome measures.2 Results:[89Zr]ICOSmAb enabled highly sensitive detection of activated T cells in the intestine, spleen and mesenteric lymph node (MLN), in the GvHD group, which was not observed in TBI and BM control mice (Fig. 1A) . Quantitative PET region of interest (ROI) analysis confirmed significantly higher PET signal in these tissues in GvHD mice: e.g. median intestinal uptake in GvHD mice was 19.53 %ID/g versus 7.62 %ID/g (p=0.00046) and 8.87 %ID/g (p=0.00013) in TBI and BM control groups respectively (Fig. 1B) . Ex vivo gamma counting of tissues further corroborated PET results (Fig 1C) . Day 4 BLI confirmed presence of luc+ positive donor T cells in lymphoid tissues of GvHD mice and corroborated ICOS-PET results (Fig. S1A) . Receiver operating characteristic (ROC) analysis (Fig. S1B) to evaluate the diagnostic potential of [89Zr]ICOSmAb for early detection of aGvHD using PET ROI data of key tissue, confirmed excellent diagnostic potential (spleen AUC=1; MLN AUC=1; intestine AUC=0.99). Flow cytometry analysis confirmed increased ICOS+ alloreactive CD4 and CD8 T cells in the spleens of GvHD mice at day 4 post-HCT versus day 0, which was also sustained later in the disease at day 7 (Fig. S1C) . No significant differences were observed in disease severity or overall survival in GvHD mice injected with anti-ICOSmAb versus isotype control (Fig. S1D) . Conclusion: This is the first report of ICOS-targeted imaging of activated T cells in aGvHD. ICOS-immunoPET allowed in vivo visualization of donor T cell activation, expansion and infiltration into GvHD target-tissues, prior to appearance of clinical symptoms. Importantly, [89Zr]ICOSmAb was able to sensitively detect GI-GvHD; the most fatal type of aGvHD. Safety evaluation confirmed that the ICOSmAb did not affect GvHD pathogenesis, deeming ICOS-immunoPET a safe, sensitive and a highly promising strategy for prediction and early GvHD diagnosis in the clinic.

Kooresh Shoghi, Washington University School of Medicine, shoghik@wustl.edu

Abstract Body : Preclinical imaging workflows have been growing in complexity resulting in generation of large datasets. In this work, we report on efforts to develop an open-source preclinical imaging XNAT-enabled informatics (PIXI) platform to manage the workflows of preclinical image data acquisition, capture imaging-associated experiments including metadata and annotations, and to implement analytic pipelines in a unified environment. PIXI is based on the Extensible Neuroimaging Archive Toolkit (XNAT) as the underlying informatics architecture. XNAT is used by over 200 academic institutions and industry entities as the backbone for data management across a wide range of imaging applications in clinical research, and thus offers a robust platform for the development and deployment of PIXI. Native features include support for DICOM image session data, clinical experiment data, and subject demographics, as well as user access control, integrated search, and reports. The PIXI platform includes: the PIXI Server, which provides core database, user management, visualization, and workflow functionality; PIXI Point-of-Service (PoS) interface for data entry and a PIXI Notebook for data exploration and analysis; and PIXI Apps to enable automated image processing pipelines through Docker container environment. The database is organized by "project" at the top hierarchy followed by "subject" and "encounter". The XNAT subject model has been extended to support non-human subject metadata. In the current development phase of PIXI, positron emission tomography (PET), magnetic resonance (MR) and computed tomography (CT) DICOM images are pushed to the PIXI server for workflow management. Basic metadata is captured through the DICOM image files for search and reporting. Multimouse images (mouse hotel images) are supported by a custom RESTful API that automatically partitions mouse hotel images into individual image datasets for incorporation into the PIXI database. Imaging workflow information can be entered or edited through the PoS interface including animal modeling information/metadata (such as patient-derived xenografts, PDX). Additional data types are being developed to capture animal modeling metadata, pathology, OMICS, image annotations and interventions. To enable open science, PIXI instances will interconnect through a federated model to allow site-to-site data and application sharing with configurable access control. Importantly, PIXI will also support interfaces to The Cancer Image Archive (TCIA) and the planned NCI Imaging Data Commons (IDC) to enable import and export of data to facilitate open science research. Overall, the development of the preclinical imaging informatics platform is expected to have a profound impact on the management of preclinical imaging datasets which will ultimately support translational precision medicine. Figure. A) The PIXI Platform comprising of the PIXI Server, the Point of Service (PoS) environment, and the PIXI Apps environment to enable automated image processing pipelines through Docker container environment. PIXI instances in the PIXI Federation will be able to communicate for data/App sharing. (B) an example of an automated pipeline. Multi-mouse images (mouse hotel images) are supported by a custom RESTful API that automatically partitions mouse hotel images into individual image datasets for incorporation into the PIXI database Abstract Body : Immunotherapies in which T cells specifically target tumor cells, including chimeric antigen receptor (CAR) adoptive T-cell therapies, are a subject of active research for treatment of multiple cancers. As these therapies require injecting massive numbers of in vitro expanded and modified T cells, off-target effects and associated toxicities are of high concern [1] . Full pre-clinical evaluation of T-cell therapies requires visualizing the immediate fate of T cells after administration, following T-cell migration patterns including accumulation and retention in off and on target sites, and assessing therapeutic and possible off-target effects [2] . Labeling human T cells with iron-oxide nanoparticles to allow tracking with magnetic particle imaging (MPI) will aid non-invasive evaluation of T-cell therapies. MPI is a non-invasive tomographic imaging method that directly visualizes superparamagnetic iron-oxide nanoparticles. MPI does not use ionizing radiation, is highly sensitive, is quantitative, and is not limited by depth within the body. In this work, primary T cells were used as a cost-effective surrogate for the engineered T cells used in immunotherapies [3] [4] . Human primary T cells were isolated from Buffy Coat samples obtained from our institution's blood bank using the Ficoll separation method. Cells were maintained in IL2 and used for labeling within 72 hours from isolation. For repetitive studies cells were frozen in regular cell recovery media (Gibco, USA) and used 48 hours after thawing with average viability of sample determined by Trypan blue to be >95%. Two ironoxide nanoparticles were tested, ferumoxytol (AMAG pharmaceuticals) and Janus nanoparticles (Song et al. Nano Lett 2018) . Imaging was performed with a Momentum MPI scanner (Magnetic Insights). For pilot studies we co-incubated particles and cells in T-cell media at 37°C for 1h. Animal studies were done using nu/nu male mice, following subcutaneous cell pellet implantation. We tested various labeling conditions such as temperature, duration, and presence of serum. The highest labeling efficacy (number of particles taken into the cell/total amount of particles) was 8.1+-0.5% with Ferumoxytol and 6.3+-1.2% with Janus particles; this was achieved at day 2-3 after isolation, after 1h of co-incubation at 37°C in regular T cell media supplemented with 10% serum. Samples with higher cell viability count had better accumulation, for example for ferumoxytol labeling efficacy by 24 hours was 5.4+-1.4, peaked at 48-72 hours at ~8% and at 96 hours dropped to 3.2+-0.4%. Result deviation from donor to donor never exceeded 1% of labeling efficacy. T-cell viability did not suffer from labeling during 24 hours of observation as determined by Trypan Blue. Various number of labeled and wild type T cells were pelleted using gentle centrifugation (600 rpm/5 minutes) and imaged in vitro. For quantitation, ferumoxytol and Janus particle standards were included in the field of view. Several cell pellets ranging from 104 to 107 viable cells were used for in vivo imaging, with pellets of prelabeled cells subcutaneously implanted into the shoulder area using a 20g needle and imaged immediately after implantation. We were able to identify on imaging even the lowest number of cells that we implanted (104). Our data shows that human primary T cells can be successfully and efficiently labeled for the purposes of magnetic particle imaging and remain viable for 24 hours. Additional studies remain to confirm our labeling does not lead to perturbation of T-cell function, to confirm longer-term viability than what was assessed here, and to translate these results to imaging the engineered T cells utilized in immunotherapies.

Carmen Azevedo, Stanford University, ecarmenazevedo@gmail.com

Abstract Body : Objectives: ImmunoPET leverages the high specificity of validated antibodies (Abs) for in vivo imaging. However, due to the long biological half-lives of Abs, application of immunoPET in the clinic is challenging because of long delays between injection and scanning. Ab fragments, 40 -50 kDa, are a promising alternative to full-sized Abs due to their faster kinetics, enabling shorter times between injection and scanning without compromising binding specificity.1 Here, we chose to radiolabel a fragment of a human-specific CD19 Ab, 16C4-TM-Fab,2 for imaging pathogenic B cells in the context of multiple sclerosis (MS). The long half-life of 89Zr (3.3 days) will allow us to track CD19-positive B cells in a mouse model of MS throughout disease progression using PET imaging. Such longitudinal studies have the potential to provide important insights into the spatiotemporal dynamics of B cells in MS in addition to helping optimize timing for immunomodulatory therapies. The aim of this study was to develop the first human-specific CD19-fragment PET tracer and assess its utility for detecting B cell infiltration into the CNS of humanized CD19 transgenic mice (hCD19-tg) induced with experimental autoimmune encephalomyelitis (EAE). Methods: Female hCD19-tg C57/BL6 mice age 21 weeks were induced with EAE, using human myelin oligodendrocyte glycoprotein (MOG1-125) administered subcutaneously, and observed daily for signs of paralysis from day 8. On day 14 post inoculation, 1.93 ± 0.31 MBq [89Zr]16C4-TM-Fab was injected intravenously into 12 mice (n = 8 EAE, n = 4 naïve). Mice underwent PET/CT imaging 17-19 hours post injection. Percent of injected dose per gram (%ID/g) in tissues of interest was determined by analyzing PET images and ex vivo gamma counting of perfused organs. Autoradiography (ARG) was performed to obtain high resolution images of tracer distribution in brain regions, expressed as mean pixel intensity/decay corrected dose. Results: Radiolabeling of desferrioxamine-star (DFO*)-conjugated Fab (1 -1.5 DFO*/Fab, MALDI-MS) was achieved by incubating 10 µg 16C4-TM-Fab with 37 MBq [89Zr]Zr-oxalate at room temperature for 30 minutes, producing a radiotracer with high radiochemical purity (>99%, ITLC, Supplemental Fig. 1a ) and molar activity of 2 MBq/μg. ARG and gamma counting data provide evidence that [89Zr]-16C4-TM-Fab can detect B cell infiltration into the CNS of EAE mice. Specifically, we observed that EAE mice had significantly higher signal in whole brain, cerebellum, and medulla detected by ARG (Fig.1a, c; p Conclusion: We successfully radiolabeled the first human CD19-Fab and demonstrated its ability to detect B cells in humanized EAE mice. The long half-life of 89Zr affords the opportunity to track B cells in individual mice over time, before symptoms arise and as disease develops and worsens. Such longitudinal imaging of B cells throughout disease progression will be the focus of future studies.

Alexander Klibanov, University of Virginia, sklib1@gmail.com

Abstract Body : There is a hypothesis that in the tumor tissue the malignant tumor cells may be exposed to the vascular lumen, partially embedded in endothelial lining, creating so-called "mosaic" vessels: up to 4% of the surface of the vasculature may be tumor cells, not endothelium [1, 2] . Currently, only tissue histology can assess the fine structure of tumor microvasculature and if tumor cells are exposed to blood. The information on the direct exposure of cancer cells to the vessel lumen is important for understanding the disease, and potentially useful for predictive diagnostics and therapy planning. Molecular imaging of tumor cell-specific biomarkers may be able to provide such information, if the imaging probe is restricted to the vasculature and cannot extravasate, so it should only target tumor cells exposed to the vessel lumen. Gas-filled microbubbles, applied as ultrasound imaging contrast, cannot cross endothelial lining. Ability to detect single microbubbles at cm depths with sub-mm spatial resolution enables detection of adherent microbubbles targeted to the biomarkers on the vessel wall. Here a formulation of small molecule PSMA ligand-decorated microbubbles is described. These microbubbles would adhere to PSMA-expressing cells in case of direct contact. Thus, lack of specific adherence of targeted microbubbles in the tumor vessels may point at the negligible level of mosaic vasculature in the model tested. PSMA ligand, 2-(3-{5-[7-(5-amino-1-carboxy-pentylcarbamoyl)-heptanoylamino]-1-carboxy-pentyl}-ureido)-pentanedioic acid N-hydroxysuccinimide ester [3] was reacted with the distal aminogroup of amino-PEG-phosphatidylethanolamine. Completion of the reaction was confirmed by TLC. Microbubble precursor medium was first prepared, as aqueous salinepropyleneglycol mixture containing DSPC, PEG stearate and ligand-PEG-DSPE in the vials with decafluorobutane headspace. Microbubbles were prepared by amalgamation (4300 rpm, 45 s) [4] . Resulting microbubbles were size-adjusted by flotation to remove larger particles [4] . Ligand-free microbubbles were used as a negative control. Targeting of ligand-decorated and control microbubbles to PSMA-positive cells (PC3/PIP) in vitro was performed in a flow chamber. Adhesion of flowing microbubbles to the cells on a dish was assessed by contrast ultrasound (7 MHz, MI 0.2, contrast pulse sequencing). Plain PC3 cells, not expressing PSMA, were used as control. Selective adhesion of targeted microbubbles to cultured PSMA-expressing PC3/PIP cells was demonstrated in comparison with control bubbles (5.8-fold difference, p In conclusion, a translatable formulation of PSMA ligand-decorated microbubbles was generated. Unlike control microbubbles, PSMA-decorated particles selectively adhered to PSMAexpressing PC3/PIP cells but not to control PC3 cells in vitro. Targeted microbubble adhesion to PC3/PIP tumor tissue sections was also observed ex vivo. However, no selective PSMA targeting of microbubbles to the tumor vasculature was observed in vivo in the murine model tested. This implies lack of PSMA availability on the luminal surface of tumor vessels in the model tested, and low/undetectable level of mosaic vasculature. In future, testing in models with higher metastatic potential may be of interest. Therapeutic interventions that alter the state of tumor endothelium should be assessed for the potential enhancement of direct tumor cell exposure to the vasculature. Abstract Body : Abstract: Anticancer immunotherapy is a paradigm shift to raise the prospect for cancers to be managed as chronic disease rather than terminal illness. The nearly neglected old idea of activating patients' own immune system to fight tumors has now resulted in an explosion of successful immunotherapies particularly in the form of immune-checkpoint inhibition. Antibodies targeting PD-1/PD-L1 or CTLA-4 to unleash T cells have shown durable regression of tumor and improved survival outcome in melanoma, non-small cell lung cancer, and many others as a new pillar of oncologic therapy in the past decade. CD47-targeted innate immune-checkpoint inhibitors have recently emerged as next generation therapy with promising initial clinical data and unique working mechanism of reprogramming tumor-associated macrophages. Despite revolutionary clinical success and active new development, the overall response rate is generally less than 20% for the most common tumors including triple-negative breast cancer. Hence, development of robust predictive biomarkers and sensitive drug response monitoring tool is a major unmet need in immuno-oncology. Cellular and tissue metabolism is a key factor to determine functional orientation of immune infiltrates and antitumor immunity. Imaging metabolism empowers robust tool for identifying early and potential responders and predicting immunotherapy outcome. In this study, we established a label-free metabolic intravital imaging technique to detect two-photon excited autofluorescence signals from two important coenzymes, NAD(P)H (Reduced Nicotinamide Adenine Dinucleotide Phosphate Hydrogen) and FAD (Flavin Adenine Dinucleotide) as a robust imaging marker to sensitively monitor metabolic responses to immunotherapy. Murine cancer models employing transplantation of a monomeric red fluorescent protein (RFP) gene transduced 4T1 human triple negative breast cancer cell lines (4T1_PB3R) in BALB/C female mice were established and tested with different therapeutic regimens including anti-CD47 immunotherapy to monitor time-course treatment responses using the developed metabolic imaging technique. We visualized the autofluorescence of NAD(P)H and FAD and found their significant increase with tumor growth using intravital two-photon microscopy with a dorsal skin window chamber. Following anti-CD47 immunotherapy (MIAP301 mAb), imaging signal was significantly decreased demonstrating sensitive monitoring potential of NAD(P)H imaging for therapeutic response. NAD(P)H intravital imaging also showed significant decrease by both Paclitaxel (PTX) chemotherapy and radiotherapy. Comparative study with conventional whole-body bioluminescence imaging demonstrated superior sensitivity of the developed metabolic imaging (p = 0022 vs p = 0.0313 for MIAP301 mAb, p = 0023 vs p = 0.0391 for PTX therapy, p = 0.0313 vs p = 0.313 for radiotherapy). Flow cytometry data validated in vivo metabolic imaging results. Intravital imaging revealed targeting ability of NAD(P)H imaging mainly for breast cancer cells and small portion of immuno-active cells (CD11c or CCR2 positive cells) and that of FAD imaging mainly for immuno-suppressive cells (CD11b or F4/80 or Dextran positive cells). These results indicated decrease of glycolytic activity of breast cancer cells and decrease of oxidative metabolism of immuno-suppressive cells could be captured by the developed metabolic imaging as sensitive predictive biomarkers. The developed label-free metabolic intravital imaging technique is a powerful tool to investigate heterogenous cell metabolism of cancer cells and immune infiltrates to unravel metabolic processes to immunotherapy thus providing sensitive and robust imaging biomarker. Overall, the combination of optical metabolic imaging and cellular-level analyses provides novel insights into drug responses and tumor heterogeneity, thus opening new avenues for improved patient outcome and effective drug development. Keywords: Metabolic imaging, Immunotherapy, anti-CD47 antibody, Immune checkpoint inhibitor, Label-free imaging Abstract Body : Nanoengineering advances have contributed to potentially promising results for the treatment of glioblastoma and (GBM) in preclinical animal models. However, the presence of the blood-brain barrier and lack of active targeting capabilities for nanocarriers continue to significantly compromise the efficacy of incorporated therapeutics. Here, we developed neural stem cell (NSC) mimetic nanocarriers using CXCR4-engineered NSC-derived extracellular vesicle functionalized PLGA nanocarriers loaded with antisense miRNA-21 and gold-iron oxide nanotheranostics (GIONs). We investigated these NSC mimetics for their GBM specific accumulation and consequent therapeutic enhancement in vitro (using 2D-NSC-GBM co-culture, and 3D-GBM cell lines), in patient-derived GBM spheroids, and indifferent orthotopic GBM mouse models. Biophysical characterization (dynamic light scattering and transmission electron microscopy) of these NPs demonstrated their size range to be 80-150 nm, and their core-shell structure composed of NSC-derived proteo-lipid layers and polymeric PLGA with a GION nanocore. In vitro co-culture (using NSCs and GBM cell lines) and the 3D tumor spheroid experiments confirmed the synergistic therapeutic response of standard temozolomide therapy with engineered NSC-EVs and NSC-EV-PLGA NPs mediated antimiR-21 delivery. Moreover, we used multimodal molecular imaging (CT/MRI/ photoacoustic and fluorescence imaging) and qRT-PCR methods to demonstrate the NSC mimetic nanocarrier accumulation and delivery of antimiR-21 into mice GBMs. To validate this further, we produced CXCR4-engineered NSCderived proteo-lipid vesicles loaded with antimiR-21 and antimiR-10b and tested their accumulation and synergistic therapeutic enhancement in orthotopic mouse GBM models. Overall, our in vitro and in vivo results suggest that engineered NSC mimetics are promising nano-vehicles for GBM-specific delivery of diverse imaging agents and therapeutics.

Bao Ying Chen, University of California, Los Angeles, BaoYingChen@mednet.ucla.edu

Abstract Body : Introduction: The immune system is complex and dynamic with different activities occurring at different times in different anatomical locations. Monitoring the immune system is challenging. Current standard in the clinic is to draw blood from patients to assess cell counts or conduct functional assays. The results from these methods can vary due to patient variability, technical variability, detection limit of the technique, and/or functional differences of immune cells in different anatomical locations. Strategies to image the immune system across the entire body would offer valuable insights to the function of the immune system in different organs and help physicians make better informed decisions for patients. Positron emission tomography (PET) imaging can non-invasively image biochemical processes in vivo3. 18F-FAC is a deoxycytidine analogue PET radiotracer that measures deoxyribonucleoside salvage, a pathway that is enriched in activated immune cells4,5 and controlled by the rate-limiting enzyme deoxycytidine kinase (dCK). Objective: We demonstrate the use of 18F-FAC in visualizing immune activation in a T and a B cell dependent mouse model of multiple sclerosis and evaluate whether 18F-FAC PET can be used as a pharmacodynamic measure of a drug that targets the deoxyribonucleoside salvage pathway. Methods: To induce EAE, 10-week-old female immunocompetent C57BL/6 were injected with either myelin oligodendrocyte glycoprotein 35-55 (MOG35-55) or myelin oligodendrocyte glycoprotein 1-125 (MOG1-125) in Freund's complete adjuvant and pertussis toxin. MOG35-55 EAE mice is a T cell dependent MS mouse model and MOG1-125 has been shown to be B cell dependent. To determine whether 18F-FAC can be used to image immune activation in the MOG1-125 EAE, mice were injected with 18F-FAC and imaged one-hour post-injection at 14 days post-immunization. To determine whether 18F-FAC can be a biomarker for immunomodulatory treatments, MOG35-55 mice were treated with a newly described dCK inhibitor DI-87, or vehicle and imaged with 18F-FAC PET. Results: Figure 1 : To determine whether immune activation is different at different organs in MS and whether these differences can be visualized with 18F-FAC PET, we induced mice with either MOG1-125 or MOG35-55. At the peak disease, mice were injected with 18F-FAC and imaged 1-hour post-injection. Levels of 18F-FAC accumulation in the lymph nodes and spleen of both mouse models were similar. Both models showed a two-fold increase in 18F-FAC accumulation at peak disease. Interestingly, in the MOG35-55 model, there was a two-fold increase in 18F-FAC accumulation in post-immunized mice compared to pre-immunized mice but not in the MOG1-125 model, suggesting that not only is immune activation different in different organs but that these differences in the biology of the immune system can be visualized with 18F-FAC PET. Figure 2 : To determine whether 18F-FAC PET can be used as a pharmacodynamic measure in drug studies, mice were induced with MOG35-55 EAE and treated with either vehicle or DI-87, a novel inhibitor of dCK, a rate-limiting enzyme in the deoxyribonucleoside salvage pathway. Mice were imaged with 18F-FAC and imaged one-hour post-injection. Decreased 18F-FAC accumulation was observed in the spleen and bone marrow of mice treated with DI-87. Interestingly, there was decreased 18F-FAC accumulation in the intestines of DI-87treated EAE mice. These results suggest that the pharmacodynamics of drugs can be visualized with 18F-FAC PET. Impact: These results are the first to show that 18F-FAC PET can be used as a pharmacodynamic measure for immune activation in a B cell dependent model of MS. We also show that 18F-FAC can be used to quantify location specific effects on immune cells of an immunomodulatory drug and a direct inhibitor of the dCK pathway. and assessing immunomodulatory therapies. If translated into the clinic, patients with autoimmune diseases could benefit from using PET imaging to guide immunomodulatory treatments.

Christiane Mallett, Michigan State University, christiane.mallett@gmail.com

Abstract Body : Introduction: Our goal is to develop simultaneous dynamic PET and MRI methods to characterize tumors more thoroughly than either modality employed alone, or with static scans; this will become more practical as the number of simultaneous PET/MRI systems increases. FDG-PET and gadolinium-enhanced MRI provide complementary information: FDG-PET measures tumor metabolism (Zhu 2011), while dynamic contrast enhanced MRI (DCE-MRI) measures perfusion (Hylton 2006) . Previous studies comparing static PET and MR perfusion have found that MR perfusion is superior to FDG PET for distinguishing recurrent tumor from non-neoplastic tumor (Kumar 2017), while FDG PET was slightly better than MR perfusion for distinguishing tumor progression from radiation injury (Hatzoglou 2013). Here, we have used kinetic modelling to characterize the tumors. We co-injected the two agents and then performed simultaneous dynamic PET/MRI in two tumor models to examine the relationship between the two methods. To the best of our knowledge, this is the first simultaneous administration of FDG and gadolinium for tumor characterization by kinetic modelling. Methods: FVB mice were injected bilaterally with subcutaneous prostate cancer tumors (MyC-CaP cells, n=3). Nude mice were injected with breast cancer cells in two mammary fat pads (4T1 cells, n=3). Mice were injected with F18-FDG (~300 μCi) mixed with gadopentetate dimeglumine (0.1 mmol/kg) and saline through a tail vein catheter. Images were acquired on a 7T Bruker 70/30 USR MRI with a PET insert. For MRI, we used a 40 mm transmit/receive volume coil and acquired 2-3 axial slices using a T1 weighted FLASH sequence at 7-14 s temporal resolution, for 240-480 image frames in the hour long scan. For PET, we reconstructed at 8 s temporal resolution during injection, and then 1-4 minute resolution later in the scan, for 35 frames in the dynamic scan. PET images were reconstructed at 0.5 mm resolution using a MLEM algorithm. Images were segmented in PMOD. The MRI images were segmented at two timepoints: 500 seconds after the start of the acquisition ("early") and at the end of the scan ("late"), and were segmented into regions with more than 40% enhancement over baseline ("enhancing regions") and regions with less than 40% enhacement over baseline ("nonenhancing regions"). Those ROIs were overlaid onto the PET images, and we used a Patlak model to calculate the glucose flux for each ROI (Patlak 1983) . The arterial input function was measured from the vena cava in the whole-body PET image. Tumors were fixed in formalin and then sent for paraffin embedding and H&E staining. Results: We used a 2-way analysis of variance to compare flux between the ROIs. There was no difference between groups (p>0.05). In MR images, tumor regions that were classified as enhancing at both timepoints had larger initial intensity. As seen in a representative tumor, the regions that were enhanced by DCE-MRI also had high uptake of FDG. Several mammary fat pad tumors were eliminated from analysis because of contamination of tumor FDG signal by accumulation in the bladder. 4T1 tumors in general had low FDG uptake and will not be used in the future. Discussion: With our current ROI-based image analysis techniques, there was no difference in glucose uptake between regions of the tumor that were enhanced and non-enhanced by DCE-MRI. However, this technique was limited because it did not account for the initial heterogeneity in MRI signal before contrast administration. In the future, we will measure MRI perfusion parameters on a pixel-wise basis from these images to more accurately characterize tumor perfusion. We will also measure blood glucose in all animals in order to use the Patlak model to determine the regional metabolic rate of glucose. There was no difference in glucose flux between regions that were enhanced after MRI contrast administration and those that did not enhance. There was also no difference between regions that enhanced early and those that were enhaced late. b) DCE-MRI results for a representative tumor. Regions of the tumor that were classified as enhanced also had a higher baseline signal, and those that were classified as non-enhanced had lower baseline signal. c) FDG-PET results for the same tumor as (b). Regions that had high MRI enhancement also had high FDG uptake. Abstract Body : Current methods to calibrate stereotaxic coordinates are either lengthy and invasive or require expensive equipment to perform. Fringe projection profilometry can become an inexpensive yet accurate alternative of calibrating stereotaxic coordinates to guide techniques such as focused ultrasound non-invasively. Techniques which target specific locations inside the brain non-invasively, such as focused ultrasound, are becoming more common in laboratory and research settings. Thus, methods to increase the speed and accuracy of such experiments while remaining cost-efficient are highly valuable. The calibration of devices which use these techniques is a step which particularly has room for improvement. Current calibration methods are either invasive and time-consuming, namely uncovering bregma-lambda surgically to use as reference points, or require expensive equipment like an MRI machine. Fringe projection profilometry is a well-established technique using a simple and inexpensive camera-projector system for analyzing the surface of an opaque object and generating a 3D point cloud of said surface. This point cloud can then be calibrated in real space relative to the camera using computer vision techniques. By using this technique on the surface of a mouse's shaved head, the geometry and location of the head, and by proxy the brain, can be used to direct braintargeting devices. In order to test the cost efficacy limits of such a technique, an economical projector and camera were purposefully chosen for this project. A Lightcrafter 2000EVM projector driven by a BeagleBone Black microcontroller is used for projection, and an AM2111 Dino-Lite microscope camera is used to capture images. A MATLAB camera-projector computer vision toolbox known as ProCamCalib is used to calibrate the system (Falcao 2009 ), while a MATLAB code published by a publicly available Brown University course is used to analyze projected gray code fringes to reconstruct a 3D surface (Lanman 2009). This method is much faster and theoretically more accurate than common calibration methods using bregmalambda as reference points since fringe projection profilometry effectively replaces the two points with a point cloud. Furthermore, the technique can be mostly, if not entirely, automated thus making it simple to use and lowering the chance for human error. Fringe projection profilometry has the potential to provide highly accurate stereotaxic calibration non-invasively using readily available and relatively inexpensive equipment. Abstract Body : Type 1 diabetes (T1D) is characterized by autoimmunity-induced pancreatic beta cell damage with hyperglycemia as a consequence. Islet transplantation (Tx) has made insulin independence possible in T1D patients. However, for 70% of transplant recipients, successful insulin independence is not permanent. An in vivo imaging method for a personalized and time-course monitoring of transplanted islets is urgently needed if we are to understand how to make islet transplants last. Currently, MRI is used for monitoring graft loss in patients who receive islet transplantation. However, due to limited sensitivity of MRI and the negativecontrast nature of the image, standardized quantification of the desired Region of Interest (ROI) is often difficult. As an alternative imaging modality, magnetic particle imaging (MPI) is an emerging modality that directly images the magnetization of iron oxide nanoparticles, with advantages including high specificity and sensitivity, the absence of the background signal, linear quantitative ability, and high potential for clinical translation. With this current project, we plan to use machine learning (ML) for quantification and comparison of iron content in transplanted islets to observe a quantifiable difference in the longitudinal cell tracking capability of MPI vs MRI. Here, we applied a canonical ML algorithm, K-means++, to segment and to calculate iron content in the MPI of mice which received islet grafts. To calibrate the algorithm with in vitro data, 3D-printed phantoms were generated in varying shapes. Mouse beta cell lines were labeled with superparamagnetic iron oxide nanoparticles (SPIONs) VivoTrax (460ul of 5.5ug/ul stock solution per 25 cm² flask, 24 hr @ 37 °C) prior to imaging and dispersed in 1% agarose gel in the phantoms. 2D MPI and T2Map MRI were acquired for all phantoms. The phantom images were used to calibrate the ML algorithm to the dataset at hand, and to develop an adequate iron quantification script post-segmentation. The main ROI and reference markers of known iron content were segmented separately in the MPI images, and a ratio was used to calculate the iron content of the main ROI of the image. For MRI, the average T2 value of the ROI was calculated after segmentation with the ML algorithm. Post scanning, inductively coupled plasma optical emission spectroscopy (ICP-OES) analysis was used to determine actual iron content in the phantoms to validate the ML-enabled quantification of iron in the images. In vivo data was then generated by transplanting the labeled human islet (800 IEQ, IIDP) under the left kidney capsule of mice (n=8). 2D MPI data and T2 map MRI were acquired for all mice at day 1, 5, 7, 14, 21 , and 30 post transplantation. The algorithm's performance was then tested on the in vivo data using intraclass correlation coefficient (ICC). Transplanted human islets under the left kidney capsule could be identified from both MRI and MPI (Fig. 1) . Quantified MPI data of transplanted islets were compared with quantitative T2 map analysis of MRI data through evaluation of the signal loss over time in the ROI via ML-enabled segmentation. Iron staining was performed to confirm the presence of nanoparticles in the graft cells ex vivo. Here, we established the feasibility of a ML algorithm to provide a method of comparison of MPI and MRI of SPION-labeled islet transplantation in a small animal model. The ML-assisted evaluation of the islet transplantation between these two different imaging modalities indicates that MPI can monitor transplanted islets with a greater degree of longitudinal sensitivity than its MRI counterpart. This provides further insight into which imaging modality can monitor islet transplantation with a greater degree of longitudinal sensitivity tool for automated quantification and prediction of SPIONs labeled cell transplantation therapy. Abstract Body : Introduction Tracking CAR-T cells with non-invasive imaging techniques could be very useful for optimizing CAR-T cell immunotherapies. Imaging could provide information on cell homing to tumors, cell fate and tumor killing efficacy. Today, white blood cells (WBCs) are routinely imaged using the In-111-WBC study, where autologous neutrophils and macrophages are labeled with an In-111 tracer. After labeling, the tagged WBCs are injected and then imaged hours later to highlight sites of infection, inflammation, and cancer [1] . Neutrophils and macrophages are thought to home to infection and inflammation, despite the radiation toxicity on the WBCs. However, lymphocytes are thought to lose function due to the radiation dose of In-111, which is equivalent to 90 Gy per 108 cells [2] . Indeed, the standard In-111 dose has been shown to impede T cell motility, induce chromosomal changes, and it even causes cell death [3, 4] . In contrast, magnetic particle imaging (MPI) uses non-radioactive and safe superparamagnetic iron oxide (SPIO) nanoparticle tracers. SPIO labeling of lymphocytes should not affect T cell viability or homing [5] [6] [7] [8] [9] . Here, we compare MPI to nuclear medicine in terms of T cell viability and sensitivity limits. Materials and Methods B3Z murine hybridoma T cell expressing receptors (TCR) that specifically recognizes ovalbumin (OVA) were cultured in culture flasks with a growth area of 75 cm2. Of the four flasks of cells, two were exposed to 5 and 10 Gy of radiation respectively, one was added 100 µL of VivoTrax, and the last one was used as a control. After 24 and 48 hours of incubation in culture medium, the density of cultured CAR-T cells was 3.3*105 cells/cm2, and they were harvested and stained with annexin V-FITC and propidium iodide (PI). Fluorescence activated cell sorting (FACS) was used to analyze counts and viability. The iron concentration of labeled cells was assessed using both the UV-Vis spectrophotometer and the arbitrary waveform relaxometer (AWR). VivoTrax labeled cells were imaged using our field free line MPI system. Results and Discussion CAR-T Cell Sensitivity Limits After 24 hours of incubation with SPIOs that contain 5.5 mg/mL iron, the iron content of labeled CAR-T cells was measured at 6.9 pg per cell, which is a factor of 4 lower than the iron content that prior published papers had with stem cells [10] . This variation could be due to the fact that CAR-T cells have less phagocytic behavior compared to stem cells. Perhaps, labeling efficiency could be improved with transfection reagents such as protamine sulfate that enhances the transfection rate of T cells. The MPI image showed a cell detection sensitivity of 66,000 cells with an SNR of 1 and an averaging data acquisition time of 90 s. CAR-T Cell Viability After 48 hours of incubation, the results showed that the annexin V-FITC+/PI-apoptotic cell population increased from 5.98% for SPIO labeled cells to 14.7% and 12.4% for 5 Gy and 10 Gy irradiated cells respectively. Similarly, the annexin V-FITC+/PI+ necrotic cell population increased from 0.14% for SPIO labeled cells to 11.9% for 5 Gy irradiated cells, suggesting that CAR-T cells experienced early and late apoptosis after radiation exposure, while SPIOs showed no visible effect on cell viability. Conclusion CAR-T based immunotherapies are very promising for treating tumors that have failed to respond to chemotherapy and radiation therapy. CAR-T cell imaging will be very important for optimizing CAR-T cell therapies. MPI CAR-T cell imaging could soon be clinically helpful for guiding immunotherapy, without the concern of tracer toxicity on CAR-T Cells.

Jonathan Fisher, Stanford University, jofisher@stanford.edu

Abstract Body : INTRODUCTION Subject motion during medical imaging scans degrades image quality and quantitative accuracy. The main approaches used to mitigate the problem can be divided into three categories: MR-based [1] , PET-based [2] , and external device-based, usually a camera [3 -6] . Here, for the first time, an inertial measurement unit (IMU) is being used for rigid-body motion correction. In a similar fashion to our previous work [4] [5] [6] , the IMU will be attached to the patient's head and track its motion in the IMU coordinate system, which will then be translated into motion in the scanner coordinate system. In this study, we performed an evaluation of this motion tracking solution for the case of motion modeled by a rotation and translation-controlled stage. Materials and methods Experimental setup A BMI160 (Bosch Sensortec GmbH, Reutlingen, Germany) IMU consisting of tri-axial accelerometer and gyroscope units and a three-axis ADXL355 accelerometer (Analog Devices, Inc., Wilmington, MA, USA) are jointly mounted to four degrees of freedom, high precision, computer commendable stage. The data from the IMU sensor were acquired at the sampling rate of 400 Hz; the acquisition ranges for the accelerometers and gyroscope were ±2g and ±125 degrees per second, respectively. The stage comprises three linear stages (Parker SERE100) with motors (Schneider electric LMDCM422), which allows translation in the X, Y, Z directions with 4e-5 mm resolution. A single rotational stage (Thorlabs CR1-Z7) is mounted to a 3D printed extension arm that is connected to the linear motion stages. The rotational stage enables motion in θZ with 1e-3 degrees resolution. The marker is mounted to the rotational stage, as shown in Fig 1. a IMU-based rigid-body motion tracking The motion tracking solution works as follows: Motion tracking in the IMU coordinate system relies on Kalman filter for sensor fusion. We used Attitude Heading Reference System (AHRS) platform available in xIMU Matlab library [7] for pose and orientation estimations. The IMU pose estimation was implemented by integrating the acceleration signals, followed by compensating drift rate while computing the translational velocities during stationary periods using a zero-velocity update algorithm. Finally, we integrate translational velocities to obtain translational positions. Rotational and translational positions are used for 6 Degree of Freedom rigid-body motion estimation. Results We generated motion mimicking a patient moving his/her head from side to side. Each interval contained 4 steps, each of 23.43 mm translation along the X direction and 6 degrees rotation about the Z axis. The simulated head motion was repeated 16 times (for 4 different Y and 4 different Z values, steps sizes in each direction were 23.43 mm), as seen in Fig 1.b The preliminary results demonstrate the use of an IMU to correct for motion in medical imaging, with an error between 5.79-21.03 mm (linear) and 0.19-1.39 degrees (angular) for all axes and an average error of at most 13.58 mm and 0.62 degrees. This is still far from our continued goal of 1-millimeter error isotopically. Conclusion and future work The main sources of error are due to the accelerometer's drift/bias and the non-orthogonality of the linear motion stage. We are currently working on improving the IMU's signal post-processing and fixing the non-orthogonality issue. In the future, we consider using a hybrid approach to combine our IMU-based method with our camera-based method [4] [5] [6] to improve both time resolution and spatial resolution. Acknowledgments This work was supported in part by NIH grants 3R01EB01946504, 3R01EB01946504S1, Academy of Finland grant 314483, Ulla Tuominen Foundation (postdoc pool), and Turku University Hospital Research Funding grant 11125 (8KLI).

Image/ Figure Caption: Fig. 1 . a. Experimental setup -the IMU tracks the 3D motion introduced by the stage. The IMU is mounted to the 4 degrees of freedom stage controlled by a computer. The yellow arrows indicate the linear and rotational motion directions. b. Visualization of the "head motion mimicking" experiment. The IMU derived positions, each represents a single pose, are shown as rectangular points with three orthogonal arrows pointing towards x (red), y (green), and z (blue) directions. The IMU coordinate system corresponds to the Earth frame of reference. Abstract Body : OBJECTIVE Gold has long been consumed by human beings for its low toxicity and high chemical stability. At present, multiple clinical trials have been undergoing for gold particles. AuNPs in ultrasmall size with advisable surface are known to efficiently catalyze oxidation-reduction reactions and thus ameliorate inflammation associated with reactive oxygen species (ROS) [1] . In this study, we aimed to synthesize AuQCs with alpha lactalbumin (α-LA). The synthesized AuQCs exhibited unique near-infrared fluorescence (NIRF) and strong CT contrast. Therefore, we hypothesized that AuQCs can enable contrast-enhanced dual-modality in vivo imaging of the gastrointestinal (GI) tract following oral gavage in mice. In addition, the intrinsic catalytic activity and anti-inflammatory properties of AuQCs should effectively alleviate gastrointestinal inflammation through scavenging free radicals, but remain non-toxic in nature. METHODS AuQCs were synthesized by a mild reduction reaction of the HAuCl4 precursor under alkaline conditions usingα-LA [2] . We first verified the in vitro influence on cellular toxicity and cell migration in Caco-2 and MC-38, and NCM460. BALB/cJ mice were fed with AuQCs and their body weight were monitored over time for any toxicity effects. Next, we conducted non-invasive whole-body dual-modality in vivo imaging of CT and NIRF on gastric emptying and intestinal motility, following oral administration of AuQCs. We evaluated the pharmacological effects of a variety of GI medications in mice by dynamic GI imaging. In addition, we corroborated the diagnostic value of AuQCs in a mouse model of intestinal obstruction (IO). To understand the intestinal permeability, we constructed two in vitro models of Caco-2 polarized cell monolayers and patient-derived human GI tissues. We tested the transport of AuQCs in both directions. The broad catalytic activities of AuQCs to scavenge free radicals were studied by catalase-like, GPx-like, and ABTS cation radical assays and were further confirmed by ESR spectroscopy. Finally, dextran sodium sulfate (DSS)-induced mouse enteritis models were used to examine the potential inhibitory effect of AuQCs on intestinal inflammation. RESULTS We found negligible cytotoxicity of AuQCs in Caco-2, MC-38, and NCM460. AuQCs also did not affect the migration abilities of cells. Mice fed with AuQCs did not have significant changes in body weight over a 30-day time frame. In vivo non-invasive whole-body CT imaging revealed enhanced contrast primarily in the upper digestive system, clearly delineating anatomical GI information 30 min following oral administration. After 3 h, AuQCs advanced to the descending colon. Stools exhibited obvious enhanced CT contrast over the control. NIRF dynamic imaging of GI motility demonstrated the pro-and anti-GI kinetic pharmacological effects. In the IO mouse model, non-invasive dynamic imaging manifested that the GI motility was remarkably obstructed. AuQCs exhibited strong in vitro catalytic activities, which can effectively scavenge various ROS such as ABTS•+, OH•, O2•-, and H2O2. The transmembrane permeability assay from both apical-to-basolateral and basolateral-to-apical directions showed that AuQCs cannot penetrate the intestinal barrier, nor can they be transported across human intestinal tissues. Finally, in a representative colitis mouse model for inflammatory bowel diseases (IBD), AuQCs can significantly inhibit DSS-induced colonic inflammation, reduce adverse symptoms, and suppress intestinal MPO levels. AuQCs can increase intestinal anti-inflammatory cytokines and inhibit the expression of pro-inflammatory cytokines, thereby reducing intestinal inflammation. CONCLUSION As there is currently no cure for IBD, AuQCs have the great potential for imaging and therapy of GI diseases in clinical settings. AuQCs can effectively scavenge multiple ROS radicals. Besides, it can inhibit the expression of proinflammatory cytokines, promote the expression of anti-inflammatory cytokines in intestine tissues, and thus mitigate the intestinal inflammation. All these preliminary results strongly suggested that AuQCs are prospective candidates for the treatment of IBD. Abstract Body : Cadmium zinc telluride (CZT) radiation detectors are suitable for various applications due to the good energy resolution, convenient operation at room temperature, and the simple pixilation to achieve high spatial resolution. Our group is developing a two-panel head and neck dedicated positron emission tomography (PET) system based on CZT detectors [1] . Each panel will consist of 150 CZT crystals (4x4x0.5 cm3) covering an area of 20x15 cm2 in an edge-on con_guration to achieve high detector efficiency at 511 keV. In this work, we present the design and development of a full data acquisition (DAQ) chain that enables a low noise and compact readout for each panel. The front-end and back-end readout electronics incorporate RENA boards (a total 150 RENA boards for each panel), and 30:1 fan-in boards connecting 30 RENA boards to the PicoZed 7010/7020 board (a total 5 fan-in boards for each panel). In each panel, 5:1 intermediate boards are used for biasing CZT detectors. The RENA board and the Picozed board 7010/7020 are capable of data transmission of 50 Mbps and 6.6 Gbps, respectively. The initial results of the readout circuit were quantiffied using a 1 kHz square wave test pulse that provides charge injection into each channel of the RENA chip in the amount of 75 fC/V. The pulse amplitude was chosen to generate approximately the same amount of charges as a 511 keV photon would provide in CZT with an electron-hole pair creation energy of 5 eV. The best case FWHM electronic noise at 511 keV was measured to be 0.69% FWHM The FWHM electronic noise at 511 keV for a complete DAQ chain was 4.33%.

References: Li M, Yockey B & Abbaszadeh S 2020 `Design study of a dedicated head and neck cancer pet system' IEEE transactions on radiation and plasma medical sciences 4(4), 489{497.

Image/ Figure Caption: (a) Illustration of a conceptual impression of the transportable twopanel head and neck gantry with an adjustable panel-to-panel separation distance; (b) Schematic of one panel system with 30-row by 5-column of 4cm 4cm CZT detectors. Each panel incorporates the CZT detectors assembled with exible circuits, the front-end electronics, and the back-end electronics. The two-panel system contains two adjustable panels, axial headholder and other mechanical supports. Abstract Body : Patients with advanced cancers die because their cancer develops resistance to all available therapeutic strategies. "Personalized cancer medicine" strives to use biomarkermatched molecularly targeted therapies to overcome known resistance mechanisms. However, there is currently no methodology to measure the highly interdependent levels of available molecular drug targets, amount of drug binding and the resulting cellular response in a single dynamic, living system. Intracellular drug target validation and target engagement quantification have proven to be challenging, and all drugs have some degree of non-specific accumulation due to variable drug affinity, biodistribution, pharmacokinetics, and metabolism. Quantification of available drug targets necessitates accounting for both the drug that binds to its target as well as the drug that accumulates in the cells and tissues in a non-specific manner. While fluorescence imaging has long been used to visualize biological specimens, recent years have seen significant advances in the development of synthetic dyes, genetically encoded biosensors, and fluorescent nanomaterials. We have developed a dynamic, fluorescence-based, three-compartment model termed intracellular paired-agent imaging (iPAI). iPAI is a fluorescence-based approach that utilizes fluorophore labeled small molecule therapeutics as imaging agents to measure drug target availability (DTA). Effective performance of the iPAI probe pair to access DTA highly depends on the inert quality and stable fluorescence signal of the fluorophore pair as drug labels. In particular, the ability of a fluorophore to diffuse across a cell membrane non-destructively and provide an unbiased fluorescence signal read-out for the tagged drugs is critical for quantitative imaging in live cells and tissues. Commercially available small molecule fluorophores have been engineered to offer high water solubility via modification of rhodamine and cyanine dyes with multiple sulfonate groups, however these fluorophores are often cell-impermeant as a result of an overall net negative charge. Herein, we report our designed and developed water-soluble and cell-permeable fluorophores, termed OregonFluor (ORFluor). In proof-of-concept studies, we have developed targeted and untargeted versions of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor Erlotinib using our novel ORFluor as drug labels. Adapting previously established ratiometric imaging methodology using bio-affinity agents, it is now possible to use small molecule fluorophore labeled therapeutic inhibitors to visualize their targeted proteins intracellularly, providing a chemical tool kit to quantify drug target availability in live cells and tissues. -2) is a respiratory track disease characterized by fever, dry cough, fatigue, and gastrointestinal symptoms. Currently, there is no definite treatment for COVID-19 although some drugs are under investigation. To promptly identify patients and prevent further spreading, they must be diagnosed in time and extra care has to be taken to ensure healthcare providers are not infected at all. Early detection and diagnosis of COVID-19 increases the chances of recovery of patients and this can be achieved through the use of computed tomography (CT) and magnetic resonance imaging (MRI) scanning. Although chest CT and digital radiography (DR) is important in the diagnosis and treatment of COVID-19, MRI is crucial for not just diagnosis of the disease but also for detection of other complications. MRI examinations for COVID-19 patients, protection of medical personnel and disinfection of MRI equipment is a challenging due high contingency of the disease. In addition to these problems, MRI examinations are costly. In order to overcome these challenges, this study proposes a computational method based of magnetic resonance fingerprinting (MRF) data, Bloch NMR response and machine learning. Clinical MRF were obtained from a recent experimental study on COVID-19. Since the specific MRF measurements in individual patients are not currently available, R computer codes were developed to simulate the measurements per subject. Taking the simulated data as individual data points, the time-independent NMR Bloch flow equation was solved analytically (as shown in equations (1) to (6)) and employed to compute the MRI signal for each subject based on spleen analysis data. The simulations were also done for cardiac MRI, hepatic panel test and brain volume data. The dataset generated from these simulations were then splitted into two (80% as training set and 20% as test set). As shown in figure 1 , machine learning algorithms were then used to train the dataset. Support vector machine, logistic regression, decision tree and gradient boosting classifier returned accuracies of 88%, 82%, 88% and 88% respectively for spleen analysis dataset. For the hepatic panel test, cardiac MRI and brain volume datasets, these algorithms all returned 100% accuracies. Logistic regression model was then selected to do deploy the machine learning algorithm with streamlit and Heroku. COVID-19 detection app making use of computed spleen analysis dataset is shown in figure  2 . The advantage of the developed app is that it does not require costly MRI scanners but a significantly cheaper NMR relaxometer can be used to take MRF data and with the app, diagnosis can be done quite easily and remotely. Swabs can be taken by patients and sent for MRF analysis and diagnosis with the machine learning app developed, with which disinfection is now much easier with lower risks of infection on healthcare providers. Despite the results that have been obtained in this study, the algorithm will benefit from training with larger amount of data for improved detection efficiency. Also, a ground truthing process in clinical settings may be done to confirm that the simulated data points are realistic for real-time diagnosis.

Michael Dada, Federal University of Technology, Minna, Nigeria, dadamichael@futminna.edu.ng

Abstract Body : Various research efforts have reported reference discrete macro-anatomical regions of the brain which were delineated according to specific brain atlas or parcellation protocol. For now, there is no widely accepted standards for partitioning the cortex and subcortical structures as well as assigning labels to the resulting regions. Previous attempts to reconcile neuroanatomical nomenclatures have been mostly qualitative while concentrating on the development of thesauri or simple semantic mappings between terms. In order to overcome this problem, we have developed a brain atlas method which is suitable for different quantitative analysis of the brain. The interaural 11.28mm and bregma 2.28mm region of rat brain in stereotaxic coordinates has been employed to demonstrate this method. The magnetic resonance imaging (MRI) scan of this brain region was imported into the Surfer (Golden Software, LLC) application. Each brain regions were traced and polygons were superimposed on these regions. The polygons were then encoded with region names as well as location information. The polygons were then exported as shapefile and the shapefile was read into python IDE using the geopandas library (the result is shown in figure 1(A) ). For segmentation, each brain regions were labelled with unique numbers while for other brain feature analysis, experimental measurements were prepared as unique columns in microsoft excel data sheets. The data sheets were then merged with shapefile to get the final form of the atlas. Using the numerical data, the atlas was then reconstructed using python codes. The two cases of brain segmentation are shown in figures 1(C) and 1(D) while the case of tissue feature distribution across the rat brain are presented in figure 1 (B) . The advantage of the method used for this study is the memory management and how fast results can be obtained. Furthermore, this method can easily be extended to the human brain.